<SEC-DOCUMENT>0001654954-24-010651.txt : 20240814
<SEC-HEADER>0001654954-24-010651.hdr.sgml : 20240814
<ACCEPTANCE-DATETIME>20240814162732
ACCESSION NUMBER:		0001654954-24-010651
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240814
DATE AS OF CHANGE:		20240814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		241208474

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cvm="http://cvm.com/20240630"><head><title>cvm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2023-10-01to2024-06-30" id="ixv-7709">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2023-10-01to2024-06-30" format="ixt:booleanfalse" id="ixv-7710">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2023-10-01to2024-06-30" id="ixv-7711">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2023-10-01to2024-06-30" id="ixv-7712">Q3</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2023-10-01to2024-06-30" id="ixv-7713">2024</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" unitRef="USDPShares" decimals="INF" id="ixv-7714">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7715">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7716">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-7717">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7718">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" unitRef="USDPShares" decimals="INF" id="ixv-7719">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7720">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-7721">54257884</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7722">47422304</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2023-10-01to2024-06-30" unitRef="Shares" decimals="0" id="ixv-7723">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2024-04-01to2024-06-30" unitRef="Shares" decimals="0" id="ixv-7724">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2023-04-01to2023-06-30" unitRef="Shares" decimals="0" id="ixv-7725">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-10-01to2023-06-30" unitRef="Shares" decimals="0" id="ixv-7726">0</ix:nonFraction><ix:nonFraction name="cvm:PurchaseOfNewlyIssuedSharesByInsiders" contextRef="From2024-04-01to2024-06-30_cvm_OfficerandDirectorMember" unitRef="Shares" decimals="0" id="ixv-7727">58000</ix:nonFraction><ix:nonFraction name="cvm:RestrictedCommonStockFairValue" contextRef="From2024-04-01to2024-06-30_cvm_OfficerandDirectorMember" unitRef="USD" decimals="0" id="ixv-7728">80620</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-10-01to2024-06-30" unitRef="USD" decimals="0" id="ixv-7729">300000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2022-10-01to2023-06-30" unitRef="USD" decimals="0" id="ixv-7730">300000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2022-10-01to2023-06-30_cvm_ErgomedMember" unitRef="USD" decimals="0" id="ixv-7731">100000.0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="From2023-10-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-07-18_us-gaap_SubsequentEventMember_cvm_MrKerstenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:MrKerstenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-07-11_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-07-29_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-11_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-10-28_cvm_OfficerandDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_cvm_OfficerandDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_OfficerandDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-05-01to2023-05-31_cvm_EquityProceedsFromSaleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_srt_MinimumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_ConsultantsOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_srt_MaximumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_srt_MinimumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-08-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2023-10-01to2024-06-30" id="ixv-8684">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;(Mark One)</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:boolballotbox" id="ixv-8685">&#9746;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2023-10-01to2024-06-30" format="ixt:datemonthdayyearen" id="ixv-8686">June 30, 2024</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:boolballotbox" id="ixv-8687">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from _______________ to ______________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File Number <span style="text-decoration:underline"><strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2023-10-01to2024-06-30" id="ixv-8688">001-11889</ix:nonNumeric></strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2023-10-01to2024-06-30" id="ixv-8689">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:stateprovnameen" id="ixv-8690">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2023-10-01to2024-06-30" id="ixv-8691">84-0916344</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">State or other jurisdiction incorporation</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS) Employer Identification Number</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2023-10-01to2024-06-30" id="ixv-8692">8229 Boone Boulevard</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2023-10-01to2024-06-30" id="ixv-8693">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2023-10-01to2024-06-30" id="ixv-8694">Vienna</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:stateprovnameen" id="ixv-8695">Virginia</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2023-10-01to2024-06-30" id="ixv-8696">22182</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Address of principal executive offices</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2023-10-01to2024-06-30" id="ixv-8697">703</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2023-10-01to2024-06-30" id="ixv-8698">506-9460</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Registrant's telephone number, including area code</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading Symbol(s)</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of Each Exchange on Which Registered</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2023-10-01to2024-06-30" id="ixv-8699">Common Stock</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2023-10-01to2024-06-30" id="ixv-8700">CVM</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:exchnameen" id="ixv-8701">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2023-10-01to2024-06-30" id="ixv-8702">Yes</ix:nonNumeric> &#9746;&#160; &#160;No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2023-10-01to2024-06-30" id="ixv-8703">Yes</ix:nonNumeric> &#9746;&#160; &#160;No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:entityfilercategoryen" id="ixv-8704">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746; </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:boolballotbox" id="ixv-8705">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:boolballotbox" id="ixv-8706">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:boolballotbox" id="ixv-8707">&#9744;</ix:nonNumeric>&#160;&#160;&#160;No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Class of Stock</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;No. Shares Outstanding</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-08-08" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF" id="ixv-8708">61,493,229</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">August 8, 2024</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">TABLE OF CONTENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PART I FINANCIAL INFORMATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Item 1.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#bs">Condensed Balance Sheets at June 30, 2024 (unaudited) and September 30, 2023</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#cso">Condensed Statements of Operations for the nine months ended June 30, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#cso2">Condensed Statements of Operations for the three months ended June 30, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#equity">Condensed Statements of Stockholders&#8217; Equity for the nine months ended June 30, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#cf">Condensed Statements of Cash Flows for the nine months ended June 30, 2024 and 2023 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#notes">Notes to Condensed Financial Statements<strong>&#160;</strong>(unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Quantitative and Qualitative Disclosures about Market Risks</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">29</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Item 4.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Controls and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">29</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><a href="#p2">PART II</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i2">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i5">Item 5.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i5">Other Information</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i6">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i6">Exhibits</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#sig">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">31</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="bs">CONDENSED BALANCE SHEETS</span></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>JUNE 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SEPTEMBER 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ASSETS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_682" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">384,652</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_683" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_684" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">551,337</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_685" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">520,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_686" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,555,249</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_687" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,248,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_688" name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">51,129</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_689" name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_690" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,542,367</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_691" name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,918,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_692" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,800,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_693" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,131,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_694" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,548,010</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_695" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,698,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_696" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,613,316</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_697" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,188,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_698" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">173,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_699" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">197,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_700" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_701" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_702" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">71,589</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_703" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">74,669</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_704" name="us-gaap:Assets" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,068,320</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_705" name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_708" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,369,441</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_709" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,009,786</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_710" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,272,149</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_711" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,049,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_712" name="cvm:DueToEmployeeCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">696,487</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_713" name="cvm:DueToEmployeeCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">557,244</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_714" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,949,245</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_715" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,771,804</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_716" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">219,019</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_717" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">197,431</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,506,341</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_719" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,585,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_720" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,477,784</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,949,565</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,486,138</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_723" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,652,949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_724" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_725" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,595,263</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_727" name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17,313,360</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies (refer to Note E)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_743" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_745" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_748" name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">0</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_731" name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_732" name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_751" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_754" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_755" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,257,884</ix:nonFraction> and <ix:nonFraction id="fid_756" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">47,422,304</ix:nonFraction> shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_733" name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">542,578</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_734" name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_735" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">515,832,848</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_736" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_737" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">507,902,369</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_738" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">487,091,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_739" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,473,057</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_740" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,214,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_741" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,068,320</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_742" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cso">CONDENSED STATEMENTS OF OPERATIONS</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NINE MONTHS ENDED JUNE 30, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_762" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,684,204</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_763" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17,203,823</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_764" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,547,866</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_765" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,804,729</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_766" name="us-gaap:OperatingExpenses" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,232,070</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_767" name="us-gaap:OperatingExpenses" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,008,552</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_768" name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20,232,070</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_769" name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">24,008,552</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_770" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">571,102</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_771" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">493,522</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_772" name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,801</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_773" name="us-gaap:OtherNonoperatingExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">61,525</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_774" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20,810,973</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_775" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">24,563,599</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_776" name="cvm:ModificationOfWarrants" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">659,456</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_777" name="cvm:ModificationOfWarrants" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">171,552</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_778" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,470,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_779" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">24,735,151</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_780" name="cvm:EarningPerShareBasicAndDiluted" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.42</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_781" name="cvm:EarningPerShareBasicAndDiluted" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.57</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_782" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">51,479,454</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_783" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">43,761,395</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cso2">CONDENSED STATEMENTS OF OPERATIONS</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED JUNE 30, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_784" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,703,160</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_785" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,727,789</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_786" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,967,075</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_787" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,453,968</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_788" name="us-gaap:OperatingExpenses" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,670,235</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_789" name="us-gaap:OperatingExpenses" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,181,757</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_790" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,670,235</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_791" name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,181,757</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_792" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">190,705</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_793" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">181,670</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income (expense)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_794" name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,382</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_795" name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,854</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_796" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,856,558</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_797" name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,367,281</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_798" name="cvm:ModificationOfWarrants" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">659,456</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_799" name="cvm:ModificationOfWarrants" contextRef="From2023-04-01to2023-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_800" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,516,014</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_801" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,367,281</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_802" name="cvm:EarningPerShareBasicAndDiluted" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.14</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_803" name="cvm:EarningPerShareBasicAndDiluted" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.19</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_804" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">53,994,384</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_805" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">44,254,363</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="equity">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid-In</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_806" name="us-gaap:SharesIssued" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">47,422,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1082" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_812" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_817" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">487,091,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_822" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,214,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_951" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_958" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">48,730</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1097" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1067" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">48,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_965" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">88,573</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_972" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">886</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">201,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1098" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1068" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">202,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_993" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,490,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1000" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,900</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,955,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1099" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1069" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,980,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_944" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1100" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1070" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1007" name="cvm:ShareIssuanceCosts" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1056" name="cvm:ShareIssuanceCosts" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">470,229</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1101" name="cvm:ShareIssuanceCosts" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1071" name="cvm:ShareIssuanceCosts" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">470,229</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_808" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_813" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_818" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_823" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT DECEMBER 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_826" name="us-gaap:SharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">50,018,601</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_827" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">500,186</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_832" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">505,950,994</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_837" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">493,800,920</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_842" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,650,260</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_952" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,373</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_959" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">274</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1057" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,211</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1102" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1072" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_966" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">162,744</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_973" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,627</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1058" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">379,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1103" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1073" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">380,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_994" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,875,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1001" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">38,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1059" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,711,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1104" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1074" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,750,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_945" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1060" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,432,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1105" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1075" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,432,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1008" name="cvm:ShareIssuanceCosts" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1061" name="cvm:ShareIssuanceCosts" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">717,621</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1106" name="cvm:ShareIssuanceCosts" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1076" name="cvm:ShareIssuanceCosts" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">717,621</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_828" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_833" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_838" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_843" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT MARCH 31 , 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_846" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,083,718</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_847" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">540,837</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_852" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">514,809,617</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_857" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">501,045,811</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_862" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,304,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_953" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">45,722</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_960" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">457</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1107" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1077" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,577</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_967" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">70,444</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_974" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1063" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">154,951</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1108" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1078" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">155,655</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1016" name="cvm:PurchaseOfStockByOfficersAndDirectorsSahres" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">58,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1023" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">580</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1064" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,040</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1109" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1079" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_946" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1065" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">728,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1110" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1080" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">728,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_848" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_853" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_858" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,856,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_863" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,856,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT JUNE 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_849" name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,257,884</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_850" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">542,578</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_855" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">515,832,848</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_860" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">507,902,369</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_865" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,473,057</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (continued)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid-In</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT SEPTEMBER 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_866" name="us-gaap:SharesIssued" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">43,448,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">434,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_872" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">486,625,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_877" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">454,897,093</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_882" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,163,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_926" name="cvm:WarrantExercisesShares" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_933" name="cvm:WarrantExercisesAmount" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1024" name="cvm:WarrantExercisesAmount" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">445,114</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1083" name="cvm:WarrantExercisesAmount" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" name="cvm:WarrantExercisesAmount" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_940" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,703,931</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,703,931</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_947" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">21,331</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_954" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">213</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">49,965</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1085" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1040" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">50,178</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_961" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">40,236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_968" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">402</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,221</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1086" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1041" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,623</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2014 incentive stock forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_975" name="cvm:IncentiveStockForfeitedShares" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">2,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_982" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1028" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">11,080</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1042" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">11,100</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_868" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_873" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_878" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,853,509</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_883" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,853,509</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT DECEMBER 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_886" name="us-gaap:SharesIssued" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">43,725,636</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_887" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">437,256</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_892" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">488,904,967</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_897" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">462,750,602</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_902" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,591,621</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_941" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1029" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,743,288</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1088" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1043" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,743,288</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_948" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,627</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_955" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1030" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1044" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,865</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_962" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">38,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_969" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">386</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1031" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100,249</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1090" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1045" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_888" name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_893" name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_898" name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_903" name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT MARCH 31 , 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_906" name="us-gaap:SharesIssued" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">43,787,825</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_907" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">437,878</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_912" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">490,803,133</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_917" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">471,093,411</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_922" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,147,600</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_942" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1032" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,551,319</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1091" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,551,319</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_949" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,855</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_956" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">129</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1033" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,534</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1092" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1047" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,663</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_963" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">36,523</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_970" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">365</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1034" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">135,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1093" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1048" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">135,669</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_991" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">913,234</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_998" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,132</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,543,365</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1094" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,552,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2014 Incentive Stock Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_977" name="cvm:IncentiveStockForfeitedShares" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">2,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_984" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1036" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">11,080</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1095" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1050" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">11,100</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1005" name="cvm:ShareIssuanceCosts" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1037" name="cvm:ShareIssuanceCosts" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">271,968</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1096" name="cvm:ShareIssuanceCosts" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1051" name="cvm:ShareIssuanceCosts" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">271,968</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_908" name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_913" name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_918" name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,367,281</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_923" name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,367,281</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT JUNE 30 , 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_909" name="us-gaap:SharesIssued" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">44,748,437</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_910" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,484</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_915" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">493,802,607</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_920" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">479,460,692</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_925" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,789,399</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cf">CONDENSED STATEMENTS OF CASH FLOWS</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NINE MONTHS ENDED JUNE 30, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1112" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,810,973</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1113" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,563,599</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1115" name="us-gaap:DepreciationAndAmortization" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,977,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1116" name="us-gaap:DepreciationAndAmortization" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,959,681</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1117" name="us-gaap:OtherNoncashExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,008</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1118" name="us-gaap:OtherNoncashExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1119" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">778,571</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1120" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">473,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1121" name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,544,569</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1122" name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,976,338</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan (Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1123" name="cvm:CommonStockContributedToEmployeeBenefitPlan" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">162,969</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1124" name="cvm:CommonStockContributedToEmployeeBenefitPlan" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">157,706</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:10pt">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1125" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,708</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">)&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1126" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">208,419</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:10pt">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1127" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">304,097</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1128" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,491</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:10pt">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1129" name="us-gaap:IncreaseDecreaseInDeposits" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">46,884</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1130" name="us-gaap:IncreaseDecreaseInDeposits" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,342,951</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:10pt">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1132" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">592,370</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1133" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">66,616</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:10pt">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1134" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">167,568</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1135" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">243,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:10pt">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1136" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">139,243</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1137" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">28,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1138" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">13,994,502</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1139" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">17,803,797</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1141" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">75,122</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1142" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">361,892</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1143" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,211</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1144" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-10-01to2023-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1145" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">88,333</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1146" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">361,892</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1148" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,730,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1149" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,552,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1150" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,173,577</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1151" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">213,796</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from the purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1152" name="us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">80,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1153" name="us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders" contextRef="From2022-10-01to2023-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from the exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1154" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-10-01to2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1155" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1156" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,315,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1157" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,157,371</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1158" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,321,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1159" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">628,621</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET DECREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1160" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,761,083</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1161" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">17,537,068</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1162" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1163" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,672,138</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1164" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">384,652</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1165" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,135,070</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NINE MONTHS ENDED JUNE 30, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets purchased under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1167" name="cvm:AssetsPurchasedUnderFinanceLeases" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1168" name="cvm:AssetsPurchasedUnderFinanceLeases" contextRef="From2022-10-01to2023-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1169" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1170" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">927</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1171" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,770</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1172" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" contextRef="From2022-10-01to2023-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1173" name="cvm:ConsultingServicesPaidWithIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">738,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1174" name="cvm:ConsultingServicesPaidWithIssuanceOfCommonStock" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">327,927</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued consulting services to be paid with common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1175" name="cvm:AccruedConsultingServicesToBePaidWithCommonStock" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">110,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1176" name="cvm:AccruedConsultingServicesToBePaidWithCommonStock" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">110,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1177" name="cvm:FinancingCostsIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,975</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1178" name="cvm:FinancingCostsIncludedInCurrentLiabilities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">58,172</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1179" name="us-gaap:InterestPaidNet" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">706,517</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1180" name="us-gaap:InterestPaidNet" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">809,495</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="notes">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NINE MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1181" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true" continuedAt="cont_545fd2"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of June 30, 2024 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1189" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1190" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1191" name="us-gaap:InventoryPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1192" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1193" name="cvm:LeasesPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_545fd2" continuedAt="cont_dc6ffc"><ix:nonNumeric id="fid_1194" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1195" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1196" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1197" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_dc6ffc"><ix:nonNumeric id="fid_1198" name="cvm:ImpairmentOfLongLivedAssetsPolicyTextblock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1199" name="us-gaap:UseOfEstimates" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1200" name="cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>&#160;</em></p><ix:nonNumeric id="fid_1201" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, <em>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </em>(<em>&#8220;ASU 2023-07&#8221;</em>), which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, <em>Improvements to Income Tax Disclosures</em>, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1182" name="cvm:LiquidityDisclosureTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true" continuedAt="cont_899a82"><p style="font-size:10pt;font-family:times new roman;margin:0px">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_899a82"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1183" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true" continuedAt="cont_8810af"><p style="font-size:10pt;font-family:times new roman;margin:0px">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In February 2024, the Company sold <ix:nonFraction id="fid_374" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-02-29" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,875,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_375" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-02-29" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2</ix:nonFraction>.00 per share and received proceeds of approximately $<ix:nonFraction id="fid_377" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">7</ix:nonFraction>.0 million, net of issuance costs of approximately $<ix:nonFraction id="fid_378" name="cvm:NetofissuanceCosts" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.7</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the Company sold <ix:nonFraction id="fid_358" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-11-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,490,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_359" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-11-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.00</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_370" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">4.5</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_372" name="cvm:NetofissuanceCosts" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.5</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In April 2023, the Company sold <ix:nonFraction id="fid_640" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">794,117</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_645" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.70</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_648" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.4</ix:nonFraction> million. The Company granted the underwriters a 30-day option to purchase up to <ix:nonFraction id="fid_649" name="cvm:AdditionalPurchaseOfCommonStock" contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">119,117</ix:nonFraction> additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $<ix:nonFraction id="fid_651" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-05-01to2023-05-31_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">200,000</ix:nonFraction>. The Company incurred issuance costs of approximately $<ix:nonFraction id="fid_1213" name="cvm:IssuanceCostOfCommonStock" contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.2</ix:nonFraction> million related to this offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Underlying share information for equity compensation plans as of June 30, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1202" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_cvm_IncentiveStockBonusPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">138,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,787,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_cvm_StockBonusPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,283,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_us-gaap_StockCompensationPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">634,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">640,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_8810af" continuedAt="cont_b055f0"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;<span style="text-decoration:underline">Stock option activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1203" name="cvm:ScheduleOfStockOptionActivityTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true" continuedAt="cont_f47b22"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Nine months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_287" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,967,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">293,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_289" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">179,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,075</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_290" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">58,787</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_f47b22"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,964,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_285" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">240,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">57,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_286" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="-3" scale="3">13,383</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of <ix:nonFraction id="fid_652" name="cvm:StockOptionPlan" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">234,332</ix:nonFraction> stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $<ix:nonFraction id="fid_488" name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">260,000</ix:nonFraction> that was amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $<ix:nonFraction id="fid_653" name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">101,000</ix:nonFraction> as of March 31, 2024 was expensed during the three months ended June 30, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"><span style="text-decoration:underline">Share-Based Compensation Expense:</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1204" name="cvm:ScheduleOfCompensatingBalancesTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true" continuedAt="cont_31a31e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_295" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,544,569</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_334" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2022-10-01to2023-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,976,338</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-10-01to2024-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">600,841</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_337" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2022-10-01to2023-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">473,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_31a31e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_336" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">728,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_335" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-04-01to2023-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,540,219</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_338" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2024-04-01to2024-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">230,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_339" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-04-01to2023-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">188,001</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_b055f0" continuedAt="cont_077932"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at June 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1205" name="cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Warrant/</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Options</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>Shares Issuable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_299" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesNMember">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_308" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_316" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_325" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesNMember">8/18/2026</ix:nonNumeric>&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_300" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesUUMember">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_326" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesUUMember">6/30/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_301" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesXMember">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_318" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_327" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesXMember">7/13/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_302" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesYMember">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_311" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_319" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_328" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesYMember">8/15/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_303" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesMMMember">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_312" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_320" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_329" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesMMMember">6/22/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_304" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesNNMember">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_321" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_330" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesNNMember">7/24/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_305" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_314" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">234,009</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_322" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_331" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember">10/30/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_306" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_srt_MinimumMember_cvm_ConsultantsMember">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_307" name="cvm:IssueDate1" contextRef="From2023-10-01to2024-06-30_srt_MaximumMember_cvm_ConsultantsMember">9/2/2023</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_315" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2024-06-30_cvm_ConsultantsOptionMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">110,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"/><td class="ffcell" style="vertical-align:bottom;text-align:right;">$<ix:nonFraction id="fid_323" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_srt_MinimumMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.39</ix:nonFraction>- $<ix:nonFraction id="fid_324" name="cvm:ExercisePrice" contextRef="AsOf2024-06-30_cvm_ConsultantsOptionMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.18</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_332" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_srt_MinimumMember_cvm_ConsultantsMember">7/27/2027</ix:nonNumeric> - <ix:nonNumeric id="fid_333" name="cvm:ExpirationDate" contextRef="From2023-10-01to2024-06-30_srt_MaximumMember_cvm_ConsultantsMember">9/1/2028</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No warrants recorded as equity were exercised during the nine months ended June 30, 2024. The following warrants recorded as equity were exercised during the nine months ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1206" name="cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants Exercised</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_340" name="cvm:EquityWarrantsExercised" contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_343" name="cvm:EquityWarrantsExercisePrice" contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_345" name="cvm:ProceedsFromEquityWarrantsExercised" contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_341" name="cvm:EquityWarrantsExercised" contextRef="From2023-10-01to2024-06-30_cvm_SeriesSSMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_344" name="cvm:EquityWarrantsExercisePrice" contextRef="From2023-10-01to2024-06-30_cvm_SeriesSSMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_346" name="cvm:ProceedsFromEquityWarrantsExercised" contextRef="From2023-10-01to2024-06-30_cvm_SeriesSSMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">418,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_347" name="cvm:EquityWarrantsExercised" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_348" name="cvm:ProceedsFromEquityWarrantsExercised" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No warrants recorded as equity expired during the nine and three months ended June 30,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $<ix:nonFraction id="fid_350" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.24</ix:nonFraction>, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_654" name="cvm:IncrementalCostDeemedDividend" contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">659,455</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the nine and three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_349" name="cvm:IncrementalCostDeemedDividend" contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">172,000</ix:nonFraction>, which was recorded as a deemed dividend. The Series RR warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine months ended June 30, 2024 and 2023, the Company issued <ix:nonFraction id="fid_354" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">321,761</ix:nonFraction> and <ix:nonFraction id="fid_1212" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-10-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">115,321</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.84</ix:nonFraction> and $<ix:nonFraction id="fid_494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.45</ix:nonFraction> during the nine months ended June 30, 2024 and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company issued <ix:nonFraction id="fid_498" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-04-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">70,444</ix:nonFraction> and <ix:nonFraction id="fid_499" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-04-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">36,523</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_500" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.33</ix:nonFraction> and $<ix:nonFraction id="fid_501" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-04-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.41</ix:nonFraction> during the three months ended June 30, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No options were issued to a consultant during the nine months ended June 30, 2024. During the nine months ended June 30, 2023, <ix:nonFraction id="fid_656" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" contextRef="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,000</ix:nonFraction> options with an exercise price of $<ix:nonFraction id="fid_657" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsOtherMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">11.61</ix:nonFraction> issued to a consultant expired.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_077932"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $<ix:nonFraction id="fid_365" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">601,000</ix:nonFraction> and $<ix:nonFraction id="fid_502" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">474,000</ix:nonFraction>, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $<ix:nonFraction id="fid_503" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">231,000</ix:nonFraction> and $<ix:nonFraction id="fid_504" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-01to2023-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">188,000</ix:nonFraction>, respectively, relating to the share-based compensation under these consulting agreements. On June 30, 2024 and September 30, 2023, consulting fees of approximately $<ix:nonFraction id="fid_367" name="cvm:ConsultingFeesIncluedPrepaidExpenses" contextRef="AsOf2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">221,000</ix:nonFraction> and $<ix:nonFraction id="fid_353" name="cvm:ConsultingFeesIncluedPrepaidExpenses" contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">205,000</ix:nonFraction>, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1184" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine and three months ended June 30, 2024, certain officers and directors purchased <ix:nonFraction id="fid_662" name="cvm:PurchaseOfNewlyIssuedSharesByInsiders" contextRef="From2023-10-01to2024-06-30_cvm_OfficerandDirectorMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">58,000</ix:nonFraction> shares of restricted common stock at an aggregated fair market value of approximately $<ix:nonFraction id="fid_665" name="cvm:RestrictedCommonStockFairValue" contextRef="From2023-10-01to2024-06-30_cvm_OfficerandDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction>. No restricted shares of the Company&#8217;s common stock were purchased by related parties during the nine and three months ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_658" name="cvm:IncrementalCostDeemedDividend" contextRef="From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">659,455</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $<ix:nonFraction id="fid_379" name="cvm:IncrementalCostDeemedDividend" contextRef="From2023-10-01to2023-10-28_cvm_OfficerandDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">172,000</ix:nonFraction>, which was recorded as a deemed dividend.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1185" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true" continuedAt="cont_a0199e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"><em>Clinical Research Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $<ix:nonFraction id="fid_472" name="cvm:ClinicalServiceTrial" contextRef="From2023-10-01to2024-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">12</ix:nonFraction> million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $<ix:nonFraction id="fid_469" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">35.8</ix:nonFraction> million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_667" name="cvm:NetOfDiscount" contextRef="From2023-10-01to2024-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">11.9</ix:nonFraction> million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomed&#8217;s discount, approximately $<ix:nonFraction id="fid_668" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.1</ix:nonFraction> million for each period as research and development expense related to Ergomed&#8217;s services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Egromed&#8217;s services and during three months ended June 30, 2023, the Company recorded, net of Ergomed&#8217;s discount, less than $<ix:nonFraction id="fid_671" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-04-01to2023-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.1</ix:nonFraction> million as research and development expense related to Ergomed&#8217;s services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at <ix:nonFraction id="fid_466" name="cvm:AnnualIncreaseToInterestPayments" contextRef="AsOf2023-12-31" unitRef="Pure" decimals="INF" scale="-2">3</ix:nonFraction>%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company&#8217;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $<ix:nonFraction id="fid_674" name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">2</ix:nonFraction>.0 and $<ix:nonFraction id="fid_675" name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2022-10-01to2023-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.9</ix:nonFraction> million, respectively, of which approximately $<ix:nonFraction id="fid_459" name="us-gaap:InterestPaid" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.7</ix:nonFraction> and $<ix:nonFraction id="fid_486" name="us-gaap:InterestPaid" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.8</ix:nonFraction> million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_484" name="cvm:AnnualIncreaseToInterestPayments" contextRef="AsOf2024-06-30" unitRef="Pure" decimals="INF" scale="-2">8.46</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_485" name="cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne" contextRef="From2024-04-01to2024-06-30" format="ixt-sec:duryear">4.34</ix:nonNumeric> years.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_a0199e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_473" name="cvm:FinancingArrangementDepositBaseRentAmount" contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.3</ix:nonFraction> million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1207" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_432" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">666,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_433" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,747,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_434" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,838,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_435" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,929,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_436" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,021,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_437" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">255,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_439" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,456,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_440" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,029,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,427,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_442" name="cvm:FinanceLeaseLiabilityCurrentPortion" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,949,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_443" name="cvm:FinanceLeaseLiabilityNoncurrentPortion" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,478,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $<ix:nonFraction id="fid_465" name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.3</ix:nonFraction> million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $<ix:nonFraction id="fid_673" name="us-gaap:OperatingLeaseExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.3</ix:nonFraction> million for each period. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_505" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-06-30" unitRef="Pure" decimals="INF" scale="-2">10.19</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_467" name="cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:duryear">7.16</ix:nonNumeric> years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1208" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_444" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">90,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_445" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_446" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_447" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_448" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_449" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">294,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_450" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">746,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_451" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,345,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_452" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">640,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_453" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,705,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_454" name="cvm:OperatingLeaseLiabilityCurrentPortion" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">219,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_455" name="cvm:OperatingLeaseLiabilityNoncurrentPortion" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,486,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1186" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">During the nine and three months ended June 30, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents is approximately <ix:nonNumeric id="fid_424" name="cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" contextRef="From2023-10-01to2024-06-30" format="ixt-sec:duryear">8</ix:nonNumeric> years. For the nine months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_422" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,000</ix:nonFraction> and $<ix:nonFraction id="fid_426" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,000</ix:nonFraction>, respectively. For the three months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_430" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,000</ix:nonFraction> and $<ix:nonFraction id="fid_431" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,000</ix:nonFraction>, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1209" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_412" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_413" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_414" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_415" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_416" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">19,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_417" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_418" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_419" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">173,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1187" name="us-gaap:EarningsPerShareTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1210" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_390" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,470,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_403" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">24,735,151</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_406" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,516,014</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_407" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,367,281</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_392" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">51,479,454</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_404" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">43,761,395</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">53,994,384</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_410" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">44,254,363</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_394" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.42</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_405" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.57</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_409" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.14</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_411" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.19</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30 :</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1211" name="cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-06-30_cvm_OptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,497,453</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_397" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-06-30_cvm_OptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">13,824,365</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_398" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_399" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-06-30_cvm_UnvestedRestrictedStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_401" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,644,703</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_402" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">13,971,615</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1188" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2023-10-01to2024-06-30" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">On July 11, 2024, Geert Kersten, the Company&#8217;s Chief Executive Officer and a director, loaned the Company $<ix:nonFraction id="fid_1214" name="us-gaap:LoansAndLeasesReceivableRelatedParties" contextRef="AsOf2024-07-11_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">200,000</ix:nonFraction>.&#160;&#160;On July 18, 2024, Mr. Kersten loaned the Company an additional $<ix:nonFraction id="fid_1215" name="us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions" contextRef="From2024-07-01to2024-07-18_us-gaap_SubsequentEventMember_cvm_MrKerstenMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">250,000</ix:nonFraction>.&#160;&#160;These amounts were repaid on July 30, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">On July 29, 2024, the Company sold <ix:nonFraction id="fid_676" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,715,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction id="fid_677" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-29_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.00</ix:nonFraction> per share, and pre-funded warrants to purchase up to <ix:nonFraction id="fid_679" name="cvm:WarrantsToPurchaseCommonStock" contextRef="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,130,000</ix:nonFraction> shares of common stock, at an offering price of $<ix:nonFraction id="fid_680" name="cvm:WarrantsOfferingPrice" contextRef="AsOf2024-07-29_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.99</ix:nonFraction> per pre-funded warrant, for gross proceeds of approximately $<ix:nonFraction id="fid_678" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">10.8</ix:nonFraction> million. </p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i2">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Company Overview&#160;and Product Candidates</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"/><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td/><td/><td/></tr><tr style="height:15px"><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A recent Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (<span style="text-decoration:underline">https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</span>)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis, before any other treatment including surgery</span>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&#160; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&#160; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, this accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET imaging)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS&lt;10) (via biopsy)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50). While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, we believe the large majority of patients in this group having low PD-L1 would still be expected to need Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI believes Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span></em></strong><strong><em> </em></strong>versus the control;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), and the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference On Head And Neck Oncology (ECHNO) and the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and 2023 American Head and Neck Society (AHNS). These publications can be accessed at <span style="text-decoration:underline">http://www.cel-sci.com.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine</span></strong><strong><span style="text-decoration:underline"> works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine causes pre-surgical responses;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-surgical responses lead to longer life;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.&#160; These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg8.jpg" alt="cvm_10qimg8.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&#160; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg9.jpg" alt="cvm_10qimg9.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group, at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg10.jpg" alt="cvm_10qimg10.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg11.jpg" alt="cvm_10qimg11.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; (the upper limit of the 95% confidence interval - for the hazard ration - in this case) is still below (better) than the hazard ratio required for most drug approvals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&#160; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&#160; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg15.jpg" alt="cvm_10qimg15.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg12.jpg" alt="cvm_10qimg12.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.&#160; CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, this accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg13.jpg" alt="cvm_10qimg13.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone. CEL-SCI expects to commence enrollment in Q4 2024 / Q1 2025&#160;and reach full enrollment in Q2 2026.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful?</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg14.jpg" alt="cvm_10qimg14.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies, but Multikine can meet the need for improved survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has shown to be safe. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IN CONCLUSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strong survival data</strong>: Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit of 0.66.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Addressing an unmet medical need</strong>: Multikine focuses on the 70% of patients not well served by the two leading approved drugs for head and neck cancer, Keytruda and Opdivo. Multikine&#8217;s proposed indication is a pre-surgical treatment in head &amp; neck cancer, where no drug is currently approved.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Multikine&#8217;s Target Population</strong>: The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FDA pathway</strong>: CEL-SCI is aiming to begin enrollment for a 212-patient confirmatory registration study in Q4 2024 / Q1 2025&#160;with full enrollment expected about Q2 2026. Potential to seek early approval after full enrollment.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Liquidity and Capital Resources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company&#8217;s capital requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, the construction and upgrade of the Company&#8217;s manufacturing and laboratory facilities and clinical trials. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Company&#8217;s liquidity and capital requirements and anticipates having to do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The cost of the confirmatory registration study is estimated to be about $30 million. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &#160;However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the completed Phase 3 study where it performed clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Approximately $11.9 million of the committed $12 million contribution has been realized as of June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, the Company&#8217;s cash decreased by approximately $3.8 million. Significant components of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $13.9 million and approximately $1.3 million in payments on finance lease obligations offset by net proceeds from the November 2023 and February 2024 financing of $11.4 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30 , 2023, the Company&#8217;s cash decreased by approximately $17.5 million. The significant component of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $17.8 million, which includes the approximate $2.3 million deposit made to the Company&#8217;s landlord as a result of falling below certain cash requirements per the San Tomas lease. Other components of this decrease include approximately $0.4 million used to make leasehold improvements and acquire research and development equipment, and approximately $1.2 million in payments on the Company&#8217;s finance leases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, no warrants were exercised. During the nine months ended June 30 , 2023, 217,752 warrants were exercised at a weighted average exercise price of $2.05 for total proceeds of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Results of Operations and Financial Condition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred a net operating loss of approximately $20.2 million for the nine months ended June 30, 2024. This net operating loss consists of significant non-cash expenses including approximately $4.1 million in share-based compensation to employees and non-employees, and approximately $3.0 million in depreciation and amortization expense. The Company incurred a net operating loss of approximately $6.7 million for the three months ended June 30, 2024. This net operating loss consists of significant non-cash expenses including approximately $1.0 million in share-based compensation to employees and non-employees, and approximately $1.0 million in depreciation and amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, research and development expenses decreased by approximately $3.5 million, or 20%, compared to the nine months ended June 30 , 2023. Major components of this decrease include an approximately $2.4 million decrease in expenses related to the Phase 3 study, a decrease of approximately $1.1 million of employee stock compensation expense and an approximately $0.1 million decrease in other research and development costs which is offset by $0.1 million increase in costs incurred to prepare for the potential commercial sale of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended June 30, 2024, research and development expenses decreased by approximately $1.0 million, or 18%, compared to the three months ended June 30 , 2023. Major components of this decrease include an approximately $0.9 million decrease in expenses related to the Phase 3 study, a decrease of approximately $0.5 million of employee stock compensation expense which is offset by $0.4 million increase in costs incurred to prepare for the confirmatory Registration Study and potential commercial sale of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, general and administrative expenses decreased by approximately $0.3 million, or 4%, compared to the nine months ended June 30 , 2023. This decrease is primarily due to an approximately $0.5 million decrease in consulting fees and a decrease of approximately $0.4 million of employee stock compensation expense, which is offset by increase of approximately $0.6 million in other general and administrative costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended June 30, 2024, general and administrative expenses decreased by approximately $0.5 million, or 20%, compared to the three months ended June 30 , 2023. This decrease is primarily due to an approximately $0.3 million decrease in consulting fees, an decrease of approximately $0.4 million of employee stock compensation expense which is offset by net&#160; increase of approximately $0.2 million in other general and administrative expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, net interest expense increased by approximately $0.1 million compared to the nine months ended June 30, 2023. While the amount of interest paid on the Company&#8217;s lease liabilities are approximately $0.7 million and $0.8 million for the nine months ended June 30, 2024 and 2023, the Company earned approximately $0.2 million less in interest income during the nine months ended June 30, 2024 compared to the nine months ended June 30, 2023. Net interest expense, which consists primarily of interest paid on lease liabilities, are approximately $0.2 for both the three months ended June 30, 2024 and June 30 , 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">MULTIKINE</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,615,922</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,919,843</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,681,127</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,661,214</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">68,282</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">283,980</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,033</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">66,575</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,684,204</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,203,823</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,703,160</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,727,789</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Critical Accounting Estimates</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management&#8217;s discussion and analysis of the Company&#8217;s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company believes some of the more critical estimates that affect its financial condition and results of operations are in the areas of leases and share-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. The fair value of the stock options is calculated using the Black-Scholes option pricing model which requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For more information regarding the Company&#8217;s critical accounting estimates, see Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023. The application of these critical accounting estimates has been discussed with the Audit Committee of the Company&#8217;s Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i3">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not believe that it has any significant exposure to market risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i4">Item 4. CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Under the direction and with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2024. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company&#8217;s Chief Executive Officer and Chief Financial Officer has concluded that the Company&#8217;s disclosure controls and procedures were not effective as of June 30, 2024 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no changes in the Company&#8217;s internal control over financial reporting that occurred during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="p2i2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, the Company issued 321,761 restricted shares of common stock to consultants for investor relations services and clinical drug and corporate development.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company&#8217;s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i5">Item 5. Other Information</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span class="atag" style="display: inline" id="p2i6"><strong>Item 6.</strong> <strong>Exhibits</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Number </strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: &#160;August 14, 2024</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:&#160;&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&#160; Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Executive Officer*&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Also signing in the capacity of the Principal Accounting and Financial Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATIONS
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong><strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">Date: August 14, 2024</p></td> <td style="width:3%;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Geert Kersten</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Principal Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">Date: August 14, 2024</p></td> <td style="width:3%;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Geert Kersten</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Principal Financial Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATIONS
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 32</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In connection with the Quarterly Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Principal Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="margin:0px">By: </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;">/s/ Geert Kersten</td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Geert Kersten</td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Principal Executive and</td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Principal Financial Officer</td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: August 14, 2024</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvm-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cvm="http://cvm.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20240630">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" id="StatementsOfStockholdersEquityUnaudited">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000009 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000010 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShare" id="LossPerCommonShare">
        <link:definition>000013 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000018 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareTables" id="LossPerCommonShareTables">
        <link:definition>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000020 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000030 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000031 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails" id="LossPerCommonShareDetails">
        <link:definition>000032 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails1" id="LossPerCommonShareDetails1">
        <link:definition>000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingCurrent" name="SuppliesUsedForRDAndManufacturingCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" name="SuppliesUsedForRDAndManufacturingNonCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DueToEmployeeCurrent" name="DueToEmployeeCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EarningPerShareBasicAndDiluted" name="EarningPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedShares" name="IncentiveStockForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedAmount" name="IncentiveStockForfeitedAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfStockByOfficersAndDirectorsSahres" name="PurchaseOfStockByOfficersAndDirectorsSahres" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" name="PurchaseOfStockByOfficersAndDirectorsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AssetsPurchasedUnderFinanceLeases" name="AssetsPurchasedUnderFinanceLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" name="PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" name="ConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccruedConsultingServicesToBePaidWithCommonStock" name="AccruedConsultingServicesToBePaidWithCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInCurrentLiabilities" name="FinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" name="ImpairmentOfLongLivedAssetsPolicyTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" name="NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfStockOptionActivityTableTextBlock" name="ScheduleOfStockOptionActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfCompensatingBalancesTableTextBlock" name="ScheduleOfCompensatingBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" name="ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" name="ScheduleOfDerivativeLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" name="ScheduleOfAntiDilutiveSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfWarrantOptions" name="SharesIssuableUponExerciseOfWarrantOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercised" name="EquityWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercisePrice" name="EquityWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromEquityWarrantsExercised" name="ProceedsFromEquityWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalCostDeemedDividend" name="IncrementalCostDeemedDividend" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingFeesIncluedPrepaidExpenses" name="ConsultingFeesIncluedPrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssuanceCostOfCommonStock" name="IssuanceCostOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetofissuanceCosts" name="NetofissuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdditionalPurchaseOfCommonStock" name="AdditionalPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockOptionPlan" name="StockOptionPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfNewlyIssuedSharesByInsiders" name="PurchaseOfNewlyIssuedSharesByInsiders" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RestrictedCommonStockFairValue" name="RestrictedCommonStockFairValue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityCurrentPortion" name="FinanceLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityNoncurrentPortion" name="FinanceLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityCurrentPortion" name="OperatingLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityNoncurrentPortion" name="OperatingLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetOfDiscount" name="NetOfDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AnnualIncreaseToInterestPayments" name="AnnualIncreaseToInterestPayments" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" name="OperatingLeaseWeightedAverageRemainingLeaseTermOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ClinicalServiceTrial" name="ClinicalServiceTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingArrangementDepositBaseRentAmount" name="FinancingArrangementDepositBaseRentAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" name="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" name="WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" name="IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsOfferingPrice" name="WarrantsOfferingPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsToPurchaseCommonStock" name="WarrantsToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlanMember" id="cvm_IncentiveStockBonusPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MrKerstenMember" id="cvm_MrKerstenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlansMember" id="cvm_IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOptionMember" id="cvm_ConsultantsOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityProceedsFromSaleCommonStockMember" id="cvm_EquityProceedsFromSaleCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsOtherMember" id="cvm_ConsultingAgreementsOtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OfficerandDirectorMember" id="cvm_OfficerandDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonEmployeesMember" id="cvm_NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvm-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_8a97a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_8a97a8" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_0bf1a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_0bf1a4" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1d94f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1d94f3" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_ce4710" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_ce4710" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_8ee743" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_8ee743" xml:lang="en-US">Supplie used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_951f27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_951f27" xml:lang="en-US">Deposits current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_ec0cfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_ec0cfb" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_4a759e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_4a759e" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_757285" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_757285" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_bec7f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_bec7f9" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_310f0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_310f0e" xml:lang="en-US">Patent costs, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_fece3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_fece3e" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_f5b34b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_f5b34b" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_1e66ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_1e66ab" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_14" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_4a5353" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_4a5353" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_2ec387" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_2ec387" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_bbc56a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_bbc56a" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_bc4d90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_bc4d90" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_DueToEmployeeCurrent" xlink:label="cvm_DueToEmployeeCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DueToEmployeeCurrent" xlink:to="cvm_DueToEmployeeCurrent_lbl_f762d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DueToEmployeeCurrent_lbl_f762d8" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_0c7cc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_0c7cc4" xml:lang="en-US">Finance lease obligation, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_7d801d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_7d801d" xml:lang="en-US">Operating lease obligation, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_730dea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_730dea" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_22" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_aa23ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_aa23ea" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_6e9935" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_6e9935" xml:lang="en-US">Operating lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_efcd3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_efcd3e" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_29c85c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_29c85c" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_26" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_804be6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_804be6" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_410c8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_410c8d" xml:lang="en-US">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_9fe456" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_9fe456" xml:lang="en-US">Common stock, $.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_80c9ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_80c9ea" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_6155f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_6155f4" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_483743" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_483743" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_32" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_c72b49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_c72b49" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_20671d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_20671d" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_614cba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_614cba" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_d1af16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_d1af16" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_2048e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_2048e9" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_b05285" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_b05285" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_b20915" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_b20915" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_3cac2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_3cac2a" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_6cc3c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_6cc3c8" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_b26126" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_b26126" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_744d41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_744d41" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_5a3110" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_5a3110" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_29ffd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_29ffd4" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_cafe6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_cafe6d" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_8d6248" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_8d6248" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_094cc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_094cc8" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_a49050" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_a49050" xml:lang="en-US">Other expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_8" xml:lang="en-US">[Other Nonoperating Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_43d8c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_43d8c6" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_9" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_110c41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_110c41" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_c49830" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_c49830" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_11" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="cvm_EarningPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EarningPerShareBasicAndDiluted" xlink:to="cvm_EarningPerShareBasicAndDiluted_lbl_300dd9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EarningPerShareBasicAndDiluted_lbl_300dd9" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:to="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_537445" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_537445" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_c30cfd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_c30cfd" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_5bba5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_5bba5b" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_68372a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_68372a" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_af3217" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_af3217" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_6b1258" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_6b1258" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_bc45c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_bc45c3" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_9838d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_9838d5" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_748e70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_748e70" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_915f0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_915f0a" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantExercisesShares" xlink:label="cvm_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesShares" xlink:to="cvm_WarrantExercisesShares_lbl_669c1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesShares_lbl_669c1c" xml:lang="en-US">Warrant exercises shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantExercisesAmount" xlink:label="cvm_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesAmount" xlink:to="cvm_WarrantExercisesAmount_lbl_b9359e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesAmount_lbl_b9359e" xml:lang="en-US">Warrant exercises amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_33df74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_33df74" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_ff5573" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_ff5573" xml:lang="en-US">401(k) contributions paid in common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_43c01d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_43c01d" xml:lang="en-US">401(k) contributions paid in common stock amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_a804c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_a804c3" xml:lang="en-US">Stock issued to nonemployees for service shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_b19c68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_b19c68" xml:lang="en-US">Stock issued to nonemployees for service amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="cvm_IncentiveStockForfeitedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedShares" xlink:to="cvm_IncentiveStockForfeitedShares_lbl_4ac9bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedShares_lbl_4ac9bc" xml:lang="en-US">2014 incentive stock forfeited shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="cvm_IncentiveStockForfeitedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedAmount" xlink:to="cvm_IncentiveStockForfeitedAmount_lbl_e895e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedAmount_lbl_e895e6" xml:lang="en-US">2014 incentive stock forfeited amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_226b3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_226b3f" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_501383" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_501383" xml:lang="en-US">Proceeds from the sale of common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_8e25f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_8e25f0" xml:lang="en-US">Proceeds from the sale of common stock amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ShareIssuanceCosts" xlink:label="cvm_ShareIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_lbl_c5b274" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareIssuanceCosts_lbl_c5b274" xml:lang="en-US">Share issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsSahres" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsSahres" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfStockByOfficersAndDirectorsSahres" xlink:to="cvm_PurchaseOfStockByOfficersAndDirectorsSahres_lbl_cf00a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsSahres_lbl_cf00a3" xml:lang="en-US">Purchase of stock by officers and directors sahres</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:to="cvm_PurchaseOfStockByOfficersAndDirectorsAmount_lbl_319f8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsAmount_lbl_319f8f" xml:lang="en-US">Purchase of stock by officers and directors amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_79ac94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_79ac94" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_da65dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_da65dd" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_c5e67a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_c5e67a" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_39a1e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl_39a1e8" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_2" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_60ef2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_60ef2f" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_e85427" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_e85427" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_5949ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_5949ef" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_9b0099" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_9b0099" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_254596" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_254596" xml:lang="en-US">Equity-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_502f41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_502f41" xml:lang="en-US">Common stock contributed to 401(k) plan (Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_67678d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_67678d" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_9" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_7a22c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_7a22c3" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_10" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl_cf3ecd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl_cf3ecd" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl_11" xml:lang="en-US">[Increase (Decrease) in Deposits]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_2d9a9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_2d9a9c" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_6707b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_6707b3" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_13" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_19b65d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_19b65d" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_14" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_0b8d4e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_0b8d4e" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_15" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_d70e88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_d70e88" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_16" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_f5bb81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_f5bb81" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_172891" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_172891" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_18" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_c82e46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_c82e46" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_19" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_c1d9cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_c1d9cd" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_20" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_716a2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_716a2d" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_1cc744" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_1cc744" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_c7b0ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_c7b0ad" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_23" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders_lbl_f7914e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders_lbl_f7914e" xml:lang="en-US">Proceeds from the purchase of stock by officers and directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders_lbl_24" xml:lang="en-US">[Increase (Decrease) Due from Officers and Stockholders]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_ee15e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_ee15e2" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_76469c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_76469c" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_8a4fb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_8a4fb4" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_975023" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_975023" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_cf74de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_cf74de" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_3da877" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_3da877" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_81d646" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_81d646" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AssetsPurchasedUnderFinanceLeases" xlink:label="cvm_AssetsPurchasedUnderFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AssetsPurchasedUnderFinanceLeases" xlink:to="cvm_AssetsPurchasedUnderFinanceLeases_lbl_066b2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AssetsPurchasedUnderFinanceLeases_lbl_066b2b" xml:lang="en-US">Assets purchased under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_54d613" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_54d613" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:to="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_db1cf1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_db1cf1" xml:lang="en-US">Property and equipment included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock_lbl_4b1cfd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock_lbl_4b1cfd" xml:lang="en-US">Consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:label="cvm_AccruedConsultingServicesToBePaidWithCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:to="cvm_AccruedConsultingServicesToBePaidWithCommonStock_lbl_b1f42f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccruedConsultingServicesToBePaidWithCommonStock_lbl_b1f42f" xml:lang="en-US">Accrued consulting services to be paid with common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_2b6add" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_2b6add" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_74cf58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_74cf58" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_4c4f3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_4c4f3a" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_0d6619" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_0d6619" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_ee757e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_ee757e" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_d10fd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_d10fd4" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="cvm_LiquidityDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_aceac5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_aceac5" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_c3e378" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_c3e378" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_4947b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_4947b1" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_852385" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_852385" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="cvm_CommitmentsAndContingenciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommitmentsAndContingenciesAbstract" xlink:to="cvm_CommitmentsAndContingenciesAbstract_lbl_1a4e05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommitmentsAndContingenciesAbstract_lbl_1a4e05" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_c808d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_c808d0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_e2bbc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_e2bbc7" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_774f07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_774f07" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_ccaf9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_ccaf9c" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_142dd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_142dd8" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_7febb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_7febb3" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_3967b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_3967b9" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_b2c260" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_b2c260" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c8dcf2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c8dcf2" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_385778" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_385778" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_2c75f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_2c75f6" xml:lang="en-US">Supplies used for R&amp;amp;amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_9ea358" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_9ea358" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_5d8321" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_5d8321" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_3cda21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_3cda21" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_48236c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_48236c" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_80e081" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_80e081" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_fd5bc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_fd5bc2" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:to="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_e108e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_e108e3" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_c0bf06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_c0bf06" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:label="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:to="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock_lbl_66a938" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock_lbl_66a938" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f184ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f184ac" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_a274c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_a274c8" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_1bc47b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_1bc47b" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_bb7f2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_bb7f2f" xml:lang="en-US">Schedule of equity compensation plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:to="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_e878a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_e878a5" xml:lang="en-US">Schedule of Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:to="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_5fa9c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_5fa9c4" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_cc125b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_cc125b" xml:lang="en-US">Schedule of warrants and non-employee options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:to="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock_lbl_a86023" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock_lbl_a86023" xml:lang="en-US">Schedule of derivative liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_c5ac94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_c5ac94" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_aab766" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_aab766" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:to="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_d44e07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_d44e07" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_934e42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_934e42" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_c6e13e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_c6e13e" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="cvm_IncentiveStockBonusPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_22" xml:lang="en-US">[Incentive Stock Bonus Plan [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_f45e15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_f45e15" xml:lang="en-US">Non-Qualified Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_e53630" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_e53630" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl_d5f111" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl_d5f111" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="cvm_IncentiveStockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlansMember" xlink:to="cvm_IncentiveStockBonusPlansMember_lbl_f55b4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlansMember_lbl_f55b4a" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_3cdc7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_3cdc7d" xml:lang="en-US">Remaining Options/shares Under Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_21ce5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_21ce5b" xml:lang="en-US">Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_b29eff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_b29eff" xml:lang="en-US">Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_74ea67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_74ea67" xml:lang="en-US">Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_37e38a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_37e38a" xml:lang="en-US">Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_dd54ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_dd54ef" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl_308365" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl_308365" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NonEmployeesMember" xlink:label="cvm_NonEmployeesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonEmployeesMember" xlink:to="cvm_NonEmployeesMember_lbl_d3bd76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonEmployeesMember_lbl_d3bd76" xml:lang="en-US">Non-employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_2eb1c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_2eb1c8" xml:lang="en-US">Stock Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_eb11cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_eb11cb" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_02885c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_02885c" xml:lang="en-US">Range Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_215897" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_215897" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_ba7c63" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_ba7c63" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_73b1a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_73b1a2" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_cef5c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_cef5c4" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_351593" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_351593" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_c1f2d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_c1f2d3" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_211a7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_211a7f" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_025682" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_025682" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_b4ccef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_b4ccef" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_dd4a6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_dd4a6b" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_e4eec7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_e4eec7" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsOptionMember" xlink:label="cvm_ConsultantsOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOptionMember" xlink:to="cvm_ConsultantsOptionMember_lbl_30064d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOptionMember_lbl_30064d" xml:lang="en-US">Consultants Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IssueDate1" xlink:label="cvm_IssueDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssueDate1" xlink:to="cvm_IssueDate1_lbl_561b57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssueDate1_lbl_561b57" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:to="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_1bd5dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_1bd5dc" xml:lang="en-US">Shares Issuable Upon Exercise Of Warrant/options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_6a6dc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_6a6dc9" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ExpirationDate" xlink:label="cvm_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_b2b5ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate_lbl_b2b5ee" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_d46bec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_d46bec" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityWarrantsExercised" xlink:label="cvm_EquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_6abf26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercised_lbl_6abf26" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="cvm_EquityWarrantsExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercisePrice" xlink:to="cvm_EquityWarrantsExercisePrice_lbl_282c18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercisePrice_lbl_282c18" xml:lang="en-US">Equity Warrants Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="cvm_ProceedsFromEquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromEquityWarrantsExercised" xlink:to="cvm_ProceedsFromEquityWarrantsExercised_lbl_490cef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromEquityWarrantsExercised_lbl_490cef" xml:lang="en-US">Proceeds From Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl_769a8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl_769a8d" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_732d94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_732d94" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_06ea8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_06ea8f" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityProceedsFromSaleCommonStockMember" xlink:label="cvm_EquityProceedsFromSaleCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityProceedsFromSaleCommonStockMember" xlink:to="cvm_EquityProceedsFromSaleCommonStockMember_lbl_527f58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityProceedsFromSaleCommonStockMember_lbl_527f58" xml:lang="en-US">Common Stock sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_4ffe83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_4ffe83" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_949bbd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_949bbd" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_cd931c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_cd931c" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="cvm_ConsultingAgreementsOtherMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsOtherMember" xlink:to="cvm_ConsultingAgreementsOtherMember_lbl_708d61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsOtherMember_lbl_708d61" xml:lang="en-US">Consulting Agreements Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="cvm_IncrementalCostDeemedDividend" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_ac7ecf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_ac7ecf" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_94ed88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_94ed88" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_c0f27d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_c0f27d" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:to="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_5f4c6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_5f4c6d" xml:lang="en-US">Consulting fees inclued prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_8eacf7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_8eacf7" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_fc47f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_fc47f1" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_ee0d2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_ee0d2b" xml:lang="en-US">Public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_189240" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_189240" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl_6332fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl_6332fa" xml:lang="en-US">Amortization cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IssuanceCostOfCommonStock" xlink:label="cvm_IssuanceCostOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssuanceCostOfCommonStock" xlink:to="cvm_IssuanceCostOfCommonStock_lbl_54dcad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssuanceCostOfCommonStock_lbl_54dcad" xml:lang="en-US">Issuance cost of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetofissuanceCosts" xlink:label="cvm_NetofissuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetofissuanceCosts" xlink:to="cvm_NetofissuanceCosts_lbl_db32e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetofissuanceCosts_lbl_db32e4" xml:lang="en-US">Net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_75a629" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_75a629" xml:lang="en-US">Sale of common stock at a public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AdditionalPurchaseOfCommonStock" xlink:label="cvm_AdditionalPurchaseOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdditionalPurchaseOfCommonStock" xlink:to="cvm_AdditionalPurchaseOfCommonStock_lbl_0557dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdditionalPurchaseOfCommonStock_lbl_0557dc" xml:lang="en-US">Additional purchase of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_StockOptionPlan" xlink:label="cvm_StockOptionPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockOptionPlan" xlink:to="cvm_StockOptionPlan_lbl_0ccbda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockOptionPlan_lbl_0ccbda" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_48605b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_48605b" xml:lang="en-US">Total expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OfficerandDirectorMember" xlink:label="cvm_OfficerandDirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OfficerandDirectorMember" xlink:to="cvm_OfficerandDirectorMember_lbl_1d135e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OfficerandDirectorMember_lbl_1d135e" xml:lang="en-US">Officer And Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_192f8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_192f8d" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfNewlyIssuedSharesByInsiders" xlink:label="cvm_PurchaseOfNewlyIssuedSharesByInsiders" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfNewlyIssuedSharesByInsiders" xlink:to="cvm_PurchaseOfNewlyIssuedSharesByInsiders_lbl_8f4867" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfNewlyIssuedSharesByInsiders_lbl_8f4867" xml:lang="en-US">Purchase of newly issued shares by insiders</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_RestrictedCommonStockFairValue" xlink:label="cvm_RestrictedCommonStockFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedCommonStockFairValue" xlink:to="cvm_RestrictedCommonStockFairValue_lbl_674aee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedCommonStockFairValue_lbl_674aee" xml:lang="en-US">Purchase of restricted common stock fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_00589b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_00589b" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_ea7dd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_ea7dd7" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_6797ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_6797ba" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_a1bf98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_a1bf98" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_6f9dae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_6f9dae" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_cce33f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_cce33f" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_2af402" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_2af402" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_d98b3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_d98b3c" xml:lang="en-US">Less imputed interest on finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_949135" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_949135" xml:lang="en-US">Net present value of financing lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_abf6e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_abf6e1" xml:lang="en-US">Less net present value of financing lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_11" xml:lang="en-US">[Less net present value of financing lease obligations - current portion]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_7ffa36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_7ffa36" xml:lang="en-US">Net present value of financing lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_efab34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_efab34" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_51fcb2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_51fcb2" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_fee9bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_fee9bf" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_9effe0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_9effe0" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_54f82f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_54f82f" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_d684f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_d684f2" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_c23ccd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_c23ccd" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_70d728" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_70d728" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_6a9de5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_6a9de5" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_4f7504" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_4f7504" xml:lang="en-US">Net Present Value Of Operating Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_29af13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_29af13" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_12" xml:lang="en-US">[Net present value of lease finance lease obligations - current portion]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_87b60f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_87b60f" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_6537bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_6537bf" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_44f742" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_44f742" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_811912" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_811912" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_86a926" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_86a926" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl_2bd404" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl_2bd404" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetOfDiscount" xlink:label="cvm_NetOfDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetOfDiscount" xlink:to="cvm_NetOfDiscount_lbl_c382d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetOfDiscount_lbl_c382d3" xml:lang="en-US">Net Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_49e755" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl_49e755" xml:lang="en-US">Interest amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl_13a8f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl_13a8f7" xml:lang="en-US">Lease expense for operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl_59f938" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl_59f938" xml:lang="en-US">Total cash payment for oprating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="cvm_AnnualIncreaseToInterestPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AnnualIncreaseToInterestPayments" xlink:to="cvm_AnnualIncreaseToInterestPayments_lbl_fd7bff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AnnualIncreaseToInterestPayments_lbl_fd7bff" xml:lang="en-US">Annual increase to interest payments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:to="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne_lbl_bbc58e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne_lbl_bbc58e" xml:lang="en-US">Weighted average time of maturity of operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_e8d5e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_e8d5e9" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_686629" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_686629" xml:lang="en-US">Weighted average discount rate operating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ClinicalServiceTrial" xlink:label="cvm_ClinicalServiceTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ClinicalServiceTrial" xlink:to="cvm_ClinicalServiceTrial_lbl_731e0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ClinicalServiceTrial_lbl_731e0a" xml:lang="en-US">Clinical service trial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingArrangementDepositBaseRentAmount" xlink:to="cvm_FinancingArrangementDepositBaseRentAmount_lbl_24a79b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount_lbl_24a79b" xml:lang="en-US">Financing arrangement deposit base rent amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_236c72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_236c72" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_f46ef6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_f46ef6" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_37c5d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_37c5d6" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_a26e3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_a26e3a" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_69b96f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_69b96f" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_db1d2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_db1d2c" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_ea80b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_ea80b1" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xml:lang="en-US">[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_04333e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_04333e" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xml:lang="en-US">[Other Indefinite-Lived Intangible Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_4e330a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_4e330a" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:to="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_33f50e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_33f50e" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_29f7f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_29f7f7" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_f53897" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_f53897" xml:lang="en-US">Loss per share- basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:label="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:to="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl_750e0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl_750e0d" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:label="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:to="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares_lbl_acfa59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares_lbl_acfa59" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_054ac6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_054ac6" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_ccd010" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_ccd010" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_ef56ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_ef56ef" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_91bc46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_91bc46" xml:lang="en-US">Subsequent Event Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_767723" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_767723" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl_eef688" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl_eef688" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_MrKerstenMember" xlink:label="cvm_MrKerstenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_MrKerstenMember" xlink:to="cvm_MrKerstenMember_lbl_42c535" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_MrKerstenMember_lbl_42c535" xml:lang="en-US">Mr. Kersten [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_0fc5ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_0fc5ef" xml:lang="en-US">Public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_2" xml:lang="en-US">[Class of Warrant or Right, Exercise Price of Warrants or Rights]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantsOfferingPrice" xlink:label="cvm_WarrantsOfferingPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsOfferingPrice" xlink:to="cvm_WarrantsOfferingPrice_lbl_2ae24d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsOfferingPrice_lbl_2ae24d" xml:lang="en-US">Pre funded warrants offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_3e1536" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_3e1536" xml:lang="en-US">Sale of common stock at a public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_9979a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_9979a2" xml:lang="en-US">Proceeds from newly issued shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantsToPurchaseCommonStock" xlink:label="cvm_WarrantsToPurchaseCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsToPurchaseCommonStock" xlink:to="cvm_WarrantsToPurchaseCommonStock_lbl_e47465" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsToPurchaseCommonStock_lbl_e47465" xml:lang="en-US">Pre-funded warrants to purchase common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl_5058b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl_5058b0" xml:lang="en-US">Amount of loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions_lbl_a285a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions_lbl_a285a4" xml:lang="en-US">Additional loan amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ShareIssuanceCosts_d">Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvm-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20240630.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20240630.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20240630.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20240630.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20240630.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240630.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240630.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20240630.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240630.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20240630.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240630.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240630.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20240630.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20240630.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmDueToEmployeeCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseDueFromOfficersAndStockholders" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapIncreaseDecreaseDueFromOfficersAndStockholders" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cvm-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20240630.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20240630.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20240630.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20240630.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20240630.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240630.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240630.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20240630.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240630.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20240630.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240630.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240630.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20240630.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20240630.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_6d1123" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_10fa8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_6d1123" xlink:to="loc_us-gaapAssetsCurrentAbstract_10fa8a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99dc0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99dc0a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_4aca7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapPrepaidExpenseCurrent_4aca7c" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_6c1446" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_6c1446" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_2fbd1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapDepositsAssetsCurrent_2fbd1f" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70d84b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapAssetsCurrent_70d84b" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_04d2b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_04d2b5" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_bef0b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_bef0b6" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_39f610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_39f610" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_f182f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_f182f4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_f860e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_f860e9" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_3d739e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_3d739e" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_42c7ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapAssets_42c7ac" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_355ef5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_10fa8a" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_355ef5" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_355ef5" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_658f65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapAccountsPayableCurrent_658f65" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_303ca6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_303ca6" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent_55280b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_cvmDueToEmployeeCurrent_55280b" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_55c87c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_55c87c" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_4c3add" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_4c3add" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_36b077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapLiabilitiesCurrent_36b077" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_d0b983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_d0b983" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_e49892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_e49892" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_332ab9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_332ab9" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_8074c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapLiabilities_8074c1" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_53cd4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_b2cd80" xlink:to="loc_us-gaapStockholdersEquityAbstract_53cd4b" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_8c3713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_53cd4b" xlink:to="loc_us-gaapPreferredStockValue_8c3713" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_7c4e8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_53cd4b" xlink:to="loc_us-gaapCommonStockValue_7c4e8e" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_b1b32b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_53cd4b" xlink:to="loc_us-gaapAdditionalPaidInCapital_b1b32b" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_5f2415" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_53cd4b" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_5f2415" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_54e64f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_53cd4b" xlink:to="loc_us-gaapStockholdersEquity_54e64f" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_b2ff00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_53cd4b" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_b2ff00" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_1e03ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_1e03ed" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_4d28ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_4d28ad" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_f18b7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapPreferredStockSharesIssued_f18b7c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_3d957b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_3d957b" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_98a372" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_98a372" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_2eda0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapCommonStockSharesAuthorized_2eda0b" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_ddb932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapCommonStockSharesIssued_ddb932" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_211808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7c3abd" xlink:to="loc_us-gaapCommonStockSharesOutstanding_211808" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_65d124" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_1e22d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_65d124" xlink:to="loc_us-gaapOperatingExpensesAbstract_1e22d3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_ca5510" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_ca5510" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_c731a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_c731a4" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_d06bb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapOperatingExpenses_d06bb8" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_ffd162" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapOperatingIncomeLoss_ffd162" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_4c9a73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapInterestIncomeExpenseNet_4c9a73" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_891082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapOtherNonoperatingExpense_891082" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_c8cd28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapNetIncomeLoss_c8cd28" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_ff55f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_cvmModificationOfWarrants_ff55f5" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_5cba4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_5cba4d" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="loc_cvmEarningPerShareBasicAndDiluted_dffd4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_cvmEarningPerShareBasicAndDiluted_dffd4d" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_bc5099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_1e22d3" xlink:to="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_bc5099" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_b0b79a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3d1a07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_b0b79a" xlink:to="loc_us-gaapStatementTable_3d1a07" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_2aef26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3d1a07" xlink:to="loc_us-gaapStatementLineItems_2aef26" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_6e3b91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3d1a07" xlink:to="loc_us-gaapStatementEquityComponentsAxis_6e3b91" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_f86071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_6e3b91" xlink:to="loc_us-gaapEquityComponentDomain_f86071" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_3e470e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_f86071" xlink:to="loc_us-gaapCommonStockMember_3e470e" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_1d5987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_f86071" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_1d5987" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_d3ea64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_f86071" xlink:to="loc_us-gaapRetainedEarningsMember_d3ea64" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_408b19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapSharesIssued_408b19" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_600f71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockholdersEquity_600f71" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares_9eb399" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmWarrantExercisesShares_9eb399" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount_92f4d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmWarrantExercisesAmount_92f4d8" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_84c265" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_84c265" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_f05a67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_f05a67" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_7733cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_7733cb" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_d7f3b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_d7f3b9" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_4dd09c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_4dd09c" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares_2a8790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmIncentiveStockForfeitedShares_2a8790" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount_924d72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmIncentiveStockForfeitedAmount_924d72" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_7bbfbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapNetIncomeLoss_7bbfbe" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_6d983e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_6d983e" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_b8c5fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_b8c5fa" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts_4e7e22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmShareIssuanceCosts_4e7e22" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsSahres" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsSahres_30911a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsSahres_30911a" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount_13651e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount_13651e" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_670e23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapSharesIssued_670e23" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_23b73b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2aef26" xlink:to="loc_us-gaapStockholdersEquity_23b73b" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_31f8d8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_e961e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_31f8d8" xlink:to="loc_us-gaapProfitLoss_e961e3" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_31f8d8" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_8c147d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapDepreciationAndAmortization_8c147d" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_374aae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapOtherNoncashExpense_374aae" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_4cb4ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_4cb4ee" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_a69ea4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapShareBasedCompensation_a69ea4" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_2f265b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_2f265b" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_a42230" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_a42230" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_a9e91c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_a9e91c" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits_0cb4e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits_0cb4e7" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0b507" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_c2a2fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_c2a2fb" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_7faee4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_7faee4" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_02797f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_02797f" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_e71459" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_e71459" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8150ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_426d35" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8150ea" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_02c66d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8150ea" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_02c66d" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_7a8be1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8150ea" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_7a8be1" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_6bc765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8150ea" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_6bc765" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8150ea" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_c23a6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_c23a6d" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_a67df0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_a67df0" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseDueFromOfficersAndStockholders_74a379" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapIncreaseDecreaseDueFromOfficersAndStockholders_74a379" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_6c67ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapProceedsFromWarrantExercises_6c67ee" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_9b3a86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_9b3a86" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_475469" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_475469" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_adb425" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_adb425" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7275a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7275a0" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c44f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c44f3" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5d54a7" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AssetsPurchasedUnderFinanceLeases" xlink:label="loc_cvmAssetsPurchasedUnderFinanceLeases_18d301" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_cvmAssetsPurchasedUnderFinanceLeases_18d301" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_62ebc1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_62ebc1" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_fa3865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_fa3865" order="33" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmConsultingServicesPaidWithIssuanceOfCommonStock_4e5ee0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_cvmConsultingServicesPaidWithIssuanceOfCommonStock_4e5ee0" order="34" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:label="loc_cvmAccruedConsultingServicesToBePaidWithCommonStock_d7b0c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_cvmAccruedConsultingServicesToBePaidWithCommonStock_d7b0c3" order="35" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmFinancingCostsIncludedInCurrentLiabilities_7d2f8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_cvmFinancingCostsIncludedInCurrentLiabilities_7d2f8e" order="36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_3a4b3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_ece1bc" xlink:to="loc_us-gaapInterestPaidNet_3a4b3b" order="37" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0b895" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_6feae7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0b895" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_6feae7" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_bc9014" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="loc_cvmLiquidityDisclosureTextBlock_47d20d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_bc9014" xlink:to="loc_cvmLiquidityDisclosureTextBlock_47d20d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_577d8d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_40e696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_577d8d" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_40e696" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_bbcf35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_2a4046" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_bbcf35" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_2a4046" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_b30b85" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_0ec23f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b30b85" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_0ec23f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_719fc5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_64c48e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_719fc5" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_64c48e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_54a066" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_f0773e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_54a066" xlink:to="loc_us-gaapEarningsPerShareTextBlock_f0773e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_e483ed" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_7a9b81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_e483ed" xlink:to="loc_us-gaapSubsequentEventsTextBlock_7a9b81" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_c666bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_c666bf" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_82c39c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_82c39c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_463970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapInventoryPolicyTextBlock_463970" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_16b384" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_16b384" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_24b469" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_cvmLeasesPolicyTextBlock_24b469" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_ae5ed8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_ae5ed8" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_12d019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_12d019" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_8e2180" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_8e2180" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_9d1613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_9d1613" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_b58511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_b58511" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_c08041" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapUseOfEstimates_c08041" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:label="loc_cvmNewAccountingPronouncementEarlyAdoptionPolicyTextBlock_5b50aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_cvmNewAccountingPronouncementEarlyAdoptionPolicyTextBlock_5b50aa" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_ab0f6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bbd3e9" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_ab0f6d" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_55cf4d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_d38406" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_55cf4d" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_d38406" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_19a6eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_55cf4d" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_19a6eb" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_c04447" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_c96791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c04447" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_c96791" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="loc_cvmScheduleOfStockOptionActivityTableTextBlock_58f454" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c04447" xlink:to="loc_cvmScheduleOfStockOptionActivityTableTextBlock_58f454" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_435949" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c04447" xlink:to="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_435949" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_b70a58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c04447" xlink:to="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_b70a58" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:label="loc_cvmScheduleOfDerivativeLiabilitiesTableTextBlock_e1dc2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c04447" xlink:to="loc_cvmScheduleOfDerivativeLiabilitiesTableTextBlock_e1dc2f" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_60ca40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0ec7fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_60ca40" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0ec7fd" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_2661b2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_0f3252" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_2661b2" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_0f3252" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_394ef1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_2661b2" xlink:to="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_394ef1" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_5a3a2e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_26aeb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5a3a2e" xlink:to="loc_us-gaapStatementTable_26aeb7" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_fff318" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_26aeb7" xlink:to="loc_us-gaapStatementLineItems_fff318" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_897318" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_26aeb7" xlink:to="loc_us-gaapAwardTypeAxis_897318" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_897318" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember_76bd55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" xlink:to="loc_cvmIncentiveStockBonusPlanMember_76bd55" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_eeeae2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_eeeae2" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_cd85c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" xlink:to="loc_cvmStockBonusPlansMember_cd85c6" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_6841bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" xlink:to="loc_us-gaapStockCompensationPlanMember_6841bf" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember_87b67d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20c2" xlink:to="loc_cvmIncentiveStockBonusPlansMember_87b67d" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a658a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fff318" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a658a" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_67effa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5185a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_67effa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5185a4" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4cc1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_67effa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4cc1e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1f4725" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_67effa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1f4725" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_77dc00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_67effa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_77dc00" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_c05fa8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b32aae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c05fa8" xlink:to="loc_us-gaapStatementTable_b32aae" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a88297" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b32aae" xlink:to="loc_us-gaapStatementLineItems_a88297" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_b929d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b32aae" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_b929d7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_037060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_b929d7" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_037060" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_311f60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_037060" xlink:to="loc_us-gaapEmployeeStockMember_311f60" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember_5e355e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_037060" xlink:to="loc_cvmNonEmployeesMember_5e355e" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4ee056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a88297" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4ee056" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_1e9ffa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_cd9f10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_1e9ffa" xlink:to="loc_us-gaapStatementTable_cd9f10" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_356eac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cd9f10" xlink:to="loc_us-gaapStatementLineItems_356eac" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_ed9754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cd9f10" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_ed9754" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_133286" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_ed9754" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_133286" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_fa9cfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cd9f10" xlink:to="loc_srtRangeAxis_fa9cfb" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_b6a0a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_fa9cfb" xlink:to="loc_srtRangeMember_b6a0a7" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a5f9a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_cd9f10" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a5f9a6" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_272eb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a5f9a6" xlink:to="loc_us-gaapRelatedPartyDomain_272eb8" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_acedd3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesNMember_acedd3" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_92821f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesUUMember_92821f" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_ab8220" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesXMember_ab8220" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_175933" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesYMember_175933" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_1d7789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesMMMember_1d7789" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_001b17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesNNMember_001b17" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_e20644" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_133286" xlink:to="loc_cvmSeriesRRMember_e20644" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_5ea3a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_b6a0a7" xlink:to="loc_srtMinimumMember_5ea3a4" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_c3d493" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_272eb8" xlink:to="loc_cvmConsultantsMember_c3d493" order="69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_7f7175" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_b6a0a7" xlink:to="loc_srtMaximumMember_7f7175" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember_c26d1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_272eb8" xlink:to="loc_cvmConsultantsOptionMember_c26d1f" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1_ad01a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_356eac" xlink:to="loc_cvmIssueDate1_ad01a5" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_c4da0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_356eac" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_c4da0c" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_7c5119" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_356eac" xlink:to="loc_cvmExercisePrice_7c5119" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_3b6f00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_356eac" xlink:to="loc_cvmExpirationDate_3b6f00" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_9b6ce1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3869a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_9b6ce1" xlink:to="loc_us-gaapStatementTable_3869a1" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5dda8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3869a1" xlink:to="loc_us-gaapStatementLineItems_5dda8f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_79b41f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3869a1" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_79b41f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_b2eac9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_79b41f" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_b2eac9" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_2b83b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_b2eac9" xlink:to="loc_cvmSeriesRRMember_2b83b0" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_8d8c59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_b2eac9" xlink:to="loc_cvmSeriesSSMember_8d8c59" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_69e759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dda8f" xlink:to="loc_cvmEquityWarrantsExercised_69e759" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice_bbb7dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dda8f" xlink:to="loc_cvmEquityWarrantsExercisePrice_bbb7dd" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised_40081e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dda8f" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised_40081e" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_8427b0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_67739c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8427b0" xlink:to="loc_us-gaapStatementTable_67739c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c08a33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_67739c" xlink:to="loc_us-gaapStatementLineItems_c08a33" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_e8fbb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_67739c" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_e8fbb8" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_3bfde2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_e8fbb8" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_3bfde2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis_d295b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_67739c" xlink:to="loc_us-gaapTradingActivityByTypeAxis_d295b8" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_c108c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeAxis_d295b8" xlink:to="loc_us-gaapTradingActivityByTypeDomain_c108c0" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79aa69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_67739c" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79aa69" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_2a4341" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79aa69" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_2a4341" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_8ec610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_67739c" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_8ec610" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_46e6cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_8ec610" xlink:to="loc_us-gaapRelatedPartyDomain_46e6cc" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_8f249c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_67739c" xlink:to="loc_us-gaapPlanNameAxis_8f249c" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_a94a6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_8f249c" xlink:to="loc_us-gaapPlanNameDomain_a94a6c" order="80" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_eebae2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_3bfde2" xlink:to="loc_cvmSeriesRRMember_eebae2" order="81" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityProceedsFromSaleCommonStockMember" xlink:label="loc_cvmEquityProceedsFromSaleCommonStockMember_5e232b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeDomain_c108c0" xlink:to="loc_cvmEquityProceedsFromSaleCommonStockMember_5e232b" order="82" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_6e8aaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_2a4341" xlink:to="loc_cvmRestrictedStocksMember_6e8aaf" order="83" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_917395" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_46e6cc" xlink:to="loc_cvmConsultantsMember_917395" order="84" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_027b02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_a94a6c" xlink:to="loc_cvmConsultingAgreementsMember_027b02" order="85" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="loc_cvmConsultingAgreementsOtherMember_3b67fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_a94a6c" xlink:to="loc_cvmConsultingAgreementsOtherMember_3b67fe" order="86" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_aa8d67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_cvmIncrementalCostDeemedDividend_aa8d67" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9023dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9023dc" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_37c52d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_37c52d" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses_c4dc26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses_c4dc26" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_7c86a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_7c86a2" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_bcb46e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapCommonStockSharesIssued_bcb46e" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_df3666" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapSaleOfStockPricePerShare_df3666" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_8cc646" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_8cc646" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_74cc48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_74cc48" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IssuanceCostOfCommonStock" xlink:label="loc_cvmIssuanceCostOfCommonStock_cd2dec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_cvmIssuanceCostOfCommonStock_cd2dec" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetofissuanceCosts" xlink:label="loc_cvmNetofissuanceCosts_4a68be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_cvmNetofissuanceCosts_4a68be" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_cda3de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_cda3de" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AdditionalPurchaseOfCommonStock" xlink:label="loc_cvmAdditionalPurchaseOfCommonStock_cced86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_cvmAdditionalPurchaseOfCommonStock_cced86" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_StockOptionPlan" xlink:label="loc_cvmStockOptionPlan_c7b8c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_cvmStockOptionPlan_c7b8c5" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_08a7a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c08a33" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_08a7a2" order="15" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_ef318d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ed4bf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_ef318d" xlink:to="loc_us-gaapStatementTable_ed4bf0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d5faf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ed4bf0" xlink:to="loc_us-gaapStatementLineItems_d5faf0" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f4186c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ed4bf0" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f4186c" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_0962b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f4186c" xlink:to="loc_us-gaapRelatedPartyDomain_0962b4" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OfficerandDirectorMember" xlink:label="loc_cvmOfficerandDirectorMember_e2e127" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0962b4" xlink:to="loc_cvmOfficerandDirectorMember_e2e127" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_d9dea4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d5faf0" xlink:to="loc_cvmIncrementalCostDeemedDividend_d9dea4" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfNewlyIssuedSharesByInsiders" xlink:label="loc_cvmPurchaseOfNewlyIssuedSharesByInsiders_40b53d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d5faf0" xlink:to="loc_cvmPurchaseOfNewlyIssuedSharesByInsiders_40b53d" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_RestrictedCommonStockFairValue" xlink:label="loc_cvmRestrictedCommonStockFairValue_a04a14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d5faf0" xlink:to="loc_cvmRestrictedCommonStockFairValue_a04a14" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_16d487" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c82fcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c82fcd" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3be483" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3be483" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_da957c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_da957c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_419cad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_419cad" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_068be4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_068be4" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_219639" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_219639" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_ae3398" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_ae3398" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_52b588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_52b588" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_de1964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_us-gaapFinanceLeaseLiability_de1964" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityCurrentPortion_1c087f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_cvmFinanceLeaseLiabilityCurrentPortion_1c087f" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_fe037c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_16d487" xlink:to="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_fe037c" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7a7699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7a7699" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e05ba8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e05ba8" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c029c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c029c0" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_c87e11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_c87e11" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_ad3e2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_ad3e2c" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_6c425b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_6c425b" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_26282f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_26282f" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_fcab40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_fcab40" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b929d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b929d" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_aef5f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_us-gaapOperatingLeaseLiability_aef5f4" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityCurrentPortion_023e35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_cvmOperatingLeaseLiabilityCurrentPortion_023e35" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_8d1ea5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a285ba" xlink:to="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_8d1ea5" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_3a4aa7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_610050" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_3a4aa7" xlink:to="loc_us-gaapStatementTable_610050" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_cba62e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_610050" xlink:to="loc_us-gaapStatementLineItems_cba62e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_4f9f88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_610050" xlink:to="loc_us-gaapPlanNameAxis_4f9f88" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_94b238" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_4f9f88" xlink:to="loc_us-gaapPlanNameDomain_94b238" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_e38d8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_610050" xlink:to="loc_srtTitleOfIndividualAxis_e38d8f" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_8454ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_e38d8f" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_8454ba" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_05e346" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_610050" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_05e346" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_bd5759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_05e346" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_bd5759" order="50" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_f44f81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_94b238" xlink:to="loc_cvmErgomedMember_f44f81" order="51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_155c3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_8454ba" xlink:to="loc_cvmLandlordMember_155c3d" order="52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_1060c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_bd5759" xlink:to="loc_us-gaapLeaseAgreementsMember_1060c4" order="53" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount_66c586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_cvmNetOfDiscount_66c586" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_326f56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_us-gaapInterestPaid_326f56" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_f61d3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_us-gaapOperatingLeaseExpense_f61d3c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_40150d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_40150d" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="loc_cvmAnnualIncreaseToInterestPayments_376263" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_cvmAnnualIncreaseToInterestPayments_376263" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne_d6bae2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne_d6bae2" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_7d9782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_7d9782" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_31014b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_31014b" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial_7a3e0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_cvmClinicalServiceTrial_7a3e0d" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount_9e7957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cba62e" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount_9e7957" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ec4f84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ec4f84" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e32a85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e32a85" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b28674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b28674" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6c0e27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6c0e27" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4bd93e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4bd93e" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a09d09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a09d09" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_caef0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_caef0d" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_95e44f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_4d6887" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_95e44f" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_574af5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_edbfe7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_574af5" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_edbfe7" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_8fb6e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_574af5" xlink:to="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_8fb6e3" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_44105d" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_bacaa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_44105d" xlink:to="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_bacaa3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_ab6f27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_44105d" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_ab6f27" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfShareOutstandingBasicsAndDiluted_f7ddb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_ab6f27" xlink:to="loc_cvmWeightedAverageNumberOfShareOutstandingBasicsAndDiluted_f7ddb0" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:label="loc_cvmIncomeLossFromContinuingOperationsPerBasicAndDilutedShares_82c517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_ab6f27" xlink:to="loc_cvmIncomeLossFromContinuingOperationsPerBasicAndDilutedShares_82c517" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_a5b25b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_693968" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_a5b25b" xlink:to="loc_us-gaapStatementTable_693968" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_84a7a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_693968" xlink:to="loc_us-gaapStatementLineItems_84a7a3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c234df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_693968" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c234df" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_108fa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c234df" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_108fa6" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_a559ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_108fa6" xlink:to="loc_cvmOptionsMember_a559ba" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_33d885" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_108fa6" xlink:to="loc_cvmUnvestedRestrictedStockMember_33d885" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4232db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_84a7a3" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4232db" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_f016d9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3a1611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_f016d9" xlink:to="loc_us-gaapStatementTable_3a1611" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3dff78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3a1611" xlink:to="loc_us-gaapStatementLineItems_3dff78" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_c65f92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3a1611" xlink:to="loc_us-gaapSubsequentEventTypeAxis_c65f92" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_5f986a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_c65f92" xlink:to="loc_us-gaapSubsequentEventTypeDomain_5f986a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_45e607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3a1611" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_45e607" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_325d51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_45e607" xlink:to="loc_us-gaapRelatedPartyDomain_325d51" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_f7e26e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3a1611" xlink:to="loc_srtTitleOfIndividualAxis_f7e26e" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c67bcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_f7e26e" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c67bcd" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_65cd3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_5f986a" xlink:to="loc_us-gaapSubsequentEventMember_65cd3a" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_a325d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_325d51" xlink:to="loc_srtChiefExecutiveOfficerMember_a325d2" order="42" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_MrKerstenMember" xlink:label="loc_cvmMrKerstenMember_be123d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c67bcd" xlink:to="loc_cvmMrKerstenMember_be123d" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_450d9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_450d9c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantsOfferingPrice" xlink:label="loc_cvmWarrantsOfferingPrice_631b29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_cvmWarrantsOfferingPrice_631b29" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_b17871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_b17871" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_d64bac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_d64bac" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantsToPurchaseCommonStock" xlink:label="loc_cvmWarrantsToPurchaseCommonStock_434f4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_cvmWarrantsToPurchaseCommonStock_434f4b" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedParties_1884e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedParties_1884e7" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedPartiesAdditions_801760" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3dff78" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedPartiesAdditions_801760" order="7" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20240630.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20240630.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20240630.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20240630.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20240630.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240630.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240630.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20240630.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240630.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20240630.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20240630.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240630.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240630.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20240630.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20240630.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedAmount" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareIssuanceCosts" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsSahres" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsSahres" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsSahres" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount" order="17" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlanMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmStockBonusPlansMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlansMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmNonEmployeesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOptionMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssueDate1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesSSMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercisePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTradingActivityByTypeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="100" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="81" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_EquityProceedsFromSaleCommonStockMember" xlink:label="loc_cvmEquityProceedsFromSaleCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_cvmEquityProceedsFromSaleCommonStockMember" order="82" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="83" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="84" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="85" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="loc_cvmConsultingAgreementsOtherMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsOtherMember" order="86" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IssuanceCostOfCommonStock" xlink:label="loc_cvmIssuanceCostOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuanceCostOfCommonStock" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetofissuanceCosts" xlink:label="loc_cvmNetofissuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetofissuanceCosts" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AdditionalPurchaseOfCommonStock" xlink:label="loc_cvmAdditionalPurchaseOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdditionalPurchaseOfCommonStock" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_StockOptionPlan" xlink:label="loc_cvmStockOptionPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockOptionPlan" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="15" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OfficerandDirectorMember" xlink:label="loc_cvmOfficerandDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmOfficerandDirectorMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_PurchaseOfNewlyIssuedSharesByInsiders" xlink:label="loc_cvmPurchaseOfNewlyIssuedSharesByInsiders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfNewlyIssuedSharesByInsiders" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_RestrictedCommonStockFairValue" xlink:label="loc_cvmRestrictedCommonStockFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRestrictedCommonStockFairValue" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLeaseAgreementsMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetOfDiscount" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="loc_cvmAnnualIncreaseToInterestPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAnnualIncreaseToInterestPayments" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmClinicalServiceTrial" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_MrKerstenMember" xlink:label="loc_cvmMrKerstenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmMrKerstenMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantsOfferingPrice" xlink:label="loc_cvmWarrantsOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsOfferingPrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240630.xsd#cvm_WarrantsToPurchaseCommonStock" xlink:label="loc_cvmWarrantsToPurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsToPurchaseCommonStock" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedParties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedParties" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedPartiesAdditions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedPartiesAdditions" order="7" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_10qimg15.jpg
<TEXT>
begin 644 cvm_10qimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" '< ?8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+J!KB!91
M"TT8D/1"PR?PJ>ODKQ]X9U3Q=\?_ (@:3I'A./7[_P#LFR6UN9M2-H-+D:,@
M3+W)SS@?W?>@#ZQ#HS,@8%EZ@'D5)7R/>ZAX_P# _B'XA:E8>)K>2_\ #>@Z
M1+?M<VQG^WR)$58 EAL#?,2V"3Q6]XY^,_BK2-=OKO0]0MC9Z5_9JW%C]D4J
M7N K.DDKL&)PWR^6#CO0!]-45\_7'Q,\9:?\:8])U/4+2/PY<ZPFF6HM8([B
M-RR9$4CJ_FQS[O5=F*RO!/Q<\?>(/&VD/?QVJZ1JFJW6GO8NL,9MEC+!2C;S
M(SC;\P90.>,<4 ?2A8#&2!G@>],DDCAC,DKJB+U9C@"OF_\ :"A\.W$>M:A#
MK2R^)]+TZ-S:7.IO;?8(-S-]HMHQM$DQ(QC/. /8ZOQ<L[/Q)X+\ 9\3V-M+
M-)'=6]AXB\R.VUC]R"8YRGW6P<X)QDF@#WQ65T#HP92,@@Y!%25\<Q^(=1C^
M'^C0^$=4?P7!8>-H]-OHTNOM]HKO@YAF8@&W'_//ISUKN_%'Q@U[0]/^(<*Z
MQIRZGHNLZ?9:;%(B!Y(9?)\P[,Y;(>0Y[?A0!]#NZ1KND8*OJ3@5)7R5\3O&
MWB/Q#9>,;6Y\06&FZ;HOB.TTF'1?* N;A5DC;SQ)N#?-G@ 8P#7>VOQ%\:2?
M$N'X8R36_P#;D6O/)/.+<;6T81>:K@= QW+'N_O T >XM/"DBQ/,BR-T4L 3
M^%3U\L_%KP[J?BS]H/4M#TGP[%KE\_A",VS37WV9=.E-RZBY!ZDKZ#DU:U#Q
M_P"/?#.KWVGR>*K>:7PM=:/I)TI[=&DUOSDC$TVYOW@)+,1MX&PY[T ?3E-)
M"@LQP!U)KYPTWXD>-&\<VGF>*[6\MYO&MQX=;1!:Q*ZVH5F67</GRN!STQUS
M63IOQ2\3^)?"/AS3[W7;>ZN-6T/7Y-4ABCC60O"76'(49CPH[8S0!]1JRR*&
M4AE/((Y!H=TC0O(P11U+' %?*>I?$C6/#_PF\,KX5\23)?Z=X2BU6:"*W@DB
M?!5 TLLI)(R&7RT&[)SGM5?Q9K.N6ME\;KR[\0"_$46D3PZ==PQO$@E2!MRH
M?X5W;>.">3EJ /KBBOG7Q#\2/&%C\0-9>UUVVM[72?$-AHL/AXV\9DOH9E3?
M+O/SY^<D;> $/O3/#/CSQ[-XYT*6^\10W>E:GXHU+0VT];&- D4*.R/Y@^8L
M-@'IB@#Z'\R/>R;UW*,L,\@>]*LD;(KJZLK?=(/!^E?+GCS4M:\/_'CQWXRL
MIIYM*TG1[*WU6RC).^VGCE4RJ/[T;JC?3=7#:A<6]QX*T*/7]8GLX-,^&\6I
M:.1=M#_I_G$%TP1OD "#'/!]Z /N D $G@#N:KB\M&!VW4)P,G$@XKFO#&I6
M^O>$K33]4NH;G5#IUN-4M-X,D3R0@LKJ.5SD]:^7M:\+^'](^&WQNO=,TN.W
MN=-UO^S[1T=@88#Y!\I3GA22?SH ^R/M%OY/G>='Y?\ ?W#'YTOG0^5YOFIL
M_O[AC\Z^1?%'@[5/#O@/6;[6-)@\,>'M8US2%M]#COS/' JL%FD+Y 7?GE1Z
M<U7\92:7H]C\3]%\$WV[P?:Q:3.5@N3);VEVUPN]8WR0N4 + ' QVH ^R.U%
M>!_'R^TO7/@=J6K:7XV>"&R7*QZ;?(([R7*XC=E)+;?O;01VS7<ZUK'B:+X5
MV&H^ [>WUB_:& 9W"3$> )'0;@)''92PR>] 'H=-+ 8R0,\"OFGXD.NI?LYZ
MUJDGC[Q ;NTEEDGCO%&GRS7&$_T=H]JE47A@BGG.<FL/XH:AIVJ:G'_;.O/%
MIUCX!EU+1WBO3&CWZNJ^8A5@'D&  .>_% 'UI17.^#[G4+SP/H%YJN[[?-80
M27&[KYAC!;/OFNBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%U>>+_!M]'J4-U;^(-+N%F%HS&W,D6QUD0-@C[SCD9Z ]* /3**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KD;WP3I]Y?37DFK>((WF8N4@UJZBC4GLJ+(
MH]@*ZZB@#D?^%?Z7_P!!SQ/_ .#^\_\ CE'_  K_ $O_ *#GB?\ \']Y_P#'
M*ZZB@#D?^%?Z7_T'/$__ (/[S_XY1_PK_2_^@YXG_P#!_>?_ !RNNHH Y'_A
M7^E_]!SQ/_X/[S_XY1_PK_2_^@YXG_\ !_>?_'*ZZB@#D?\ A7^E_P#0<\3_
M /@_O/\ XY1_PK_2_P#H.>)__!_>?_'*ZZB@#D?^%?Z7_P!!SQ/_ .#^\_\
MCE'_  K_ $O_ *#GB?\ \']Y_P#'*ZZB@#D?^%?Z7_T'/$__ (/[S_XY1_PK
M_2_^@YXG_P#!_>?_ !RNNHH Y'_A7^E_]!SQ/_X/[S_XY1_PK_2_^@YXG_\
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MM^(@V>>8I"=I_NB@#Z$_X5_I?_0<\3_^#^\_^.4B^ -+4AO[;\3''KK]X?\
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M@8 [LE0Q'4YK[([4 9UWI6FZC"D.H:?:W<2'<B3PK(JGU (XJZJJJA54!0,
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M% ')?8?B/_T,WA[_ ,$LW_R51]A^(_\ T,WA[_P2S?\ R576T4 <E]A^(_\
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M5*MC\1MPW>)O#Q'?&BS?_)5=910 4444 %%%% !1110 4444 %%%% !1110
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M'?W7 / .*E\2:OXB74=(D\+^*+.>+6KN**SM/L2RJ8A\TTGF!\E0@8YQU(%
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M^$_>_P#QJNMHH Y+_A8&C_\ 0)\2?^$_>_\ QJC_ (6!H_\ T"?$G_A/WO\
M\:KK:* .2_X6!H__ $"?$G_A/WO_ ,:H_P"%@:/_ - GQ)_X3][_ /&JZVB@
M#S;Q5XBTCQ'X6O\ 1UT_Q)!+<1_NI?\ A'KX[)%(9&_U79@*QKG_ (1?4-4_
MM'4+;QFJSS17EUIL6CWWV2:XC"[7*F'/!13@$ [02*]BK)U?^VA8_P#$A6R>
M[W#B]9Q'M[_=!.: /-M)7PGI.KV^I+:^-+K[&DL=E;7>CWLL5FLA&\1CR<\@
M ?,6P.!6P?$7AEO%$'B!M'\3M=P6K6D*G0;WRXT9@S%5\KACA03Z "N:;XL:
MM':6D5Q#H=K=73W4T5Q-/*+>2VA<1B10%+DN^[!Q@*NX]17HL]]KUYX=LM0T
M>/2UNID2:07,[/"JE<G:\8^;V/0B@#A8QX6LM5_M73[/Q@9+>2>ZL;&;1KTV
MEK<2AMTBIY.1DN_<@;VP!FMGPOXDT7P[X5TW1%TWQ'(;2$([CP]? ._5F'[K
MNQ)K=\#ZYJGB/PI#K&J6MO;FXDD\C[,S%)80Q"2#< 0& W#V(KJZ .2_X6!H
M_P#T"?$G_A/WO_QJC_A8&C_] GQ)_P"$_>__ !JNMHH Y+_A8&C_ /0)\2?^
M$_>__&J/^%@:/_T"?$G_ (3][_\ &JZVB@#SOQ%XGT/Q!X8U+19=-\2Q+>V[
MP^8/#UZ3&2,!O]5V.#^%<]=+X;UBX6\U>W\8J]RD!U&RMM'O1:WDD0&"RF$G
M&0/NE<@#.:]EKE?&GB";POX2NM;AABE,+Q(3.Y2*(/(J&1R 3M7=N.!G XH
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M ,#$_P :YKQ5XJ^'OB31DL1\0M)LIH;B*[@F6YC<))&X9=R$X9<CD'K7J=%
M'@R+X)@N(]6M?BYI$>N&:>2:Y=8'@<2JBLJP%L)@1)@@YZYSN-:2:IX'M?"\
M?AVP^*VFQV5O;006Z3M!.H,9.XR!O]8'R 5XQCC%=H/'%NOB>RT&[T'6;2:^
MF>&WFFM@(I"BEB<ACQ@$YQZ5>\0>+-'\-76D6NJ3.L^KWB65K%&F]F=B!DCL
MH)&6Z#(]: .1\)^)OAQX6TN:V7QUH]U<W=P]U<3_ &B*(/(V!\J*<*H   [
M5TO_  LWX>_]#KHW_@8G^-==10!R/_"S?A[_ -#KHW_@8G^- ^)GP]9@J^--
M')/ 'VM/\:ZZB@ HHHH **** "BBB@ HHHH \4TGX9^(O#]AI=WI+6YU=;2_
MM;L7ER]Q GFEGB:-7R%^8*&"A00QSG%16?@'Q=!J']O3:;;7$L%U9W*Z=/=H
M?M'EPR1/EEC5%(+AE^7'':O<** /%M>^'^O:M?P7CZ/:K;W>F"PN-.L[X016
MA\XOD-Y9+*0W.P*<KQUX]G PH')QZTZB@ HHHH **** "BBB@ HHHH ****
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M\>,MW_9K 8A$/^D;S)Y>S9G[P;@CV-=;;7$%W:0W=M()()D62-UZ,I&0?RH
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M1?\ \'E]_P#'J .OHKD/^%<>%_\ J+_^#R^_^/4?\*X\+_\ 47_\'E]_\>H
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M*ACJP+' !UR]Y/\ W^H XC6/ ?B*2ZOWL=/B"?VG8ZHLD$T2/=+' (GA^92
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MXEW)-'%'+;O9R0JAVKYI<E@&9CP.0.*ZRX\!^#[6'SKJ;5(8]RIN?7;T#<Q
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M<>%_^HO_ .#R^_\ CU'_  KCPO\ ]1?_ ,'E]_\ 'J .OHKD/^%<>%_^HO\
M^#R^_P#CU'_"N/"__47_ /!Y??\ QZ@#KZX[QSH]QK/AV&.ST][ZYMKJ*XB6
M*[^RS1E3]^*3H' )P&X()!ZT[_A7'A?_ *B__@\OO_CU'_"N/"__ %%__!Y?
M?_'J /+5^&>O6MV?$%QH\VKW%\]V9]-;5RDD'F>7Y3F;(#LOE_-Z%AMSBO0K
M6'QY9^!)='6.&XUJWL((8-1EN,B:=AMD=@1G]WP>?O\ M5>;PS\/[>SCOKC5
MKN*T=S&LS^(KL(S D%0?/P3D'\C4]]X/\"Z;:I=:C?W]I Y"K)-X@O$5B>0
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MTR73M4M5NK.;'F0OG:X!S@XZCV[UI*JJH50%4#  Z"@!]%%% !1110 4444
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M'\2K>UN/!X6^N+FWM5NX))9X+,77E!7!W/&004! SP<=<&K7]B?$/_H?-/\
M_!'_ /;Z/[$^(?\ T/FG_P#@C_\ M] 'F5S?V-UX)D36K>."7=>VNBZY+HGF
M0R0Y3DP* $>3D [0"$R.N#T?]JZ"GP^T33?$&B7<3Z;;V9D2>U>Y33I&B812
M29^^ 5YZX)&<=:ZK^Q/B'_T/FG_^"/\ ^WT?V)\0_P#H?-/_ /!'_P#;Z ,[
MX5QR0^ UC:$A?MMTR3B$PI=*TS,)DB/^K1LDA.PZ5Z'7&_V)\0_^A\T__P $
M?_V^C^Q/B'_T/FG_ /@C_P#M] '945QO]B?$/_H?-/\ _!'_ /;Z/[$^(?\
MT/FG_P#@C_\ M] '945QO]B?$/\ Z'S3_P#P1_\ V^C^Q/B'_P!#YI__ ((_
M_M] '95Q'Q&M[>Y\$SPWLEQ!:_:+=Y)H+471C59D;<T9SN3CYN#@9.#4O]B?
M$/\ Z'S3_P#P1_\ V^C^Q/B'_P!#YI__ ((__M] 'FXU'3Y_"K+K4,<<:7%W
M;Z+X@FT/?!L(3+/;J  S9=0=H#!#ZX/5Z'JVEV?PHLK'5- N'ETG1K>XFTV>
MV>=ON$(H+*0SDKTZC/.*W?[$^(?_ $/FG_\ @C_^WT?V)\0_^A\T_P#\$?\
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M1ERL2L%S@=R3@#O@^E0Z-XNTG6'OT7S[&?3MANH+^(P/"K@E&(;C:<'!SV-
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M5%<;]H^*'_0)\+_^#"X_^,4?:/BA_P! GPO_ .#"X_\ C% '945QOVCXH?\
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M4?:/BA_T"?"__@PN/_C% '945QOVCXH?] GPO_X,+C_XQ1]H^*'_ $"?"_\
MX,+C_P",4 =E17&_:/BA_P! GPO_ .#"X_\ C%'VCXH?] GPO_X,+C_XQ0!V
M5<;XLO+I==\*Z3;SO"E]J),SH<%DCC:39]"0OY4?:/BA_P! GPO_ .#"X_\
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MNV6BV.GZMJ&IVL;)<Z@8S<,6)#>6FQ< \#CTH VZ*** "BBB@ HHHH ****
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M:Z>)F,TK3S37$K2RS2-U=W;DG@#Z 5O4 %%%% !1110 4444 %%%% !1110
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MY*X!S@4 83?$35EU#16MM';4+75K[4((8+=1YQBMP0C99@/F*,W/8@=:V/\
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M\:>\P(9E;;E]NX[0V0 >];Z>'5?Q)I^N7M]/=W-A9&TA60*%#,1YDV /OL%
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MH171UY=X=\:> ]!TIK-_&EE=R/(TK2+;K N3C@)&H   'J?>M_\ X6E\/_\
MH:;/_P >_P * .RHKC?^%I?#_P#Z&FS_ /'O\*/^%I?#_P#Z&FS_ /'O\* .
MRHKC?^%I?#__ *&FS_\ 'O\ "C_A:7P__P"AIL__ ![_  H [*BN-_X6E\/_
M /H:;/\ \>_PH_X6E\/_ /H:;/\ \>_PH [*BN-_X6E\/_\ H:;/_P >_P *
M/^%I?#__ *&FS_\ 'O\ "@#LJ*XW_A:7P_\ ^AIL_P#Q[_"C_A:7P_\ ^AIL
M_P#Q[_"@#LJQ=<NM3L]&N+C2-/34+Q%S'!),(E)]68@X Z^M8_\ PM+X?_\
M0TV?_CW^%9VI_$?P3>Z5<6MCXXM+"XE7:MP(_,,?OM88/'K0!3OO'GB&'X6>
M'O&5EHMK/)J$-K->![@I':B4H#M&-SG+X ]N:[773K8L VARV,4ZMF1KX,4"
M8Y^[WKR"6X\'2?#>P\#+\652WL_+07/V.,R/'&5,:$;=O!4<XR:W]1\5>#=6
MT?4M+O\ XF!X=0MXK=_+14* 9$I7"\>8#@^G;% '6^!]:U;Q%X2@UC5H;:)[
MB20P&VW!)8 Q$<F&Y&X#=CT(KK:X2#XD_#FVMHK:W\2V,<,2!$1=P"J!@ <>
ME6?^%I?#_P#Z&FS_ /'O\* .RHKC?^%I?#__ *&FS_\ 'O\ "C_A:7P__P"A
MIL__ ![_  H [*BN-_X6E\/_ /H:;/\ \>_PH_X6E\/_ /H:;/\ \>_PH [*
MLK6+C4+?2+BXTNQ6^O47,5N\HB5S[L>@[_A6%_PM+X?_ /0TV?\ X]_A5+4?
MB1X)N],N+:Q\;6EC<2(52X">88SZ[6&#^- &=+\1+Z'X1Z=XJ72X;C7]1LVE
MM].B<^6TBH6?YCR(U"DD^GN16QXB\67>C_#BV\31PVXFF2U+O,6\FW$K(K2-
MCYBJ[LX')Q7G$%C\)9/"%KH.L>-AJ4UE:S65I?J[VTL,,@&5Q%M5N0#\P.<<
MUH3:A\/6T*ST>V^(A@MM-6U:P##S?L\T!)$A+*2^[."K$CCC% '?> _$MUXK
M\,OJEPEON6ZFMUEMMWE7"HVT2*&^90?0\\5V->4>&?%GP_\ #MG=I)XX@U&[
MO;E[NZN9%V;Y& '"JN%& !@5TO\ PM+X?_\ 0TV?_CW^% '945QO_"TOA_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?+"[B<@KMX&-I&,5>F\,^)O^$"T_PW=6=OJ\NEP6;QW3WLD$TTZ??*.!F-E
M&UCG/((H [+P_KUGX@L)+RVCGMY8)FM[BVN$*202KU5A^(.1P00:Z*N$\ ^&
M+[P[INH/J"B*[U2^DO9(A<-<>3D*JJ9&Y<X49/')..*[N@ HHHH **** "BB
MB@ HHHH *XJ3X9^"9I))I=(=I)&+,?MDXR3R?XZ[6B@#C/\ A5O@7_H"O_X&
M3_\ Q='_  JWP+_T!7_\#)__ (NNSHH XS_A5O@7_H"O_P"!D_\ \71_PJWP
M+_T!7_\  R?_ .+KLZ* .,_X5;X%_P"@*_\ X&3_ /Q='_"K? O_ $!7_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2-K*SL<C!YJJGP_\,QV4-KY-V98K[^TA=F\E^TFXV[#(9=VXDI\I&<;>,8H
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M'GKZ5ZCI%QJEUI=O<:QIZ:=?.N9K9)A,L1ST#@#=^5 &O1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #=JDAB 2.A]*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !3&16(+*"5.1GL:?10 G4<\BC&!@<"EHH **** "B
MBB@!N!NW8&>F:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_10qimg9.jpg
<TEXT>
begin 644 cvm_10qimg9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M *\HL?AW+:_#_3I_$D.L>(-7ATNSLUM+::&VET]8VCD/D%2@WI(BMN+$GRU
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M"L:D>6W RN]3N^;H*N7'C"2S\06]A<BT-MY<332I(=SAHW<RQCO&NSD^_MR
M=Q16%H>L0ZM"6:2!;Q.9[:.4.UODG:K^C8X/N".U;;,J(6;@"@!U5C(\QVP\
M+WD[?AZTW:]Q\TH*1?\ //NWU_PJT  , 8% $4<:QKM4=>23R2?>IJ*CDE6,
M#/+'HHZF@!S,JJ69@H'4FJW[Z8\92'UZ,W^ _6A8F9A)<8)'*H.B_P")JW0
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M3U-&BBBD4%%%% !1110!!=_\><__ %S;^51V/_(,M?\ KDG\A4EW_P ><_\
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M *%V'_O^W^%'_"^-0_Z%Z'_O^W^%>,T5\%_:U;^;\$?9_P!CX?\ D_%GL_\
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M2=2GO;43%Y04422%EB0N7*H.P+,3_P#6 KHJ *BQ-(P>?MRL8Z#Z^IJW110
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M_L^?\E"NO^P>_P#Z,CKZ# ?[Q'U/FLQ_@2]#ZAQ=?\](O^^#_C1BZ_YZ1?\
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M=JZG_A'[#_GI-^8H_P"$?L/^>DWYBOT*C0IT(\L$?FU?$5*\N:;N<M175?\
M"/6'_/2;\Q1_PCUA_P ])OS%;F!RM%=5_P (]8?\])OS%'_"/6'_ #TF_,4
M<K2R-%;Q^9<-@=E'5JV=8TZVTO2WO;<N[JP4!^G-<3++)-(9)&+,>YH FNKR
M6Z.#\D8Z(.E?4OP=A#_"G2V\R1?GFX5L#_6M7RC7UI\&O^23Z5_OS?\ HUJ
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MVQ\*9T%KX=TWP59^*O$DUX;:^F\F&.S R@R1N8G_ '2?RJ]<>%8(/'MEX?\
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MN$N;2"P@DN!NMX%*^>SA6*X8%P>I("^U=)KFDW6K?9%M[Y;3[--YQ1X!*DC
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M]JM_^>GZ&@![*VTA2 >V:\U\:_#&X\=I'%JNO/%%%)YB+%'T.,=Z]'^U6_\
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M-I(1<0SD2R"4[I ['.[<WS'OGD8K7DTFR^PV-@L9CMK22,Q1(<+^[^X#Z@$
MX]0*** *NEZ!IVE:E<W=KYQD?,:K)(66%"QD*H.P+,3^78"NBHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10qimg8.jpg
<TEXT>
begin 644 cvm_10qimg8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH **
M** "BBB@ HHKXTN/'7Q6AUWXDZ/I-]J%[!K&L7^G:9>M*S#16MF$DQ!_@4P.
M=N,?,@QTH ^RZ*^<?!'Q:U;3?#'@W3=9NK>Z:^\(W&L27^H7#>;+<1-A4+$\
MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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M@:UCNV3,B1,<L@/H3VKG)?A3\-9["VT^;P3I#6MM))-!"ULI6)GQOVCL#@9
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M]]BC[5;_ //Q'_WV* )J*A^U6_\ S\1_]]BC[5;_ //Q'_WV* )J*A^U6_\
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M5%;_ /'K#_N#^52TB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **JM-EBL,9D(ZD' 'MFG^;<?\^I_[[% $]%0>;<?\^I_[[%'F
MW'_/J?\ OL4 3T5!YMQ_SZG_ +[%'FW'_/J?^^Q0!/14'FW'_/J?^^Q1YMQ_
MSZG_ +[% $]%0>;<?\^I_P"^Q1YMQ_SZG_OL4 3T5!YMQ_SZG_OL4>;<?\^I
M_P"^Q0!/14'FW'_/J?\ OL4>;<?\^I_[[% $]%0>;<?\^I_[[%'FW'_/J?\
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MC_GU/_?8H GHJ#S;C_GU/_?8H\VX_P"?4_\ ?8H GHH'3THH **** "BBB@
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M'D2?\_4OY+_A0!/14'D2?\_4OY+_ (4>1)_S]2_DO^% $]%0>1)_S]2_DO\
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MI*ZQ;:C'')']GV;8$D(B+(I1&*^JJQ _#T%=)0!4,<EP?WF4B_N=V^OM[59
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M!=H (&.&//S"N]KYB^ O_)1I_P#KPD_]#2OIV@ HHHH **** "BBB@ HHHH
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MY4?_ #S7\JS[J./^V-/_ ':])>WL*I;DRV%^R:?_ ,_DW_@8_P#\51]DT_\
MY_)O_ Q__BJO^5'_ '%_*CRH_P#GFOY4KON.R[%#[)I__/Y-_P"!C_\ Q5'V
M33_^?R;_ ,#'_P#BJO\ E1_\\U_*CRH_^>:_E1=]PLNQF:?+'%->0_:MZ),
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M]@DY)Q_&E?3/VBW_ .>\?_?0KYG^ ZJWQ$G#*"/L$G7_ 'TKZ:\J/_GFOY4
M-^T6_P#SWC_[Z%'VBW_Y[Q_]]"G>5'_SS7\J/*C_ .>:_E0 W[1;_P#/>/\
M[Z%+Y\'_ #VC_P"^A2^5'_SS7\J7RH_[B_E0 _M1110 4444 >::C?7VE^(M
M8ET_5+N#3S<++>2Q:6DT-J_EH&W.7#'Y0I.%.,UZ6.GK7F&M+')JNM77]FSM
MIEE(O]HPKJ#0_:B(T9F\G;AAM*CEEW[<<]_35*LH*G(]J '452:YMX[=YVN(
MUA3.Z0L JXX.3T&*:]]9+;Q7#W<(AF(6.3S!M<GH >AS0!?HJN)(VE:-6!=<
M%E!Y&>F?RJQ0 4A.!D\"HI)%B7<WT '4GT%0"-YOFF&$[1?X^OTZ4 +O>X^6
M'*1=Y.[?[O\ C5B.-(TV(N!_.I** "BBB@!*CIKLL:%V8*H'))P *\VOOC9\
M.;&^ELY=<:5XFVL\,#NA/LP&#]15TZ52K_#BWZ$2J1A\3L>G50N?^0Q8?27^
M0KSW_A??PS_Z"\__ ("R?X57D^.7PP:YBG;5[C=%NVXM),<]>U;+"UE]A_<9
M>WI/[2^\]:HKRW_A??PS_P"@M/\ ^ DG^%'_  OOX9_]!:?_ ,!)/\*7U:M_
M(_N'[:G_ #+[SU&G5P7A?XF^$/&6K2Z9H-]+<744)G96@= $! SDCU85WG:L
M)0E!\LE9FL91DKQ=RE9_\?NH_P#79?\ T6E7JHV?_'[J/_79?_1:5>H8T%%%
M%(84444 %%%% !0>E%!Z4 ?#GC[_ )*'XC_["%Q_Z,:N;S71^/C_ ,7'\1_]
MA&X_]&-7-5^EX)_N(>B_(^,J_'+U'9HS3:*[[D#LUW?P_P#]3J/^\G\C7!5V
M?@NX^S6&I28SAD_D:\?-OX$OE^AVX#_>(_/\CT'3-2UC1=0FN-/6R/G+L=I[
M<2/M[J">@/<=Z?:ZQK=G=B2&+3 %F::-WLD9H&/7RR1\OT[5T]U;Z7)J=I;>
M3IEOH$S*+>_BN%\^;]V3M8EL@LPP<K@<576S\-QL//9A(S6226PNUS;M,S*Z
ME@/FV@ ^V>:_/3ZDY=!/#KT6MPLCW\<AF\V50^7/\6#WR<_6K.FZIKECITFF
M?:XWM6$@#/&&E59#EU#]0&/)%=+%:Z!-;6$+0HR1O?1SW4=RJL6B+>6&'^T
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MUSX G_BY,_\ V#Y/_0TKZCKY:_9__P"2DS_]@^7_ -#CKZEH **** "BBB@
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ML?G^1U>ZC=46ZC=7PI](2[J-U1;J-U %;5V_XDMW_P!<S7 $UW>KM_Q);O\
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MO^_9H^U#_GC-_P!^S0!\,ZEX,\<ZCJUW?R^&M1:2XE:5CY)Y))/]:J?\*_\
M&O\ T+&H_P#?DU]W?:/^F,W_ '[-+]H'_/&7_OV:]F.:UHQ44EH><\#3;O=G
MPA_PK_QK_P!"QJ/_ 'Y-'_"O_&O_ $+&H_\ ?DU]W_:?^F,W_?LT?:?^F,W_
M '[-7_;%;LA?V?3[L^$/^%?^-?\ H6-1_P"_)K=\/^$/%5@EP+KP[J2%RNW%
MNQSC/I7VA]I7_GC-_P!^S2_:!_SQF_[]FL*^9UJ]-TYI69I2P<*4E.+9\D_\
M(_X@_P"@!J7_ ("M1_PC_B#_ * &I?\ @*U?7/VH?\\9O^_9H^U#_GC-_P!^
MS7E'<?(W_"/^(/\ H :E_P" K4?\(_X@_P"@!J7_ ("M7US]J'_/&;_OV:/M
M0_YXS?\ ?LT ?'M]X8\27.G3V\/A_4C)(NU0;9AS6IX.^"_B&_NDEU.QDLX<
M\M*,'\!7U=]J'_/&;_OV:/M0_P">,W_?LT 8GAOPGI?ANQ2"T@7>!RV.3715
M!]J'_/&;_OV:?'*),X1UQ_>7% $E%%% !1110 4444 %%%% !1110!D:II=M
MK%O'#<F6-HI!-%+#(4DB<9&Y2.G!(]P33(]#L8= ?0XU<6LBLLG[P[Y-Q)<E
MNI+$G)]S6U10!AKX=TU==&L*LHF!WB(2'R@^SR_,"=-VSY<^E;E%% !1110
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M9?+9P2H(9,$D$8..M6;7QI<7FJ?V?%IZ"634A;P$R<2VNUR9QQ_TRD&/8>M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10qimg10.jpg
<TEXT>
begin 644 cvm_10qimg10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %T B0# 2(  A$! Q$!_\0
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MH GHJ'S8]H;<,')!SUQ2B6,R&,2*7 R5SR!]* ):*** "BBB@ HHHH ****
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MNZ* /+_A?H^I> ?@S8V_BCS9;ZUCFO+BWM4:8P[W:3R8U7).T$* /3CBN?\
MAUXBOOB-\0+GQ)KG@'7="FTFWD@L'U:W,$<$<C $1@C+R.$&]N H4*.I)]PH
MH X73=)CUA=0U;5[-K.UFMY+"SM'7RC;6F,,Q'\+/C/LH0=C7D]]H]OX)\+K
MJN@W$OV"_O;'3?[6U)5(^SQ HDQ0 +Y,2 [%(_>.P9L@C/TE1@8QVH X'P?X
MCU=OA98>)/%]K=17AA:66-;5C.R;R(R8D!(=EV$J!P2>E><_!7PC<:MITWCC
M7)=<TS6KO7KK4[K3+E9+>-F.Y8@\;J,D(5((R.G<<?0E% 'S;;^#-<U"Y^(G
MQ0CT>^.O6NHW,WAS3Y3(GF/#"8HYFC8_/DEBB].3C[U8ECH/B#3M*U+Q=IFB
MZQ)'8>$I+"662"5+W7-4N2"[,N!(5C<@;B..=O S7U;10!\57OPW\4:1HWBU
M1I^MWK:/X5L]"1889<7]S<,'E=-OWXXB^6"YR4YSSGZ7BNH_"?P<LY/[%U75
MX=/T^&!K*WA+7<R *APF<YQEL9S@>M=]10!\_>%=%M/A_I?CC4M-T+7+_P
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M8EFW <==\?IF/P5U[1+/1[_5]1U*#[/:VUG:23L6WK\QV*0H7[W..G%>NT4
M?/7B^T\1:7X!\":3I,FH36.JWD;^(M5-A-<2N%ASB:)-LGELP"D#;A4"]#@\
MAXN\.:EX:M['P_IOAG7M2\/VVB:AJ\-LEHS_ &O59G*(9$C&R/8K&18^-N.!
MN%?6E% 'S%I7PQD\6>(O"?A?6=+U33_#F@^$8[>\9S) ]Q<3,-T88' )"DOC
MG#;3UXZ+P#H-S'\;=7U!=$O#H\\/]I1W.I6KPW.FW3 0FUWGB:,Q_,H!8)@=
M#U][HH **** "BBB@ HHHH **** "BBB@ HHHH *\M\17VI6?Q-CNF2*9;>.
M".PLY878S>8Q$KQL.%<< D]A[UZE28&0>] 'BMMIMG?:K;:7=0S17T$VH/K$
MRH5;RCDH6;&&!/EE1STK;\*W1TWQ,FGR:7<2->*6AFEX:*)@7SM P 3][&,$
M@8XKT_'7WI<#.>] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45#-,(83(P) QP.])YLW_/J?\ OH4 3T5!
MYT__ #ZG_OH4>=/_ ,^I_P"^A0!/14'FS?\ /J?^^A1YT_\ SZG_ +Z% $]%
M0>=/_P ^I_[Z%'G3_P#/J?\ OH4 3T5!YT__ #ZG_OH4>;-_SZG_ +Z% $]%
M0>=/_P ^I_[Z%)'/NF\EHRC;=W)SQ0!8HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #M24=JK37"P[=R
M2-DX^1"V/RJ6[*[&E<L_A157[4N^1/+DR@R3L.#]/6D^V+B(^3+^\.!\AX^O
MI4\R[CY66Z*J?;$S+^ZE_=]?D/S?3UH^V)F(>5+^\Z?(?E^OI1S+N%F7,453
M^V+ME;R9?W9P1L.3]/6E-VOF1IY<F7&0=AP/J>U'/'N'*RW15+[8GE/)Y,V$
M.TCRSD_0=ZH:AXBTC2;B"/4[H6K3J6C+J<-CKSCMD?G34HO1,EZ;FYFDKE?^
M$]\)^29/[57 ;;CRVS^6.E/_ .$X\*^;Y7]KQYV[L[6Q^>.M.XKG3T5E6NK6
M=]IL-_:&6:WF.$98VY[9QUQ5G[0OFO%Y<N47<3L.#]#W-'S*L7,48JG]M3RH
MY/)FPYP!Y9R/J.U.^U+OD3RY,H,D[#@_3UJ>>/<=F6L48JI]L3$1\F7]Z<#Y
M#\OU]*7[6G[W]S+^[Z_(?F^GK1SQ[A9EK%%5?M:?NOW,O[SI\A^7Z^E)]M39
M*WDS?NS@C8<GZ>M',NX69;XI:J?:E\R./RY,R#.=AP/J>U,^VIY3R>3-A#MQ
MY9R?H.]'/'N*Q=YI*JBX7SEB\N3YEW9V' ^I]:9]NC\@S>3/@-MV^6=WY>E'
M-%=1V9=I<55^T+YYB\N3(7=G8=OY^M1_;H_)$WDS8+;<>6=P_#THYHKJ%F7\
M452^TKYLD?ER91=Q.PX/T/<TGVV/RHY/)FPYP!Y9R/J.U'/'N'*R[69JFKZ;
MH\,4VIWL=JDTGE1ES]YL$X'O@$_A5K[4NZ1?+ES&,D[#@_3UK@OB9<'[%X:N
M([6ZE_XF7^KBA9Y/]1+_  CFFI1>B8K=SHI/%?AV]5;6UU6*6:1U5$ .2<CV
MKDI+K5H/B7<7CW4T.EQZC';23&<E%#0*1&8N@#,1\_8UA0:M-#<Q3?V+K;>6
MP;!T^7G'X5TC>/&=9%?P;JC"0@N#82?,1W/R\]!5)A8CN/&%])H<EKM%MYMA
M)-#*)2\K.I.1[8 []>U=)9^)I)O"-[KSVF?LV_%LI_>KMXQ(/X6[D=A7.?\
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M%% !1110 4444 %%%% !1110 5SGB+_D-^%_^PBW_I/-71US7B/_ )#?A?\
M["+?^D\U)@;^:7-1;J-U9FA+14>ZEW4 /HIFZC=0 ^BF;J-U 6),T9J/=2[J
M!6'YHS3-U&Z@"0'D5SO@SG1;EO[U_<G_ ,BM6^I^85@>"?\ D6BW]Z[N3_Y&
M>KB)G2T4451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<&BW'Q(T?Q0T]K+-Y&EV*+Y80J-SNLK[?O8 (Y_"O5: "BBB@ HHHH ****
M"BBB@ HHHH B[FN<U[_D8M'_ .N<_P#[3KH^YKG->_Y&+1_^N<__ +3JH?$8
MU?A^XYSX@:IIEMIMO:7DT9E$BS"UGCD,5R.5",RJ0#D@@'N!FD^',OVC0KB9
MKB-Y/.2*2&/>5@9(E4C+@')QDX&.:Z#7M-FU&R@-MJ'V"XM)UN(9F4,@89&'
M4]002/;K4>@Z?-9B]NKK4TU&\O9A-/+$ L:D*%"J 3@  =>36W4YY?"S9T;_
M )!*_P"_)_Z,:M6LK1O^02O^_)_Z,:M6L'\3.FG\*]$.HHHI&H4444 %%%%
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M ,@E?]^3_P!&-6I6+^)G33^&/HAU%%%(U"BBB@ HHHH **** "BBB@ HHHH
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MTK8KY_\ A>UO8_$MM-D\,>#=,O/+O;=VT.%UN87@E5") Q^5'!# XYXKZ H
M**** "J5]';R6$\=TX2!D*R,7V *>O/:KM5IH8KB!X9XUEB<%61AD,/0B@#R
M2Q9&LVT2ZN'M=)?Q ;>9([IGC2+R=R1B7.<,P&>>"<5 DE_;:;9:ZNM2_NGF
MAMB=SN+:-W7S.N"NT@\C)(7FO5UT31UTLZ6NFVPL3UMQ&-A]\5.-/L1%Y8LX
M0GE>1MV#'E_W<>GM0!G>&KJQNM!A_L]IO)B)A(GYD#*<-N/<Y[UO56M;6VLK
M5+:TA2"%.%2-< ?A5F@ HHHH 9G );@>IKE=:GAF\1Z3Y,R28CGSL8'',==0
MRJRE6P0>"#WKA[KPN-!O6U30;-9(3DRVH'S*.I,9_P#9?RK2E92U,*W,XZ(Z
M@=*4=JSM,U:UU.W$D#\]"IX(/H1VIUYJ"PNMO!&T]R_W(DZGW/H/>MTFSCG.
M/+8GT6:'["D/FIYGF2#9N&?OMVK9Z"N8TKPQ9V=\=6N((FU!LG<J\)GKCU/O
M72_Q5S3MS.S.R@I*G&,E9I$M%%%2;C>U>4Z?<W7BSQ3=7#:MJ%M832M':);7
M#1J(D&-V!UW$$_3%=/X[U:73_#;VMH^V]U%Q9P$=5+?>;_@*AC^58/@^&.WU
MZSMX5VQQ1E%'H N!291HV^CZ/=7-Q;6_C34Y9K;)F1=08F/'7//:K4GA.UCC
MCDD\4:PJ2,%1C?-AB>@'UKG;?P[K6FW,^I+;SW#W'V^&.':H-HTC,R.,?>5L
M '.<9%6+BS\77#S0Q0S32)):S0/<C$4+KC*X'4#KD?C3).B_X0E?^ADUO_P,
M:JTOA6SAGA@F\4:RDLY*QH;YLN0,G%2N=<;P9;B-;Q;X.HN@Y'GE=W[W8>F<
M9VX[8JEHNFZI)XML]1OENS;007,<#3M\P0NFP2#^]C=[X S0!:D\)VT+Q)+X
MHUE&E;8@:^8;CC.!^ J?_A"5_P"ADUO_ ,#&K$UJS\1W/B-9;>.Y>Z@N9)+-
MC_QZI'Y!"D_[6\\YJFS>-HM)B\I;^XN!,K@G*^60!O4@\N"<X["@#H)/"=M%
M-%#)XHUI))21&IOFRY R<?A1=>%;2RM9+J[\4:Q!!&,O(]\P"BLG^P]6N-4C
MCF;4U:+4+J<SF3A(V1_+V'L.0"!6];:E>'PG*VI:1<WVH6D"&6W,0S<2[0P"
M]CSCGL: ,6?3_#]K:P75QXZU&."X!:*0Z@VUP.N#FK2>']*D>1(_&.JLT14.
M!?ME2W3OWJEI^DW6J>%[+3)-*EM!=WS3ZB+B()L7/F,J#G"L<*/;-2:IH]]8
M^(#JFBZ69 DN-CY97=OF+!<\+N.,]B2>U &;KFGSZ7JC6D.N:NZA0V6O7SS7
M.W+7 \1>'O,U"]N%-V_R3W#2+_J7YP>]==XLW'7R6X;RDR/0XKD+S_D8?#O_
M %]O_P"B7J.HSK]U&ZH\T9H&2;J-U1YHS0!)NHW5'FC- $FZC=4>:,T 2;J7
M=46:,T 3;J-U0YI=U %;66QX?U(^EK+_ .@&O1]%&/#^G#_IVC_]!%>9:XV/
M#>J'_ITE_P#0#7IVD#&A:>/2WC_]!%4A,O4444Q!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7(?$*]U+3_ 6I76EQ[IU\L.XM_M!AB,B
MB241?QE$+/M[[:Z^N4\9-:0>$;Z2^U34M+@55_TG3%9KE&W#;L"JQ))P,8.<
M\T ><?"OQ-#KOBB/^S+^+7IA%>QZIJGV%(I75)P+5I)51<LR9^3T&<#%>Y5X
MSX8U[XO_ &IF;PV=6\/ C9<:OY>FZBX)Y/EH64X'/S",FO9J "BBB@ JN7G^
MT%?*'E;<A]W)/IBK%-J6KC14\Z\\I6^S)OW8*^9P!ZYQ3O,N/-=?)&P+E6W\
ML?3':K-%3R^;'?R*?G76V,_9DW$_.OF?='KTYIWF7.^4>0-JCY#O^\?Z5:HH
MY7W87\BKYMYB+_1URW^L_>?=^G'-+YMU^]_<+\O^K^?[_P!>.*LT4N5]W^ 7
M78K>;<[H_P#1UPWWSO\ N?IS3?,N]LI^SKD'Y!YGWA^7%6Z*?*^["Z['+ZCX
M?DNM0CO]/Q8W9 \V0'*O[,O<^]7;&Q;3X)&BM1)<,WS2/)EI/<G''TK;HJGS
MM<O,[&:A!2YN57*_F3^<J^2/+*Y+;N0?3%,\Z\\G=]F3?NQM\SC'KG%6Z*CE
M?=_@:778K^9/YQ7R1Y>W(;=SGTQ3/.O/*5OLR;RV"OF< >N<5;HI\OFPNNQY
MAXFTOQ#X@\>F/36L!%I5FNU+MG W3%LN-HZX3;^?K3+;POX_M)EGMIM"CE7H
MPDEX_2NIAD\OXB:V/6PLV_\ 'YQ_2MG[0?6J46)R.-_L_P"*?_03T7_OY+_A
M5FQM_B9;W2-<W6ASPDC>I>7./;CK74_:#ZT?:#ZT[,GF1(MUY9"7<9@/][JA
M_'_&K@(8 J<@]Q6>9\@@\@]C4 S"=UK(8?\ 8ZH?P[4[,+HY[5;7QXVMW,>C
MZCIZVG#H+IG#X/7[HQ@&JG]G_%+_ *"6B_\ ?R7_  KI[B\**EQ-&8Y8OXEY
M5U/4>WK^%7!<9 (.0>0:5F.YQO\ 9_Q2_P"@IHO_ 'W+_A1_9_Q2_P"@IHO_
M 'W+_A79?:#ZT?:#ZT68N8XW^S_BE_T%-%_[[E_PH_L_XI?]!31?^^Y?\*[/
M[1[TOVCWHLPYCSZZ\+_$"\G,UU<:'+(1C<9)NGY5@ZMX?\2:5K/AZZU=M,-O
M]M9!]E:0ON,,F/O#&.*]?^T'UKC?'DV[_A'1_P!1+_VA)1RCYC.WT;ZAW4;J
MDHFWT;ZAW4;J )M]&^H=U&Z@";=1NJ'=1NH FW4;JBWTNZ@"3=1NJ/=1NH I
MZZW_ !36J?\ 7K*/_'37K&FC&D67M G_ *"*\BUYO^*:U+_KW<?I7K]B,:?:
MC_IDO\A5(3+-%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5AZ_KECX;T&XU?4%E:*$JH2%-\DKLP5$11U9F8 #U-;E<IXVT_^T_!U
M_9_V3<ZLS!&6VM;A;>;<KAE>.1B KJ0&&3U44 8?@'Q%:S6\.GS#48[O4;F_
MN8X[] &C*7!$D)(9AE=PP <8KT>O%_AWI_AG3_%3V\^L>))O$@BGEBL/$:JD
ML$<D@>5XPBA&W-C<P+=N@KVB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#BII-GQ'U;WTVS_ /1EQ6CY_O6+J;^7\1[[_:TRV_26;_&I
M_.]ZZ81O&YR3G:31I^?[T>?[UF>=[TOG>]7R$>T-+S_>CS_>LWSO>CSO>ER!
M[0TO/H\^LWSO>CSO>CD#VAI>?[T>?[UF^=[T>=[T<@>T-+S_ 'H\_P!ZS?.]
MZ/.]Z.0/:&E]H]ZY3QK+N?P\/^HB?_1,E;/G>]<QXNDW3^'Q_P!1 _\ HF2I
ME&T67"=Y(3=1NJ+=1NKD.TEW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4N
MZH=U&Z@";=2[J@W4NZ@"GKS?\4[J'_7$BO9[48LX!Z1K_*O$]</_ !3][[IC
M]17M\0VP(/110)DE%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *XGQ8-<U*#4-!TN2UCEELTG@"ZD]I<.PE D&44LD>W'SCG+8XZU
MVU<!XK\*^*-0\5VGB/PIXBLM)N8K&2QF6\LC<JZ,ZOD8=<$%??K0!E_#OPYJ
M6CWTEPWACPW96<\1_P!/T_49KVYE.1@-)(@+#K_%7J=><^ ?"_C;PK#:Z7K'
MBC3=4TBU@,44,&G&"7=G()?>1Z\8KT:@ HHHH *8S;5+8)P,X'6GT=J .*7Q
MO;P_VB-6TR\TZ2S@%T(Y0K--$6VJ5P>I;C:>>14,OQ M+5DCO-+NK:\64QW%
ML[+NA'RG.<X;(8$ <GGTK-;PYXHU:YU]=8M[."34%7[/<I.7,0C<-#'MQ]W(
M)8]R:TX/#NM7D=_<:HMK!=ZM<(;CRCO%O"B;0$)'+'U[;O:@#I--U"/4X9+B
M&-E@$C)%(?\ EJHXWCV)SCUQFM:N6\*Z;KNEVMQ!K5XLZ@JL"J<A0!@D<# /
M&%[8KJ: "BBB@ HHHH **** "BBB@ HHHH \Y\0MY?Q%F_VM+B_263_&H_.J
M/Q<WE_$1#_>TM?TF;_&J'G&O4H1O31Y5>5JC-/SJ/.]ZS/.-'G&MN0Y^<T_.
MI?.]ZR_.-'G4<@<YJ>=[T>=[UE^>?6E\^CV8<YI^=[T>=69Y]'GFCV8>T-/S
MJ/.K,\\T>>:.0/:&GYU<[XFDW7>@#_I^/_HF2K_GFL/7Y=U]H(_Z?6_]$R5E
M5A:#-:,[U$:&ZC=46ZC=7D'M$NZC=46ZC=0!+NHW5%NHW4 2[J-U1;J-U $N
MZC=46ZC=0!+NHW5%NHW4 5-<;_B177N%'_CXKW<< "O ]<;_ (D=S]4_]&+7
MOM F%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RKQ
MY)Y?Q M/]K2V_28?XUY=\2/B)_PKW0['5#IO]H"ZNOLY3S-FWY2V>GM7I7Q(
M;9X\TP^NFR_I*G^-?.G[0[^9X0T!6&1_:@R#W_=FO7IWCA^9?UJ>/4M+$<K_
M *T.\U+XM>%K'X<Q^-8[H7%O.NV"V#8E>7O&1V([GTJ_X!\<+XV\&P>(9+1=
M.\V9XA"9=WW3CJ<=:\HU7X-Z#IS:[XA$WF:7'ITUS:Z<<[8IS$<M_NCJ/_K5
MR-K));_ OPE=;GC@MO$#/-("0$7/4X[5=ZBE[RZ"<*<H^X^O](^J;S44M+&Z
MN-RN\$+S>7NY;:I/]*X_P[\3--U3X<)XTUB-=+M3*T)CW[R6#;0!ZDGM7FLV
MO6.M?'K4[C2M06\LQX=G3?$Q*%A&<X['K7%75E'<?LX>'KR1)&%IK$BR%6.U
M49CDD#Z=:<I.[<>E_P +"C35DI=;?B?2VN>)M0TS4='M]-TIM5@U"X\FXGBE
M %JO'S'U_P#K52\-^.O^$@\9^)_#IL1;C0I%C\_S,^=DD9QVZ5X_X@;PK:ZU
MX A\#W ?36UC,GE3NX+DQY!)/ICBL#Q!?>(;7Q/\3SI.Y+.6]B349X?];'!N
M.2H_G2E-I_UVN.,%)6_K>Q]&ZMXFU"Q\1Z-INGZ2=0L]0=DN+V.4;;4#N1WK
M>-[" 2T\8 .TDN!@^GUKY\O7T6W\<_"*+PS<-)I19BC!SF3YER7_ -K.<YKG
MK70=/UG3/BGJ6I-<RW&FW$\EH!.RI$X+D-M!P3P!]*OVC3:M?_AKF?LDTG>W
M_#V/J9KE44M(ZHJ]69L ?C0MPK*&5@RGD,IR#^-?+6N:IK6H>'?AO'JETDFC
MSVY^T->2ND$LH8A1,R\XP!7HOPKAN--OM=L4US2[VP+1SP66G7#SQV1.00&;
ML<=,U4)\\N5+^K7,YT^2/,W_ %>Q[#Y_O61K$N[4M"'_ $^-_P"B7J7S_>LW
M4)=VK:&/^GMO_1+U6(A:G+T(PT[UH^IT.:,U%NHW5\X?3$N:,U%NHW4 2YHS
M46ZC=0!+FC-1;J-U $NZC=46ZC=0!-NHS4.ZEW4 5=8YTB5?5XA_Y$6OH"OG
MW4SNL0O]Z>$?^15KZ"H$PHHHJA!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >-?%-]GC?1O?3KC_P!&Q5P]U#9WJ*E[:0W2(VY5F0.%/J,]
MZ[+XO-Y?B_0V];&Y7_R)$:X+SZ^GP$.:BOF?*YA/EK/Y&B[I)$T4B*\;#:RL
M,@CTQ586>G"Q:P&GVPLVZV_E+Y9_X#C%5_/H\^N_V9YWM63PV.EVS*UMIEI"
MRIY8,<*J0G]W@=/:G+:Z>MB;%;&W6T;.8!&/+/\ P'I5;SZ//H]FNP_:ON2Q
MZ=I,*0I#I5G&L+;X@L*@1M_>''!]ZF6"R1[AULX%>YXG81C,O^]_>_&JGGT>
M?1[-=@]J^Y/'8Z7"83#IMK&8"6BVQ*/*)ZE?3\*>MK8(EPB6-NJW.3,HC $O
M^]Z_C57SZ//H]FNP>U?<M/:Z?+8"PDL+9[,<"W:)3&/HO2EL[:QT^'R=/L8+
M.(G)2",("?PJI]HH^T4>S0>U?<T_.JG<R;M:T0?]/3?^BGJ'SZKF7=KVBC_I
MY;_T4]<V+A:C+T.K!SO6AZG9[J-U19HS7R1]D2[J-U19HS0!+NHW5%FC- $N
MZC=46:,T 2[J-U19HS0!+NHW5%FC- $=X=T=NO\ >NH!_P"15KZ$KYZF^::Q
M7UO;<?\ D5:^A:!,6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 )D9QGGTIN],$[AA>ISTKCKN2Z3XC:
MC]E+&5=!#1KVW^:^./RK@]-L]/O;6/[+JC) =)CO=4=B95-R'/$BY^\<N-O!
MX% 'M^1G&1GKBEKSKP1J$?V^73;O[6^HK$$S/SMCCP G7@C<"2>I)QTKT6@
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MC=45% $NZC=46:7- "_>U#2U_O:C;#_R*M?0]?.\1_XF^B_]A.U_]&BOHB@
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M:_\ HP5]$5\\V8W>(=!7UU.W_P#0J^AJ "BBB@ HHHH **** "BBB@ HHHH
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10qimg11.jpg
<TEXT>
begin 644 cvm_10qimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
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MR P]JM5-FG9@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_K5WM6/;R26^MSVLFTI.#.C!N>, @BEL1LS:HHHIEA1110 TKD8-4O[(TO\
MZ!\'_?L5?YHH3:V8&0OA_1%NWNUTNV$[J$9_+&2!VI+?P_HMJC1V^EVT:LQ<
MA8QR3U-:]%/GEW8K&->:)8S6$T<%G!'*R$(WEC@]CQ3=/UJQFT^%[BZA@FVX
M>,R#*D<'^5;E1>3#GF)"?]T4<UU9ZC(H+RUNMWV:X2;;][8P.*LUC36%['J+
MW6GSV\0DC5&22(GH3R,$>M2>5KW_ #]V?_?EO_BJ'%/5,#5HK+\O7O\ G[L_
M^_+?_%53OH?%;6I%A?6"3[A@R0,1C//\7I34+]4!T&:*P+N;7+*U-U));3)&
M071(6R1GG')JY_;NE_\ /P?^_;?X4N2737T TZ*R_P"WM+_Y^3_W[;_"JMQX
MJT.VN+>":\*O<,4C'E/R<9]*E1D^C^X#>I*R)O$6DV\$DTMT52-2S'RVX _"
MJO\ PF/A_;:-]N.+PXA_=/\ -QGTXI\LWLG]PKG0TM<O)XX\-Q7#V\E^0Z2K
M"V8GP&;ISBNFZBI<90MS)J_<>X^BBBJ H:K>-8Z=)<*,L.E>5^$OC%I?BC4=
M6LM/D>2;3)3#<1R1[&5LD9'J,@\UZ5XC_P"0+-7P1H=AXJTN?Q#XV\%QO=:B
M-9N]*NK8 L'CD^X^!_=;FNNBH\NJN<E64N:R=CZO\-_&+2O$/C'4_#]G,TT^
MED"Z(CP@R<85N^#7=7WBBS6S;[))NF/0>E?#^F>'I_"'_"T=)M[J6:\MM!AD
MEG5CO:9OF=@>O4FNIN/%VEWE_P#!ZUL=>CFF\R(WB13Y(S&%Q)@]2V>#S6BA
M!ZR5B.>:TB[K_@7/:M-^-UA<^']=UZ1IHK'1KB2VNGDBR0R=2H&<CFKMY\5)
MA=:&D%M=S1:TI>">& F.-=NX&0_P9'K7S1"FG7WP=^)VGS7 ^V6NKW-VMNDN
MV08( 8J.2OZ5K6,VFV=Y\);/P[JSSV<K3&Z5+II093""R-SV/\)Z5LE'^5&5
MY:^\^OY7/HWP3\3H/%GAN36+,2B$RR0IYR[6W(<'\*L>$?B0=<O]2CN+2\MH
M[&X-LQN83'YA'\2?WE]Z^3OA[=7TR^&-+\2&:Q\&R:M="&>&7:MW=[\JDQ!R
MJ=@.YINJW^JRZ7K,,.L7EM*?'*6R31S'=$A5AA>>@].E1:#C\([S4K<VQ]U+
MXFTMLYFV_44L?B73))?+\S:<XR17Q=JXU;X?^-/&&D^%-1U"[ \/B^1;J=IW
M67?AI!GN!DU3\)G5H=;\'ZAH=Y;6]W?NINS-X@^UMJ,9&9-T)'RL.3VQC%1[
M&G>UF;>TG:]T?>BLKJ&4Y![T_O69H;2-H\)DSG'&?2M2N&2Y6T=47S13"BBB
MD4%%%% !1110 4444 %%%% !1110 4444 %%%% !6-X>_P"/2[_Z_)O_ $*M
MFL;P]_QZ7?\ U^3?^A4 ;-%%% !1110 4444 %%%% !7*>+H?#Z:6-0\1::;
MBW@.#-&IWQ ]\@AL>N*ZNO-/B9>72KIUK:7T5N\<HN&@EMUF6Y49&/F!"X//
MO0!T_A.Z\*W>CB3PE):R6.[YC;]=W^UGG/UYKI*Y?PC&W_",VM[<-YUY<KNG
MG*JK2')QG: , <#T%=10 445Q>H>/M)TW5;K2[NTU&*Z@ 95^RD^>"<9CP?F
MZ$]N : -CQ%G_A'KOGL/_0A6;JWC3PWH>I6VGW^IQ+>7,BQQ0*=SLS' X'0>
MYJQKEY:7?A>6:&X1X;B)7C.[&]21@BO.-:^!^EW'BJV\0Z3>R6S)<)//;S,T
MBR@-DX;.Y3^=95)3C'W5<ZL/"C*35:3BK:65[OLSV@2*1G>*7</[PK$7POH^
M!FW)/_75_P#&E_X1?1_^?=O^_K_XU5Y=C/EI_P S^[_@FUYB_P!X4>8O]X5C
M_P#"+Z-_S[-_W]?_ !H_X1?1O^?9O^_K_P"-.[["M3[O[O\ @FQYB_WA1YB_
MWA6-_P (OHW_ #ZM_P!_7_QH_P"$7T;_ )]6_P"_K_XT7EV"U+N_N_X)K^8O
M_/05E:KM5[*ZPN8KA02>,!N#S^-)_P (OHO_ #ZM_P!_7_QJ*3PEH,T9CFL?
M,0]5:1R#^M2^9]/Q&XTVOB?W+_,W%DC;[K@_0YI?,7^\*Y(^#=.M;UI-.T^!
M8G0*R--(O(/7@U-_PC,?_0.MO_ J6CFEV(_=]W]QTOF?[0I?,7^\*Y0:+80W
MT%O>6,2),&VNEQ)P0,]S6@OAG0W&4M]P]1,Y_P#9J:DWT*2IO[3^Y?YF[O7^
M\*3S%_O"L;_A%]%_Y]6_[^O_ (TG_",:+_S[M_W]?_&B\NP<M/N_N_X)M>8O
M]X4>8O\ >%8W_"+Z-_SZM_W]?_&C_A%]&_Y]6_[^O_C3O+L%J7=_=_P39\Q?
M[PH\Q?[PK&_X1G1?^?=O^_K_ .-'_"+Z+_SZM_W]?_&E>78.6GW?W?\ !-GS
M%_O"CS%_O"L;_A%]%_Y]6_[^O_C1_P (OHO_ #ZM_P!_7_QIW?8+4^[^[_@F
MSYB_WA1YB_WA6-_PB^B_\^K?]_7_ ,:/^$7T7_GU;_OZ_P#C1=]A6I]W]W_!
M-GS%_O"CS(_:L7_A&-'_ .?5O^_K_P"-)_PB^C_\^K?]_7_QI7EV"U/N_N-K
M<G]X4T^42"=I(Z'TK)_X1?1?^?9O^_S_ .-'_"+Z+_S[-_W^?_&B\NWXE6I]
MW]W_  35W1D8W"D_=<?=XZ<=*S/^$7T;_GT;_O\ /_C2_P#"+Z+_ ,^A_P"_
MS_XT7EV_$+4_YG]R_P RQJ%K'>:?<6Z,D<DJ$!\9P>QKG[BV\=?V5;1VFK:4
MMXO^N=X&VL/;FM;_ (1?1O\ GV/_ ']?_&C_ (1?1_\ GW;_ +^O_C6D:DHJ
MUD_77] <:;^T_N_X)F7D/CAH8!8ZMI22"(B4R0,07XY'/3K6A!<:M:2V,6H7
M%K-YN4D,2%,$*3D9/3BG?\(OH_\ S['_ +^O_C4%QX0T&XC,<UEO&".97R,C
M''-'/)Z22MY;BY:?=_=_P36NHH=0L&B\P%)!PRG(KE='\!Z#H[SBU@A@%PYF
MD2%0F]CU<XZGWK1M?!/ANTM(K6&Q/EQ*%7,SDX_.E_X0OP[]H^T?8SOV[,^:
M_3.?6JC4E"ZCL1*C1F[R;^[_ ()B'X?^'TU&ZO56V2XO5\N:3RUWSJ/X6/\
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M'_\ A.O!OA&>1M<\1V>F:EXHOH]4U&WTM;BZM8T+;)$3821,Y&YL,!@;0,T
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M%XAUBRDN(;"WCNFBCD:W$BVD:]&?G.7.  ?7BO:JKM#"V_=$IWXW9 ^;'3-
M'+ZEJ&J77@^&XETO:;BWBDFS)M\IB02-IYXKH;JYM[&QFO+N9(+:"-I99)&P
MJ(HR6)/0 #-5O$G_ "+=W]!_Z$*R/B):W5Y\*O%UC8V\ES=3Z/>10PQ*6>1V
M@<*J@=220 * +:^-/";>%F\4+XDTUM!7KJ(N4\@?-M^_G'7CZUJ6=Y:ZA86]
M_8W"7-K<1K+#-$VY)$895@1U!!SFOD/3_AWXRB\.)\.Y/#E]_P (I+I0\4.&
MA;B[^Q%/L6,?>^T;7V_>XZ5M7VH?%+PUX"_L+3=%\5_:+OP;H\>F'3[9V2QN
MHD_TD-C_ %3XP",9..E 'TA9^)]#O-:U;1X=03[=I,L4-Y&X*>4\J!XUR0 Q
M*D'@FJFJ>./#.CWKV=YKEN+J.[MK&2!"9)(IKC_4*ZJ"5W]B<#'-?/'Q$\'^
M)M1U7QKJD>F^)%BB\0Z%?[M)A;S[B-+1$EDB&T^8T;9(QT8<]*T?&&E^/M2U
MS7X])L=6NHX]:\,SZ3)?VKLHV1YED<@<A7P9#V.>E 'T;<:MI=KJMEI-QJ$$
M.H7ZR-:VSR 23B, N57J=H(SCIFM:OF9;CXD-IOA.3[/XF_M.'2_$"ZLUQ$[
MLM\(5\K:P7 0OGRMO!&,9YIFGP?&C1M O?[/U7Q%K.I:IX,AU(#5(P19ZD64
M/#%E0%<(6^0\Y&30!].45XI\!YO%\VG:S_PDVH:_=6ZR1?9H]?LY8KB)BI\S
M$DBKYBDXZ#Y>E>UT %%%% !1110 4444 %%%% !1110 Q@&4JW(/!%8=K#=Z
M>9X;>Q$L!E+QXE VJ0.,'I6_2<4FKB:N9OVK5/\ H%_^1U_PH^U:I_T"_P#R
M.O\ A6E11\Q6?<S?M>J?] O_ ,CK_A1]KU3_ *!?_D=?\*T:*+>86?<S[6^D
MGNI;>:U,#QJK??# @Y]/I6C5"XTVQN9?.GMP\F-N[D''X51MTDTV]NHX;&9X
M)&5H]C @<8/4\<TM5N%VMS=Q2UEPZAONTM9+6:!Y%+*7 P<=>AK3SQ3W&G<6
MBBBF,**** "BBB@#G]:_Y#.C?]?)_P#1;5N]ZPM8_P"0UHW_ %\'_P!%M6[W
MJ5NS2?PQ]/U'T4451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5C>'O\ CTN_^OR;_P!"K9K&\/?\>EW_ -?DW_H5 &S1
M110 4444 %%%% !1110 5YA\7+-E\-Q:M:::MS=QR+$TYC:3R8CDD[00,9QR
M>F:]/KS_ .(\=Y)X>2.SG5YYKB-(;1[7SA.W)VX]QW;@8H O?#VXDNO .DS2
M"+YXR5\H@J5W''0D XZC)YKLJPO"\=_#X7L8]4LQ9WBQ_O(%" (<]/W?R_E6
M[0 5FR:IID;3I)J-LC6^/-5IE!CSTW<\9]ZTJ\FU7X?ZQ=Z_J6I6L=@D,UQY
M[6LLSNEZQ&T.^1\A4'@#()':@#T+Q)SX;NR.F%_]"%:XZ5QNH:3+:>"X;>34
M;AFM+>*%MK864J0,D$9YKLNU !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!0NK"WNVC:7>&CSM9'*D9Z]*R;
MKPK8W>I6=^]Y?K):%BJI=.%;(QR,\UTM%2XI[DN,7NCG[:5["]NH)([R6'<K
M1':T@QCG!^M7H]3@EN%M_+FCD92RB2,KD#K6C6-KFEW>HVI.G:DVG7:HRQSK
M&'VY'H:6J6@6Y5H;%+7.RZ7KS:7';IXDD2Y0+NG^S(2V.O'O6IILTD^F033,
M&D9/F(&,FFGY G=V+]%%%44<]K'_ "'-%_Z^3_Z+:M[^(U@ZQ_R'-%_Z^3_Z
M+:M[^(U*W-I_#'T_4?1115&(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6-X>_X]+O_K\F_P#0JV:QO#W_ !Z7?_7Y-_Z%
M0!LT444 %%%% !1110 4444 %<-\1%TZX\._9;UQN1Q<!5\HNJKU?$C*,#/7
M-=S7$>(/"/\ ;>OP:G]L5(@J+/!)$'$PC?>@S_"-WWAW H M^!DNH_!.F)>+
M")/+)'DE2I4L2I^4D9QC.">:ZRL#PWH[:'H$&G/<"XD1G=W5=J[F8L0J]@"<
M >E;] !117 W_P 2-)MM5OM+L;6XU*\M2B;8-NV5SN+*K$X^4*2?RZT =#XC
M_P"1?O/ER=H_'YA7B7B;XC?$*U\?:=I+:+)I-A)=I&"<.9UW 8#_ '1GVKUW
M6-9TVZ\+":.Z1?MD,<L*N<,RL1CBMR>UM[B,+<0I*%(8;U!P1T//>L:L)324
M96.S#5Z=%N4X*5U;6^GFB@NIZYL'_%/L?^WA*=_:>N_]"\W_ ($)6WVI:NS[
MF/M(_P J_'_,PO[3U[_H7F_\"$H_M/7O^A>;_P "$K:HHU[D^TC_ "K\3%_M
M/7O^A=;_ ,"$H_M/7O\ H76_\"$K:HHU[A[2/\J_$Q?[3U[_ *%UO_ A*/[3
MU[_H76_\"$K:HHU[A[2/\J_$Q?[3U[_H76_\"$H_M/7O^A=;_P "$K:HHU[A
M[2/\J_$Q?[3U[_H76_\  A*/[3U[_H76_P# A*VJ*->X>TC_ "K\3%_M/7O^
MA=;_ ,"$H_M/7O\ H76_\"$K:HHU[A[2/\J_$Q?[3U[_ *%UO_ A*/[3U[_H
M76_\"$K:HHU[A[2/\J_$Q?[3U[_H76_\"$H_M/7O^A=;_P "$K:HHU[A[2/\
MJ_$Q?[3U[_H76_\  A*/[3U[_H76_P# A*VJ*->X>TC_ "K\3%_M/7O^A=;_
M ,"$H_M/7O\ H76_\"$K:HHU[A[2/\J_$Q?[3U[_ *%UO_ A*/[2U[_H76_\
M"$K:HHU[A[2/\J_$Q?[2U[_H76_\"$H_M+7O^A=;_P "$K:HHU[A[2/\J_$Q
M/[3U[_H7F_\  A*7^TM>_P"A>/\ X$)5S4M4M],@,DQYQG'2N(TWXM^$=6UA
MM+L=>T^ZNP2/(AN%9^.O&>?PI/3[7Y&<L13B^5Q7XG5_VKK7_0NO_P"!"4O]
MK:U_T+K_ /@0E7(M4L9(U;[0HSV)J0ZE8J>;A/SH_P"WOR#V]/LOO9F_VKKC
M _\ %.O_ .!"50AU#Q39V-M;Q>%1*5(5B;U!QZ]*-9\;:+HUY:VUU>01-=2"
M&#S) IE?^ZN>I]JW8=5L9(E?SE4GL3TI6_O?D'UFBW9)?>_\S-;5/$FTX\+Y
M/8?;$_PJM;:UXNDC<W'A!8F&-H%\AS^E;<NK642,WG*<#H#7-Z3X_P!(U;Q)
M>:#;3QR7MD5^TPJ?FAW?=S]:&O[WY">)I)I67X_YF)J'BC6+77M&C\0:'#I<
M<MX(X'-XK>8Y1AMQC]:[2XU"_MH'N)-- 5!EMLX)Q^5>0_%CP7XF\4>,-(GM
M=5AM[5'6.T4[MR2$%BQQ_NC\J]:M[/4V\+QV=]-%)J'D!)'3(1GQSC/.#6-.
M4W*46G9;/34]/$TJ,:-.I"2<I)W2OIKH;X;<H8=Z6LU;C5%4#^RTX'_/P/\
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M+I=UXBU/X96&L6&M36O]AZK<Z8T<>L7%VU_=B>(I);2')GW!7C5'.T!R<\4
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M&]'_ * U=-Z5S&OP^7=^'8\YV7@_] :NG]*M;L]>7\.%^S_,DHHHJS(****
M"LN^_P"0IIO_ %T?_P!!-:E9M_:37$EO-;S+%)"Q8;EW Y&*3V)EL:'X4<^E
M8]Q;ZXUM(MM?VZ3%3L9H"0#^=16%KXFC,O\ :&J6<V<;/+MBN..?XO6E?R#F
M\C=HK$%MX@_M$N=3M/LGEX$?V<[MV>N=W2K/DZQ_S^0?]^3_ (T7\@OY&E16
M));>(O[0B>/4K06@4^8AMSN+=L'=5GR=8_Y_(/\ OR?\:+^07\C3_"C\*S?)
MU?\ Y_(/^_)_QH\G5_\ G\@_[\G_ !I_(+^1I?A1^%9ODZO_ ,_D'_?D_P"-
M'DZO_P _D'_?D_XT?(+^1I?A1^%9ODZO_P _D'_?D_XT>3J__/Y!_P!^3_C1
M\@OY&E^%'X5F^3J__/Y!_P!^3_C1Y.K_ //Y!_WY/^-'R"_D:7X4?A6;Y.K_
M //Y!_WY/^-5VM]>_M"U==0MOLBD^?'Y)W.,<8.>*/D%_(VZ***905C>'O\
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MBB@ HHHH **** "L;P]_QZ7?_7Y-_P"A5LUC>'O^/2[_ .OR;_T*@#9HHHH
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MA_\ 7Y_[3:NB'6HCNS:I\,?1_F244459B%%%% !1110 4444 %%%% !1110
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MTH Z&BN>M]:U"[=DM+.RN&7[PBOE8CZX%6?MFO\ _0%B_P# H?X4 ;%%<_\
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M %%%% !1110 4444 %%%% !1110 4444 %8WA[_CTN_^OR;_ -"K9K&\/?\
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M+V:\#^&A=3J4DER-\@/4$]2*C6WTE+%K%8_"RVC-O: !0A;UQTS74_V+H_\
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M>T?^UTOOL=F$6(P>7Y*\L6S^=:7]BZ/_ - FS_[\+_A0 ?VUH_\ T%K/_O\
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MY/-;O]L:/@?\3:S_ ._Z_P"-4[KP_H\UY;3"SLXQ;L7=?)7D%2.:N_V+H_\
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M'(/S=C5J'1-'C@CC.F6;%5"Y\A><#Z5<AAAMXEAMX4AC7HB*% _ 4 6****
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M$O-.U#6;Z\T=M+DNG51&MP)8Y0N?WG4G<223GM@=JZ/7+::\\/ZA:0QO))-
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M@1,N%], %,CZF@#V9YH8PQDE1=N-VY@,9Z9IRR(Q*JX)&,@'.,]*\5O?A_\
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M+C\PR;5#D;=V.<>E2=1SR* /(M/\>:]=""W:XTC^T?MOE&V#!Q.C8($;JVW
M3)9NQP,<UZ]61_8.A_N?^)19_NF+Q_N%^1B<DCC@YK7H \B\3?%+4M,\3ZIH
M6F:7@VL*".:YC90TAD56?)PIC4-UR,GO7H6@ZC+JWANRU)G4RSQ!F**5!/?
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MN56(Y /<4EUI>G7P9;ZQM[E3C<)HE<''3J.U6HXHX8DBA18XT 5548  [ 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10qimg12.jpg
<TEXT>
begin 644 cvm_10qimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &F ;T# 2(  A$! Q$!_\0
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M=@P/7K5G4_@[H^LGQ1)J&N:I/<>)=,MM+O9SY08K","083 =NIXQSP!7J5%
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M0S0[F64#=A=NYN!@<]*X*YOTO6EM/#^O:GXC\-QWVAS"[OI'G,=X=07S$5V
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ME@OO.FECM9'+M:P-(QBB)+,1M4C@LV.F3BO2Z "BBB@ HHHH **** "BBB@
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MLR;9=_\ />/_ +]'_P"*HV7?_/>/_OT?_BJL44BBOLN_^>\?_?H__%4;+O\
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M #\3_P#?RC[*/^?B?_OY0!9HJM]E'_/Q/_W\H^R_]/$__?= %FBBB@ HHHH
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M6/7D8C^)(].E\"/K_P#9C_Y)CJ'_ &$W_P#1<=>Y=S7AO[,?_),=0_[";_\
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MTJJBA54!1T IU% !1110 4444 -[UGZ5_P >]Q_U]3?^C#6AWK/TK_CWN/\
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M]NYK+GN9)SC[J=EH ^W=/O[75-,MM2LY/-MKF-98G*D;E(R#@\BM"N;\ _\
M)-_#O_7A#_Z *Z2@ HHHH **** "BBB@ HHHH \]\56]@WBK3TN;UMMU]FCN
MK5;,S;T6X!BR^<1JTAVG=G<.!T-;OA&.WA\+VD=M.)XPTOS"(Q!3YC%E"G[H
M4Y7'M7*^(M0T?4-2^T?:=<TN2.06\5U:VZR1W\D,N]8D!#;G#JV.!G#<D9KL
M?#5J]GX?M+>2SELI I9H991+("6))=AP6.<G'&2<4 ;U%%% !1110 4444 %
M%%02S+$H+<D\*HY+'VH E9@JEF( '4GM5;S9I?F@50G]Z3//T% A:5@]QTZK
M&.@^OJ:MT ?.G[05Q>O<:/I\TQ^R/&\C0HS!68' )'?BO"?L-I_SQ'ZU[Q^T
M)_R&=%_ZXO\ ^A5XM!:7=RDSVUK-.D">9*T<981K_>8CH/<U]SE/)'#PDTNO
MYGRF.<G6DOZV*'V&T_YXC]:/L-I_SQ'ZUKV>DZMJ$,EQ8Z7>7D*_?D@MWD5?
MJ0,"H[?3]0O(IY;33[FXCMQNF>*%G$0_VB!Q^->Y]9H]T>=[WF9GV&T_YXC]
M:/L-I_SQ'ZU>-O.+5;HP2"W=C&LI4[&8#)4'H2 1Q45:\T)?"@O+N<AJ2K'J
M4T:C"J< >G%4ZNZK_P A:X_WOZ52KR:OQ/U/2A\*/O'X1_:O^%/>&=GE8^R#
MKG^\:[C_ $S_ *9?K7&_"'_DCOAG_KT'_H1KN>]? UOXLO5_F?34_@7H95C]
ML^TZCCR/^/GG[W_/-*O_ .G?],/UJ'3_ /CYU+_KY_\ ::5?K)[EHK?Z=_TP
M_6C_ $[_ *8?K5FBD,K?Z=_TP_6C_3O^F'ZU9HH K?Z=_P!,/UH_T[_IA^M6
M:* *W^G?],/UH_T[_IA^M6:* /%_VA/M'_"O+3S/+Q_:,?W<Y_U<E?+6:^J?
MVB/^2=6?_81C_P#1<E?*G-?:9%_!^;/G,P_C?(=FC--YHYKZ(\T=FC--YHYH
M [WP-IFGW6GW5U<6J23B7RQ(>H7 ./SKKO[(TW_GU7\S7.?#[_D"W?\ U\?^
MRBNWM;6ZOKM+6UA:>=ONQIU/K7YWF7^\2]?T/J<'_!B9?]D:;_SZK^9H_LC3
M?^?5?S-;S:+J"ZV^CO'&MY&"SJTJA5 &22Q.,8J63P[JT=Y9VOV99'O<FW:*
M1723'7# XX[UYIV'.?V1IO\ SZK^9H_LC3?^?5?S-=#)H.IPWIM)(4WB W6\
M2*4\H?Q[AQCM]:S.U 'E^L*L>MW<2<(DA51Z"J%:.N?\C!??]=36=0!]D^ _
MM7_"NO#VSRMOV"'&<Y^X*Z/_ $[_ *8?K6)X!_Y)OX=_Z\(?_0!724 5O]._
MZ8?K1_IW_3#]:LT4 5O]._Z8?K2_Z;GGR?UJQ10 4444 %%%% '%2> X6F5[
M;Q%K5ND=Q)=1117"!(G<MNVY0_WWZYZUTME8M9V45JUY/=F,8\ZX8-(_.>2
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M^\PK5(U+6C8Y35?^0K<?[W]*H5=U3_D*W'^]_2J)-15?O2]3JA\*/O?X0_\
M)&O#'_7H/_0C7=_Q&N$^$/\ R1OPS_UZ#_T(UWM?!5?XDO5GTE/X%Z%+3_\
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M@MQ(-S2-"/[BX)_$F@#Q+XNQ:?=_%3P5IVJ1J]A<LRSJ[[%*Y[MD8Z>M<$-
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M*LQ/ "C/-55FA+B6XDWR#H C;5^G'ZT /VR7/WP8H?[G1F^OH/:KBJ%4*H
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MS_WP?\*/M5O_ 'S_ -\'_"@#Y7^)5QXX\9.MN/#]^;:*7>JB(^A&?UKS7_A
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M$C4*H["GU7^V6_\ ?/\ WR?\*G!R 1TH 6BBB@ HHHH **** "BBB@ HHHH
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M#/33=-CMGM8["V2WDY>)8E".?<8P:DAM;:';Y-O'%MS@(H&,XST^@_(5<HH
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M&+*ODKA2>I''!/>M*B@#F[KPW9W6M6VH37$Y%N4:.W 01@H<KSMWX!P<;L9
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10qimg13.jpg
<TEXT>
begin 644 cvm_10qimg13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& =4# 2(  A$! Q$!_\0
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M2M:Z3)****DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45PGC#QE<>$YK)5TM)[:X5
MVDO+F<P01%<8C+A&"LV3C?M7Y3EJ9_PL328;?5+B]L-0MHM-O#9L[0Y$A$?F
M%E(.-NWG\L9R*I0DU=(5SO:2N%N/B5X;M[V6)IIFMX8&N)+H1_NE141SR>2<
M2Q\ ?Q#WQ-/XVM)/ U_XHT>QN-36R$F^U0K&ZLG+!BQP,=203QTS0XR6Z"Z9
MVU%<U:ZTVI:<)M/T^1KM[.*[C2?='"QD4E4\W:1D8YP"1D''-<QHOQ*AN-*@
MU#Q!IHTK[1%/<QK;2/=*D$+;9))&"*$ ;ZYR._%2E)WTV"YZ7FC-<(WQ)\,I
MHO\ ;+37 MEF:&4"$EH2JAV+8X "D'J<YXR>*;'\2M%VWC2:?J<;07TMC&@M
M6=KAHXS(S(!VV@GG'ZU7++L%SO<T9K@V^)_A5;)[MIKI1OB6-'MV1YA)&9$9
M V,J45CGC[IJ7_A8GALWD5K:R7ET954QR16KLCL\)F1 V,;F0$@>V.*.678+
MG<4E>>:A\1$M_!>@^)+?3X[==9E2-%U6X^QI &C9]SOM; ^3 XYR*31_B=X;
MU1+:*87%E>3VPN'@D0DQ'RS+Y9/<[ 6'&",=SBCDE9NVPE),]$HK@8_B)H[Y
MF,=SY,D%O+;1B"3[1<&9I%0+&1W\LD<],DX%-NOB-H>ZS32EN-1>ZFMD<K&R
M);B:;RAYC$?*V0_RGGY2..*.678=ST&BBBI&%%%% !1110 4444 -HKD/%WB
MBX\-K:-'IXN(IB_F3S2M%##M (#.%;:6S@$X7@Y(J"'QQ8E=2:>WO(EL)8X6
M81[EE9T#C8P.",'KP,8/<52A)I-+1F+JP4N5O4[?\*2N*;Q]H.Z$+)*T,D/V
M@SA,1QIY1ERQ//W!G !]*LV_BJ'5-"NM2T6W-Y+ XC,$KB$*W!RS'("A6#$C
M/';/%-TY+=6!5H/9W.KQ2US6@^(EUK3[>[:QGMWF@:;[I:+ <K\LF #G&X="
M5(.*P]'^(UOJ&DIJ%Y:HAG<)!;V+R7,S'878,OEK@JHR<$CWZ97))WTVW%[6
M"MKOL>AT5PB>.K6:_BAM[?S+22YCB2Z$F%,;VK7'F8QT 7&/Q]JG3Q_X?-OY
MS27*KM\Q1) RED\MI%8<<AE1MOJ1CK3]G+L-5H/J=C]:7Z5S%OXPT.XL)[^.
MX*PP1^:VX89AY8E(4'EB%89 Z'BBX\9:-;MY:_:;B7S!$L4$#.[,8?.  '^Q
MS4\DKVLQ\\=[HZ>DS7,7WB_1;+3["^\V>>*^B::W%O"TC.BIO)P.F%YYJL?'
MWAO[3+;I>;S%$TY=4)5@L8E('J=A!_\ K\4*$GT8.I%=4=A^5'Y5QH\;:;YL
MH:&X.?)\F%(7,TID5V V8X^5">O0<XJ-O'VDR7FGV^GK+?"\F@C:5498XA*"
M5RQ'WL#.W^55R2[![2/='<T445!J%%%% !1110 4444 %%%% !1110 4444
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M#'X%\-I +;["SQK+#*OF3.Y7R3F)02<A5R0%Z8)]:^3_ /A87CS_ *&S4_\
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MI47AG3_-$_B+7)IH?[.5DQ;E)#'AFSUR#D]!CKQ66OCGQ(OB6[\0--:RW=Y
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M444 %%%% !1110!4DM[>1]\D*._'S,H)X.1^1YJ:2..:,QRQJZ'JK#(-2T4
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MD<D8DC(96Z$5V4LFP]1:-W]?^ >#B\RQ&%E:233V=CZR_P"%^> O^>E]_P"
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MU.U_Z[G.I)6NCWN'X<^!+73=5-K=1WS75OLCN+K4(%%@[/;E(^F3)MD<^9T
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M+$8Y(P:IT=!@45V)65B6%%%%,04444 %%%% !1110 4444 %:VC?:_./E_\
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M20.<! J[FYZ9"D$C.0#FJ@Y0?-'1B=GN>6?\,O\ PW_Y[:S_ .!@_P#B:/\
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M_P")KUB.021B1<[6 (R"#^1J:E]=Q'\[^\G^SL-_(CR'_AGOP/\ \]M2_P#
MD?\ Q-'_  SWX'_Y[:E_X$C_ .)KUZBE]=Q'\[^\/[/PW\B/(?\ AGOP/_SV
MU+_P)'_Q-'_#/?@?_GMJ7_@2/_B:]>HH^NXC^=_>']GX;^1'D/\ PSWX'_Y[
M:E_X$C_XFC_AGOP/_P ]M2_\"1_\37KU%'UW$?SO[P_L_#?R(\A_X9[\#_\
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MBN>)?^_=K_\ &J:?AWXMS\OQ?\1@>\%J?_:5'+'^9?C_ )!=]CTBBO.1\/\
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MH07SP2-*PC=E,21*N 5*D$0J2""#DTG_  K?3FB"76I74K_Z."R1PPC$)E*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I/8\T4
M4 92Z)I"WT-TNG6ZW$"LD;B,#8"03CTY _*DL-+TS3;6.SL;&&W@B78B(@
MZ?R HHJ@)A9V<<26JVL*Q[&C"+& H7NN/0^E/_L^S\KR_LD/EE=A38,8SG&,
M=,\T44 +]GM5#1K;Q@;?+("#!7^[].>E,^QVOF[?L\6.?X!WSG^9_,T44 2+
M968B2U6VA$<?W4\L;5^@[=:C"6L;C; H/8A1QU/\R?SHHI %K;VD94V]O'%P
M2-B!< G)''OS6A112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cvm_10qimg14.jpg
<TEXT>
begin 644 cvm_10qimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& C$# 2(  A$! Q$!_\0
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M'AAG!'8Y%2S1:C;Z99ZE).PMKPR")A*23Y9 ;([<D5']G4?/[P^N5?(^S/\
MA:6@_P#0.U3_ +\+_P#%4G_"TM#_ .@;JG_?A?\ XJOBK[5< 9-S)C_?-6M-
MBU'5M2@T^QG9YYV*KNFVJ, DDDG   ))[ &F\MHK5W^\/KE7R/LO_A:6B?\
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M_O#ZY4\C[5_X6EH/_0-U3_P'7_XJC_A:6@_] W5/_ =?_BJ^*OM-S_S\2_\
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M4*7*[_UT_P A2G=6"BBBND@**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K>\%_\E \._P#82M__ $8M
M8-;W@O\ Y*!X=_["5O\ ^C%K&K_#8(^VJ***^:.LZ"BBBO,/;"BBB@ HHHH
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M(IVB9,,&&QP"1RHR""".O:IV\81S%HKG0H9+)M-33&MUN9%)C27S4;?R=P.
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MQQ'H.I76AZ#_ ,(;/9Z?_P ([C2)_$&EW^I7EQ(SN!;1HD@$,HX.]B6 *]%
MK+LY(M2TGX;:I\7K#6=5\$P:#-9RH\%Q((=42=DS<1H-Y_=J%4D'GGU-?9E%
M 'ROXJO+?X=^&O!OQ:\$Z)K-KIEM9W.AS6&IB3[4T,N]K4L)&+;5G (R?NN
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M_P#T8M8-;W@O_DH'AW_L)6__ *,6LZO\.0(^VJ***^8.LZ"BBBO,/;"BBB@
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M30U3>\A>\NA)JNJ2:EX2T5;W4'O+Z"\NP3-*9)4C98BN23G:6WD>^:YVM_\
MX0SQ;_T*^K_^ ,O_ ,31_P (9XN_Z%?5_P#P!E_^)KKC.G%63$U)]# HK?\
M^$,\6_\ 0KZM_P" ,O\ \31_PAGBW_H5]6_\ 9?_ (FNCVL.Y'++L8%%;_\
MPAGBW_H5]6_\ 9?_ (FC_A#/%O\ T*^K?^ ,O_Q-'M8=PY9=C HK?_X0SQ;_
M -"OJW_@#+_\31_PAGBW_H5]6_\  &7_ .)H]K#N'++L8%%;_P#PAGBW_H5]
M6_\  &7_ .)H_P"$,\6_]"OJW_@#+_\ $T>UAW#EEV,"BM__ (0SQ;_T*^K?
M^ ,O_P 31_PAGBW_ *%?5O\ P!E_^)H]K#N'++L8%%;_ /PAGBW_ *%?5O\
MP!E_^)H_X0SQ;_T*^K?^ ,O_ ,31[6'<.678P**W_P#A#/%O_0KZM_X R_\
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M *#NI_\ @+:__&ZK^SZW=?C_ )"^N4^S/JGY:/EKY6_X7EK'_0=U/_P%M?\
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M_P"0?6J?9GU1\M+\M?*W_"\M8_Z#NI_^ MK_ /&Z/^%Y:Q_T'=3_ / 6U_\
MC='U"MW7X_Y"^N4^S/JJBOE7_A>FL?\ 0=U/_P !;7_XW1_PO36/^@[J?_@+
M:_\ QNCZA6[K\?\ (?UNGV9]4_+1Q_D5\K?\+RUC_H.ZG_X"VO\ \;H_X7EK
M'_0=U/\ \!;7_P"-U7]GUNZ_'_(7URGV9]4_+1\M?*W_  O+6/\ H.ZG_P"
MMK_\;H_X7EK'_0=U/_P%M?\ XW1_9];NOQ_R#ZY3[,^JJ*^5?^%Z:Q_T'=3_
M / 6U_\ C='_  O36/\ H.ZG_P" MK_\;I?V?6[K\?\ (?UNGV9]4T5\K?\
M"\M8_P"@[J?_ ("VO_QNC_A>6L?]!W4__ 6U_P#C=+ZA6[K\?\A?6Z?9GU1\
MM+\M?*W_  O+6/\ H.ZG_P" MK_\;H_X7EK'_0=U/_P%M?\ XW3^H5NZ_'_(
M/KE/LSZIHKY6_P"%Y:Q_T'=3_P# 6U_^-T?\+RUC_H.ZG_X"VO\ \;I_V?6[
MK\?\@^MT^S/JGY:;A?[M?+'_  O+6/\ H.ZG_P" MK_\;H_X7EK'_0=U/_P%
MM?\ XW1_9];NOQ_R#ZY3[,^JJ*^5?^%Z:Q_T'=3_ / 6U_\ C='_  O36/\
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M]JG_ .?E_P E_P **Y?8R-/;1-NBBBL#J"BBB@ HHHH **** "LBW_Y&^_\
M^O.W_P#0YJUZR+?_ )&^_P#^O.W_ /0YJ:ZDOH:O>N7^('_)-O$G_8-N/_19
MKJ.]<O\ $#_DFWB3_L&W'_HLT4OCCZBG\+/B:VT75-8DU&33;-KE+"%KFX*$
M#RHAU8Y//X<U6TJWCN];TZTE&8I[J*)QG&59P#^AJ.:66.XG$4KQB0;'",1N
M7T..H]J73[K[#JMG?;/,^S3QS;,XW;6#8S^%?60YM3Y_30[5O".E_P#"?:;!
M:F6Z\/7^H26BY;$D+H2'@<CHPP"#_$I!]<8-AX7EN[;3S/JUC8W>IKNL;6X+
M[IP6*J2P4K&&8$*6(S[#FKF@^-)M#\57NK&Q6[LKVX:XELI'P-^YFC=6QPZ%
MN&QR"1T-0V?B#2ECTF?5='FO+_2(UBMVCN!'%.J,6C$J[2?E)Q\I&0 #CK6?
M[U%>ZS+TW1;S4M5ET\&.T:W222YDN252V2/[[/@$\=, $DX Y-;W_"*0W/A_
M3FTF\M=0N;S49XA=JSQJD20H[>8K@%-OS,21TZ9K(TW7I+76;V_O[<7T6I1S
M17L6[RS*LIW,589VL&PP.#@@<$5KV7C"ST6&P@T+2[B-+2ZEN&DN;K,DZRP^
M4Z$HHV':!@KTZ\T3]I?W11Y>I5L_!]QJEU:1:-JEI?Q7,YMC-M>(0R;&<!PZ
M@@,$;#=.#G&*!X3@_LZWU1O%&EC3)9C:M=8E(CF !V;-FYA@@[@-N,\]C<3Q
MI]GU&PGB.KWL-M(\KKJ&H&4N6C9%4  *-NXG."3[5SAU 'PI#H?D\QWC7?G9
MZYC5-N/^ YS[ULO:/?\ 0'RHU)/"<]D]T-<U2RTB."[>R62;?()I4QOVA%)V
M#*Y<\?,.IIS>#[JUM[RYUC4[+2[>RO!93/*S29<H'4H$!+J5.01VYJSJ7BG2
M]>N+G^W-(NG@-Y+>6_V6Y6.2(2;=\3%E(925!R "#GUJAKGB637-.NK66S2!
MIKX7:^6V5B18!"D0!Y.%4<D\XH7M7:X/D6Q/-X/N+)]0.K:I:6%O970LS<%)
M)4DD*;U(V*2J%2#N;'7IG.+"^%+6^T[PK%INHPMJFLS30,C!]A*R%58,1@ 8
MQ[YS4L/C*U7Q%<ZV;;4[::5XF*6=Z$29$C1?+E5D(925)SCHQ&*CL_%UE!-H
M]W)HS"ZTJ]FN8E@F"0F.63S#'M*DC!. <XQCBM'[7^K=O\RO<_KU,R#0K.:[
MEMV\26"^7M&](YI5+'KC:A^53P7Z>F:U)O"MO:>'-VK7UKI-Y;:M<6-Q-*7D
MW;(XRJJJ D@$L=V.A^@K/TG7X=/T!]+ECOHB+G[2LUA=?9VE.T+LD."2HQD8
MY&6]:TM4\6:/KQO%U;1;I8[C49=2#6MV%DC:1$4IED(*_)U(SR/?.+]IS>7R
M$N6Q7G\+SVNC7=J]LL^K+JMK:0/ ^Y9DEA=UV'H0WR$'^7-4KSPXUO:WDUKJ
MMIJ$FGX^V10!P8AN"[E+*!(H8@$KTR.QS6DWC8LUS,NGFVFCN[2[T[R9,I:F
MW0QQHP8$NNTC/()(]ZBUKQ9_:=C=0PR:NINW#21W.HM+#$N<E$7 W G'W\X
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M]Y: D!9-P0,1EMK*>A)I^WM:Z'[,\KI-R\_,..OM75Z\FEGQCIT5Y;36,1$
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M;MK!BIP<'.#4E !15&.\LYKN6UCNHI+B'!DB5P73/3(ZBKU !1110 5D6_\
MR-]__P!>=O\ ^AS5KUD6_P#R-]__ ->=O_Z'-374E]#5[UR_Q _Y)MXD_P"P
M;<?^BS74=ZY?X@?\DV\2?]@VX_\ 19HI?''U%/X6?"UQ_P ?,GUIL<<DTT<,
M2EI)&"*HZL2< ?F:=<?\?,GUJUHD[6WB/2[A75#'=PMN8 @?.,DYXK[+:)\X
MBG-%):W,MO.IBFA=HY$/5&4X(_ C%,W<!-W .X+GH?7%>C^(9M0TV'QC?7VF
MPKJ3:RD4$MU9INCB87'S(I&.0H^;!]>O-7-0M-)M8YX8+*\N_#2:>)8_)TV'
MRV'E#$PNB^[S/,ZYYR"NWM67MMM/ZT-?9GE991G+#CD^U6+NUNK"X:QO(V@E
MCVNT3'[NY0P..G*D'\:]&GTF6'P[KFFWD#W"Z?I/VJWN4TV&*V,JA&#PRCYY
M,@MDG.X;B0,58UZ:]77/$VL7VGPSA-'M9=/EN+5/+)+6P,B<8?!8^H[=.*/;
M7>G];!R:'E0;!5@V#G*D'G/M2[RL@<.1)G(;/S9]<UZ99WR7OB+PG9S:;IWE
MZY8C^TB+2,&Y8M+'NZ?(0$4_)M^;FGZ;:V$>EZ!]EL[J]TJ>R26^6'3(98YW
MP?/$D[.#&RG('*[0%(SG)OVUMT'L[[,\NR >O)/ZU8FMKJ""TDGC9(IXS+;E
MCPR;BI(]!N5A^%>BZ9<6JZYX,T2#3;(Z?J=BBWAEMD>2Y5Y)5&YB,J0 ,%<<
MC-8/B"35+GP+X0F>-I-/CLWC\Y85"K*)Y0%+@?>VXX)]_>FJK<DK?UJ+DLK_
M -=#D,C.,\^E*6SM#.3M^503T]A7J'A'2#+'HFFWEO)>:=JL$DDIAT^(P*#O
M 62<_.)%('0@J=H -0Z1<0C6/!N@G3;#[)J6EQ"^WVR,]P7$HRS$94C QM(Y
M&>:MSU:2V'R;'G=G:SW^H6^GVJ^9<W,BQ1)N W,QP!S[FHW5DD9'X9"5.3T(
MXKTSPW#J46J>#1HNDV]SH4JVLUU=&V1PT^\&9I9B,QNC<*-RX 7 .>>9\-V\
M<WBG4HVM8KG4(X;EK&VN%!66Y!^52IX8@;B%/!8 <]*PC6O?R%R['+[@1G=D
M>N: W!VMPXP<'[P]#ZUZ#9V^N3RSW.JZ%;C7TT]Y-,BFLTCDN6$JAW:' #NB
M%R@*\X/WMM6X8EBBBU'7='M/[<_L;4)Y[6:W6,.J;/(EDB  5\E^P+!03UY3
MK6Z!R'G-K;7%Y,4LXVEDCC>8[#RJHI9F_  G\*AR"<YR2<_CZUZCH-]?7?\
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M9CDD]2?6DHI**6J'>X4444Q!6]X+_P"2@>'?^PE;_P#HQ:P:WO!?_)0/#O\
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M1#'$[''NI7..^,5O>&/!-K_PF$UKXC8S:9!*MO"T3%1?22H6A*$?PE/WI(Z
M =ZU=2,+WZ*X*#E:QP&6X^8\=.>E*'<1M&KL$?[R@G#?4=ZU[7P[=7&H^'[
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M+]@WB1FQG>'"X.>,>YSYKQGWI 58?*01[4>QOU)]H>K8T^&SM6MK._O/#/\
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M_*FW9#ET* @A<C!!/(S53PW:V=UX>T"348XY-.M]:N/M)E.(D+0Q"(2GLC.
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M***+L0?Z/_SS'_?(H_T?_GF/^^1111=@'^C_ //,?]\BC_1_^>8_[Y%%%%V
M?Z/_ ,\Q_P!\BC_1_P#GF/\ OD44478!_H__ #S'_?(H_P!'_P">8_[Y%%%%
MV ?Z/_SS'_?(H_T?_GF/^^1111=@-_<_W?\ QT4O[G^X/^^1111=C'XM?^>(
<_P"^13MMM_SQ7_OD445-V;V1+M3^[1112)/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677621212560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,493,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677619160512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 384,652<span></span>
</td>
<td class="nump">$ 4,145,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">551,337<span></span>
</td>
<td class="nump">520,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingCurrent', window );">Supplie used for R&amp;D and manufacturing</a></td>
<td class="nump">2,555,249<span></span>
</td>
<td class="nump">2,248,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits current</a></td>
<td class="nump">51,129<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,542,367<span></span>
</td>
<td class="nump">6,918,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">7,800,909<span></span>
</td>
<td class="nump">9,131,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">1,548,010<span></span>
</td>
<td class="nump">1,698,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,613,316<span></span>
</td>
<td class="nump">10,188,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">173,028<span></span>
</td>
<td class="nump">197,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">2,319,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">71,589<span></span>
</td>
<td class="nump">74,669<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,068,320<span></span>
</td>
<td class="nump">30,528,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,369,441<span></span>
</td>
<td class="nump">2,009,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,272,149<span></span>
</td>
<td class="nump">1,049,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DueToEmployeeCurrent', window );">Due to employees</a></td>
<td class="nump">696,487<span></span>
</td>
<td class="nump">557,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation, current portion</a></td>
<td class="nump">1,949,245<span></span>
</td>
<td class="nump">1,771,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">219,019<span></span>
</td>
<td class="nump">197,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,506,341<span></span>
</td>
<td class="nump">5,585,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">8,477,784<span></span>
</td>
<td class="nump">9,949,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">1,486,138<span></span>
</td>
<td class="nump">1,652,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,595,263<span></span>
</td>
<td class="nump">17,313,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively</a></td>
<td class="nump">542,578<span></span>
</td>
<td class="nump">474,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">515,832,848<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(507,902,369)<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">8,473,057<span></span>
</td>
<td class="nump">13,214,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 24,068,320<span></span>
</td>
<td class="nump">$ 30,528,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DueToEmployeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DueToEmployeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677620682128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">54,257,884<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,257,884<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677621167920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,703,160<span></span>
</td>
<td class="nump">$ 5,727,789<span></span>
</td>
<td class="nump">$ 13,684,204<span></span>
</td>
<td class="nump">$ 17,203,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,967,075<span></span>
</td>
<td class="nump">2,453,968<span></span>
</td>
<td class="nump">6,547,866<span></span>
</td>
<td class="nump">6,804,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,670,235<span></span>
</td>
<td class="nump">8,181,757<span></span>
</td>
<td class="nump">20,232,070<span></span>
</td>
<td class="nump">24,008,552<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,670,235)<span></span>
</td>
<td class="num">(8,181,757)<span></span>
</td>
<td class="num">(20,232,070)<span></span>
</td>
<td class="num">(24,008,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(190,705)<span></span>
</td>
<td class="num">(181,670)<span></span>
</td>
<td class="num">(571,102)<span></span>
</td>
<td class="num">(493,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(4,382)<span></span>
</td>
<td class="num">(3,854)<span></span>
</td>
<td class="num">(7,801)<span></span>
</td>
<td class="num">(61,525)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,856,558)<span></span>
</td>
<td class="num">(8,367,281)<span></span>
</td>
<td class="num">(20,810,973)<span></span>
</td>
<td class="num">(24,563,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="num">(659,456)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(659,456)<span></span>
</td>
<td class="num">(171,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (7,516,014)<span></span>
</td>
<td class="num">$ (8,367,281)<span></span>
</td>
<td class="num">$ (21,470,429)<span></span>
</td>
<td class="num">$ (24,735,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EarningPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">53,994,384<span></span>
</td>
<td class="nump">44,254,363<span></span>
</td>
<td class="nump">51,479,454<span></span>
</td>
<td class="nump">43,761,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677620313376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">$ 32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">$ 486,625,816<span></span>
</td>
<td class="num">$ (454,897,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises amount</a></td>
<td class="nump">447,291<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">445,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,703,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,703,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock amount</a></td>
<td class="nump">50,178<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">49,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service amount</a></td>
<td class="nump">91,623<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">91,221<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedShares', window );">2014 incentive stock forfeited shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedAmount', window );">2014 incentive stock forfeited amount</a></td>
<td class="num">(11,100)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">(11,080)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(7,853,509)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,853,509)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,725,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">26,591,621<span></span>
</td>
<td class="nump">$ 437,256<span></span>
</td>
<td class="nump">488,904,967<span></span>
</td>
<td class="num">(462,750,602)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">486,625,816<span></span>
</td>
<td class="num">(454,897,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(24,563,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,748,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2023</a></td>
<td class="nump">14,789,399<span></span>
</td>
<td class="nump">$ 447,484<span></span>
</td>
<td class="nump">493,802,607<span></span>
</td>
<td class="num">(479,460,692)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,725,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">26,591,621<span></span>
</td>
<td class="nump">$ 437,256<span></span>
</td>
<td class="nump">488,904,967<span></span>
</td>
<td class="num">(462,750,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,743,288<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,743,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock amount</a></td>
<td class="nump">54,865<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">54,629<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service amount</a></td>
<td class="nump">100,635<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">100,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(8,342,809)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,342,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,787,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2023</a></td>
<td class="nump">20,147,600<span></span>
</td>
<td class="nump">$ 437,878<span></span>
</td>
<td class="nump">490,803,133<span></span>
</td>
<td class="num">(471,093,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,551,319<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,551,319<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock amount</a></td>
<td class="nump">52,663<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">52,534<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service amount</a></td>
<td class="nump">135,669<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">135,304<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedShares', window );">2014 incentive stock forfeited shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedAmount', window );">2014 incentive stock forfeited amount</a></td>
<td class="num">(11,100)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">(11,080)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(8,367,281)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,367,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock amount</a></td>
<td class="nump">1,552,497<span></span>
</td>
<td class="nump">$ 9,132<span></span>
</td>
<td class="nump">1,543,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(271,968)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(271,968)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,748,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2023</a></td>
<td class="nump">14,789,399<span></span>
</td>
<td class="nump">$ 447,484<span></span>
</td>
<td class="nump">493,802,607<span></span>
</td>
<td class="num">(479,460,692)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock amount</a></td>
<td class="nump">48,907<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">48,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service amount</a></td>
<td class="nump">202,307<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">201,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(6,709,524)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,709,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock amount</a></td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="nump">4,955,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 500,186<span></span>
</td>
<td class="nump">505,950,994<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(20,810,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,257,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="nump">8,473,057<span></span>
</td>
<td class="nump">$ 542,578<span></span>
</td>
<td class="nump">515,832,848<span></span>
</td>
<td class="num">(507,902,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 500,186<span></span>
</td>
<td class="nump">505,950,994<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,432,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,432,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock amount</a></td>
<td class="nump">53,485<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">53,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service amount</a></td>
<td class="nump">380,870<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="nump">379,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(7,244,891)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,244,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock amount</a></td>
<td class="nump">7,750,000<span></span>
</td>
<td class="nump">$ 38,750<span></span>
</td>
<td class="nump">7,711,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(717,621)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(717,621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,083,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">14,304,643<span></span>
</td>
<td class="nump">$ 540,837<span></span>
</td>
<td class="nump">514,809,617<span></span>
</td>
<td class="num">(501,045,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">728,120<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">728,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock amount</a></td>
<td class="nump">60,577<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">60,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service amount</a></td>
<td class="nump">155,655<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">154,951<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(6,856,558)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,856,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfStockByOfficersAndDirectorsSahres', window );">Purchase of stock by officers and directors sahres</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfStockByOfficersAndDirectorsAmount', window );">Purchase of stock by officers and directors amount</a></td>
<td class="nump">80,620<span></span>
</td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">80,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,257,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="nump">$ 8,473,057<span></span>
</td>
<td class="nump">$ 542,578<span></span>
</td>
<td class="nump">$ 515,832,848<span></span>
</td>
<td class="num">$ (507,902,369)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfStockByOfficersAndDirectorsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfStockByOfficersAndDirectorsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfStockByOfficersAndDirectorsSahres">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfStockByOfficersAndDirectorsSahres</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677609804512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (20,810,973)<span></span>
</td>
<td class="num">$ (24,563,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,977,603<span></span>
</td>
<td class="nump">2,959,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">5,008<span></span>
</td>
<td class="nump">12,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">778,571<span></span>
</td>
<td class="nump">473,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">3,544,569<span></span>
</td>
<td class="nump">4,976,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan (Increase)/decrease in assets:</a></td>
<td class="nump">162,969<span></span>
</td>
<td class="nump">157,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(15,708)<span></span>
</td>
<td class="nump">208,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="num">(304,097)<span></span>
</td>
<td class="num">(24,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Deposits</a></td>
<td class="num">(46,884)<span></span>
</td>
<td class="num">(2,342,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(592,370)<span></span>
</td>
<td class="nump">66,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">167,568<span></span>
</td>
<td class="nump">243,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="nump">139,243<span></span>
</td>
<td class="nump">28,173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,994,502)<span></span>
</td>
<td class="num">(17,803,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(75,122)<span></span>
</td>
<td class="num">(361,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(13,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(88,333)<span></span>
</td>
<td class="num">(361,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">12,730,000<span></span>
</td>
<td class="nump">1,552,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(1,173,577)<span></span>
</td>
<td class="num">(213,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders', window );">Proceeds from the purchase of stock by officers and directors</a></td>
<td class="nump">80,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(1,315,291)<span></span>
</td>
<td class="num">(1,157,371)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,321,752<span></span>
</td>
<td class="nump">628,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(3,761,083)<span></span>
</td>
<td class="num">(17,537,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">4,145,735<span></span>
</td>
<td class="nump">22,672,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">384,652<span></span>
</td>
<td class="nump">5,135,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AssetsPurchasedUnderFinanceLeases', window );">Assets purchased under finance leases</a></td>
<td class="nump">20,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities', window );">Property and equipment included in current liabilities</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingServicesPaidWithIssuanceOfCommonStock', window );">Consulting services paid with issuance of common stock</a></td>
<td class="nump">738,832<span></span>
</td>
<td class="nump">327,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AccruedConsultingServicesToBePaidWithCommonStock', window );">Accrued consulting services to be paid with common stock</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">91,975<span></span>
</td>
<td class="nump">58,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 706,517<span></span>
</td>
<td class="nump">$ 809,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccruedConsultingServicesToBePaidWithCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccruedConsultingServicesToBePaidWithCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AssetsPurchasedUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AssetsPurchasedUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479024/942-230-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677617715440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of June 30, 2024 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>&#160;</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, <em>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </em>(<em>&#8220;ASU 2023-07&#8221;</em>), which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, <em>Improvements to Income Tax Disclosures</em>, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677621209504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677620637856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Underlying share information for equity compensation plans as of June 30, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;<span style="text-decoration:underline">Stock option activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Nine months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,967,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,964,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,383</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that was amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"><span style="text-decoration:underline">Share-Based Compensation Expense:</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,544,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,976,338</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600,841</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">473,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">728,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,540,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,678</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,001</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at June 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Warrant/</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Options</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>Shares Issuable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 &#8211; 9/2/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">$1.39- $2.18</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/27/2027 - 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No warrants recorded as equity were exercised during the nine months ended June 30, 2024. The following warrants recorded as equity were exercised during the nine months ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants Exercised</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No warrants recorded as equity expired during the nine and three months ended June 30,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the nine and three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine months ended June 30, 2024 and 2023, the Company issued 321,761 and 115,321 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.84 and $2.45 during the nine months ended June 30, 2024 and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company issued 70,444 and 36,523 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.33 and $2.41 during the three months ended June 30, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No options were issued to a consultant during the nine months ended June 30, 2024. During the nine months ended June 30, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $601,000 and $474,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $231,000 and $188,000, respectively, relating to the share-based compensation under these consulting agreements. On June 30, 2024 and September 30, 2023, consulting fees of approximately $221,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618237808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine and three months ended June 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $80,620. No restricted shares of the Company&#8217;s common stock were purchased by related parties during the nine and three months ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618075488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"><em>Clinical Research Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $11.9 million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomed&#8217;s discount, approximately $0.1 million for each period as research and development expense related to Ergomed&#8217;s services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Egromed&#8217;s services and during three months ended June 30, 2023, the Company recorded, net of Ergomed&#8217;s discount, less than $0.1 million as research and development expense related to Ergomed&#8217;s services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company&#8217;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $2.0 and $1.9 million, respectively, of which approximately $0.7 and $0.8 million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Company&#8217;s finance leases is 8.46% and the weighted average time to maturity is 4.34 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">666,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,456,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,029,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,427,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,949,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,478,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.3 million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $0.3 million for each period. The weighted average discount rate of the Company&#8217;s operating leases is 10.19% and the weighted average time to maturity is 7.16 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,345,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(640,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,705,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,486,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677709291376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">During the nine and three months ended June 30, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents is approximately 8 years. For the nine months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $25,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $7,000 and $9,000, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">173,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677617514080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,470,429</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(24,735,151</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,516,014</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,367,281</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">51,479,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,761,395</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,994,384</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,254,363</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.42</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.57</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30 :</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,497,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,824,365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,644,703</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,971,615</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618091664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">On July 11, 2024, Geert Kersten, the Company&#8217;s Chief Executive Officer and a director, loaned the Company $200,000.&#160;&#160;On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000.&#160;&#160;These amounts were repaid on July 30, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for gross proceeds of approximately $10.8 million. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677620653824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;amp;amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, <em>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </em>(<em>&#8220;ASU 2023-07&#8221;</em>), which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, <em>Improvements to Income Tax Disclosures</em>, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ImpairmentOfLongLivedAssetsPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677617686240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">666,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,456,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,029,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,427,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,949,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,478,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,345,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(640,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,705,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,486,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618072112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of equity compensation plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfStockOptionActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Nine months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,967,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,964,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,383</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,544,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,976,338</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600,841</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">473,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">728,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,540,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,678</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,001</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock', window );">Schedule of warrants and non-employee options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Warrant/</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Options</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>Shares Issuable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 &#8211; 9/2/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">$1.39- $2.18</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/27/2027 - 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock', window );">Schedule of derivative liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants Exercised</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfCompensatingBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfStockOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfStockOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677617543200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">173,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677619962752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,470,429</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(24,735,151</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,516,014</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,367,281</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">51,479,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,761,395</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,994,384</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,254,363</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.42</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.57</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,497,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,824,365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,644,703</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,971,615</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677616857872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">17,787,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">1,283,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">634,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">138,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677713699408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,964,500<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,967,500<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="nump">179,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">13,383,000<span></span>
</td>
<td class="nump">27,075<span></span>
</td>
<td class="nump">58,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677619207920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 728,120<span></span>
</td>
<td class="nump">$ 1,540,219<span></span>
</td>
<td class="nump">$ 3,544,569<span></span>
</td>
<td class="nump">$ 4,976,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 230,678<span></span>
</td>
<td class="nump">$ 188,001<span></span>
</td>
<td class="nump">$ 600,841<span></span>
</td>
<td class="nump">$ 473,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677621224160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember', window );">Consultants Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">9/2/2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">9/1/2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/18/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/30/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/13/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/15/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/22/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">200,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/24/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">234,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/30/2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfWarrantOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfWarrantOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618424816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 4)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">217,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds From Equity Warrants Exercised | $</a></td>
<td class="nump">$ 447,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">17,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds From Equity Warrants Exercised | $</a></td>
<td class="nump">$ 29,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds From Equity Warrants Exercised | $</a></td>
<td class="nump">$ 418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromEquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromEquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677612341792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">3,875,000<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,257,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,257,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,730,000<span></span>
</td>
<td class="nump">$ 1,552,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetofissuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockOptionPlan', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingFeesIncluedPrepaidExpenses', window );">Consulting fees inclued prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,000<span></span>
</td>
<td class="nump">$ 188,000<span></span>
</td>
<td class="nump">$ 601,000<span></span>
</td>
<td class="nump">$ 474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember', window );">Consulting Agreements Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember', window );">Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,444<span></span>
</td>
<td class="nump">36,523<span></span>
</td>
<td class="nump">321,761<span></span>
</td>
<td class="nump">115,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=cvm_EquityProceedsFromSaleCommonStockMember', window );">Common Stock sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssuanceCostOfCommonStock', window );">Issuance cost of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock at a public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AdditionalPurchaseOfCommonStock', window );">Additional purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 659,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdditionalPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdditionalPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingFeesIncluedPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingFeesIncluedPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssuanceCostOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssuanceCostOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetofissuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetofissuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockOptionPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockOptionPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=cvm_EquityProceedsFromSaleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=cvm_EquityProceedsFromSaleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677620628256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative ) - Officer And Director [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 04, 2024</div></th>
<th class="th"><div>Oct. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="nump">$ 659,455<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfNewlyIssuedSharesByInsiders', window );">Purchase of newly issued shares by insiders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RestrictedCommonStockFairValue', window );">Purchase of restricted common stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,620<span></span>
</td>
<td class="nump">$ 80,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfNewlyIssuedSharesByInsiders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfNewlyIssuedSharesByInsiders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RestrictedCommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RestrictedCommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerandDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerandDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677617165536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 666,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">2,747,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,838,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,929,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">3,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">12,456,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on finance lease obligations</a></td>
<td class="num">(2,029,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Net present value of financing lease obligations</a></td>
<td class="nump">10,427,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityCurrentPortion', window );">Less net present value of financing lease obligations - current portion</a></td>
<td class="num">(1,949,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityNoncurrentPortion', window );">Net present value of financing lease obligations - non-current portion</a></td>
<td class="nump">$ 8,478,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677612249104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">2,345,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="num">(640,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net Present Value Of Operating Lease Obligation</a></td>
<td class="nump">1,705,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityCurrentPortion', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="num">(219,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityNoncurrentPortion', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 1,486,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618700400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000.0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Total cash payment for oprating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">300,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AnnualIncreaseToInterestPayments', window );">Annual increase to interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne', window );">Weighted average time of maturity of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Total cash payment for oprating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingArrangementDepositBaseRentAmount', window );">Financing arrangement deposit base rent amount</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net Of Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ClinicalServiceTrial', window );">Clinical service trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AnnualIncreaseToInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AnnualIncreaseToInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ClinicalServiceTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ClinicalServiceTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingArrangementDepositBaseRentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingArrangementDepositBaseRentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677704687808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total</a></td>
<td class="nump">$ 173,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677617575584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677618830672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (7,516,014)<span></span>
</td>
<td class="num">$ (8,367,281)<span></span>
</td>
<td class="num">$ (21,470,429)<span></span>
</td>
<td class="num">$ (24,735,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share- basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">53,994,384<span></span>
</td>
<td class="nump">44,254,363<span></span>
</td>
<td class="nump">51,479,454<span></span>
</td>
<td class="nump">43,761,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677620508384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">17,644,703<span></span>
</td>
<td class="nump">13,971,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">17,497,453<span></span>
</td>
<td class="nump">13,824,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">147,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140677621090800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th"><div>Jul. 18, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jul. 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from newly issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,750,000<span></span>
</td>
<td class="nump">$ 4,980,000<span></span>
</td>
<td class="nump">$ 1,552,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Public offering price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsOfferingPrice', window );">Pre funded warrants offering price</a></td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock at a public offering price</a></td>
<td class="nump">3,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from newly issued shares</a></td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsToPurchaseCommonStock', window );">Pre-funded warrants to purchase common stock</a></td>
<td class="nump">7,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Mr. Kersten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions', window );">Additional loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the amount of new advances made to related parties in the form of loan and lease receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_MrKerstenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_MrKerstenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&'L#>[N]1$+"54+"<*C)&^I$4%(/!AO<N-;@!ZO:8E6A",.AZ //(^W&#)'
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M38CJ> N1E/5?\+C%>@.PJ$HITNU@Q2"-L\U_]F,[$3L#(.D9@+8#T&L'X.T
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MR#6\NDSD-@N8*I#WYY2*YX9:R-N-6_ 74$L#!!0    ( &Z##EG;W:G)PP0
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M;M%\3&A.M%K5N^4WI6'O71\NI8"'M1+ [W.E]/ZD2M!^TAG]"U!+ P04
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M0PB!:Z,-DV&DDA)"*K7N7@=/"'PR(0P&GL,BO9U,U@I, 7.$$/9!#?<[8(1
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M./#(K#Z^=B>0(P;8VAVBV+=VAY@.K=V)L\,(D_<NG>]=P*.1]E@"LG=)"\9
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M\!X[U.1%BN' (XL4>/FC(&J@Y0^BV%?^(*9#Y8_RV*'BV/'T-]M )*"",RE
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MP4.BS/ [%T=#8'F$.D9_K&1#V[;QT&IMV8GU\ 211<7>6*TR"+'M6+:T6A7
M-*EK& ,B6V!B/3'G%1.)D:7;)']E R(5'*0>/+\O4K8C+G8&Z(-;8&(],9?O
M*<24PF4>GH)RS[0,TM>N,G5<@SJ=Q'.LO\4G]O3[@K;^O[J]^8H6RV_^^FZQ
M_!U-9W>+;XN[A;]6KUDMEW]ZS7Z0M^.M6LMEHN?RJBK"#62K$N6/:%N(,>2O
M-1,8U!=;40>I^H#(,#UU+$SZ ZBRHS9V/:(>/M)2E^BIZXOU&\6 +-84:MN
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MRBC'I,/Q70BRE4<&BA3:PIZ^"7O%YN,HA+ J"G&O<ZJBC$*Q+7>D P:%U=!
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M$L"5OL"0 DQ').E)-B#P\F<EXE>V+G*X)FC($8HX\+4V<8IP"LCRP;,$!%6
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M4Y"=B= <K);<<K>E<A?4U.VBX;XN:3-*>=F!!)=0GBIF'6[7)O%JV'3%K5H
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MGAM/1L+8KXKVH=8K_I)WI^M:+_GG0DEXA BP/M>Z[AY(0/]I]^0_4$L#!!0
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MMGS_^L></WB07 "_SS2+T@Y<@=TGU.@O4$L#!!0    ( &Z##EE^KF*4H0@
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MLTKF&6E9X841A<[ W-F^N/;5OLDQ)ZK'K<8I[AAJEL+:#%"R4#9;=X6I.IL
M!+L#D<MOZ)FV!*\AK 6.\PBCR"P'& @5))>9:L'DG/&R-/HI&":#1BRJG#MM
M<+L0*EV'T'T:F+0UY)P(2'4K)'[-UDBFK<O_O9*&$J]4!;LTC? 0U4(DPL(A
MCJ81'.4D(88$C'[>AIFTC1;?:P KXWF.9U ',),\60+0K59X!O]Q#2\<?Q;
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M(8I-_*076+:Y<;KT7U-!%DX7_I*&DC!T ._G6KOFA@RTG]<O_P=02P,$%
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M9\9TDZ&R ?1](Z79.W:#^FZ<_@502P,$%     @ ;H,.607;KRT2!   80D
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M__@ R[NKY]M98!#:*@1%#W/=P<3OP$SA7@I3:;@5)2V/[0.D-/"*][RNX[.
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M//- =1=Z-S"R<9?H2AJ\DIU8X1N(*JN ZVN)S:@?6 ?#JVKQ+U!+ P04
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M)M'100"Z\\IN8U7C_>E!67([OZSH\X+:!=!]J91=;QS!YH,U_@-02P,$%
M  @ ;H,.6=C84/IE!P  *Q8  !D   !X;"]W;W)K<VAE971S+W-H965T,34N
M>&ULM5AK;]NX$OTKA!<H6B#Q*VF2-HD!QTUVO6C<;)S<Q?U(2[3%&XE422J.
M[Z^_9TA)MG<5=6^["S2U'IR9,V<>'.IBK<V3381P["5+E;WL),[E'WL]&R4B
MX[:K<Z'P9JE-QAUNS:IG<R-X[(6RM#?L]T]Z&9>J,[KPS^[,Z$(7+I5*W!EF
MBRSC9G,E4KV^[ PZU8-[N4H</>B-+G*^$G/A'O,[@[M>K266F5!6:L6,6%YV
MQH./5X,3$O K_B7%VNY<,W)EH?43W4SCRTZ?$(E41(Y4</P\BXE(4]($'%]+
MI9W:)@GN7E?:;[SS<&;!K9CH]'<9N^2R<]9AL5CR(G7W>OV+*!UZ3_HBG5K_
M/UN'M>^/.RPJK--9*0P$F53AE[^41.P(G/5?$1B6 D./.QCR*#]QQT<71J^9
MH=701A?>52\-<%)15.;.X*V$G!O-'V]OQ_?_9E]NV'SZ\VQZ,YV,9P]L/)E\
M>9P]3&<_L[LOGZ>3Z?6<O;W3J8RDL.\N>@ZF24$O*LU<!3/#5\Q\8+=:N<2R
M:Q6+>%^^!\@U[F&%^VK8JO#70G794?^ #?O#XQ9]1S4/1U[?T3_-0S!SW&R&
M:NRCS7DD+CLH(BO,L^B,WOPT..F?MSAQ7#MQW*9]-.$V85S%S%]<?RWD,T^%
M<K8):*NJ9J"OZF<MX-_7X-^W@K\S:#7&;;P!TIVC^%T3\A_7LP?PI 9XTJIX
M7N1YBK"SPHJ8H2&R^S<\R\^KOT_>8L95L42O*8Q4JR;TWV>D03E[\]/9<#!H
M2YS3VK73=LZX>RU-OD-P#\)9#>&L5=-G@=[:B*!5KCE1@[**H+;L_%##^] >
M%Z>CI\,K3E&9Z R;HN6TK30!_H:FA!O1H&G_IH+N[>Z_>DB$?\#5AB7<LJF*
M$ /L;>7B+[E?=I=R90_83*O#WPJ>RJ6$P:85#2;VWEQI5=CPR"<A5W\RN5W2
M)7A65,N-8-BA_!;\+-(-[>/"& !QF@&Z@RODZ;!_[@7\]>"\R\9I6JI(.*PL
MA, &GN=&/T-VL?&")0>>J=-SRRQ!270:"V.[NRSMKV#:>Q_ *>V8,[ #6'R1
MB@/O(6FG*N,I0X,K!--+_VQ?WB7<$1DBRU.]$0+520Z"ZO]"CUSBW>8 VSE<
MB06XC1F8)37B)1+65DHQ##UA^LJ-C$2U(D99T7OQ(DPD02?\-J5L^<2O[S*,
M)C4@:6T!>M;2)8P*@11&6L4RO-8J!1[WA^Q9^$24Z.$<XEG(#.H[P=D ZUFG
M2(Q4HJN6")^YD5Q%'F7,)4(;I=I25_(2M7>-(0C1,=(^'2X-B)/*"=2N8X;\
MWL$A*WREU<?N'++@V!9F4ZYV>XRM$$P7**#'T)LQ\94BB8P+!.;(1JA$1=2!
M#0QZ-I="HKV*D!X\BG2A7-F)UXGP,$!"%!4F>%'K\Z:@KXJ&$;X?T>Y()K G
M21V'I*F6>+ 0)5-;/1KISC! 6X=<)$8I)7VHJ IB08;04^(M-9S^\71CI><]
MD6 948#3=;HL! I):H">^L2L/-^276XY,C!]E7+TNWF$>@(7F8Y%RJ*$JQ6J
M0*X4NDD$[)10UO>S@"7:;2+DD8)IHDYA/.=K;F+KJR262Q0<+N&+Y"FRIS2[
M+(A\MC0Z"U09$6D3;W&!=P-.2SJ[[!YI U>)N)"P%:<%!LU0,J\W*\_L'X.Q
M%?Q6Z_1QL\7B/P@<A:VLN0,"Y\]+5!]AV_8EOE.+_BD=NKQ/*:+@&?6ZJ>XQ
MMM $XQFK6FK)WQJE EDJ 4H=QY9<FJI/!9)"$5!)4%!]"OGY&^7(30J@,BM2
M7E<Z]0W":BG#H=SGA7,XTM'D1'AV'8J,]%&CXBSPP-#"4 M..^3<7A)$VKK0
M Q>BRHAXIYU9)RD+8@0:/ENHKEM7&>*6S7O0WYYR^JV;+M)$<!.%Z?63P%ZD
M_5B(_F2;YYZ_4>$^YIV3V:#5Q SI\5ECH[@#6>BC&>CTPT,CW._4Q:ZY4<B0
M\*9!_3[XX1;\L-4@BDYG@CWPE^:A[O\09Z_KV@>W/>L-6D]AHRGV)&FJY$ZU
M6AVFDB8+U*%X)1W^1HW[J+>'NT'[Z>[1^OWJNBR99I@_HF(?U_;<-F@_<-T+
MZJ_HX>,8O10^C\.N27UG3GL8M:U&L*UZFR?[J6(X^@L<^P<G89BYD0I]";M(
MHUUT>_RPM^64>3.>7Y5#YKMJ7FH4>\S]1#'376_J<'!TL&-IJK#K%)G?W*M)
M?8)V+$.5(6??/NA<1NQH>/+N([L-W;I*C_V5J,1FQ17F\?RQPE!![[8=:0;;
M ^V@_; YPZZ\XSU.SDI32\]>.PQ^0Q^",T-KSQ9H)</^\*@,$#C_ZUP/CP[[
MISAZB)6GZU[DVOCU):/#LSX81;W162 0A:TW+*,)OI;\)"V-I'Z6VV/26RB9
M!.'HWM&/0_YP\"=,V[:UBZ4I<+V=[W>9,"O_E=(R;S=\RJN?UE]"Q^'[WW9Y
M^(QZR\U*8L!(Q1*B_>XI:LR$+Y/AQNG<?PU<:.=TYB\3P3'RT *\7VKMJALR
M4'\?'OT/4$L#!!0    ( &Z##EE)*B B5P,  '\)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;*U6[Y/:-A#]5W:<3.8RXSO;PK^X #-WY-I>)I";
M0-OI1X$7\,26'$D^DO^^:QDX<@&W2?L%O/*^MV^E)TN#K52?] ;1P)>R$'KH
M;(RIKCU/+S=8<GTE*Q3T9B55R0V%:NWI2B'/+*@L/.;[L5?R7#BC@1U[4*.!
MK$V1"WQ0H.NRY.KK+19R.W0"9S_P,5]O3#/@C0857^,,S>_5@Z+(.[!D>8E"
MYU* PM70N0FN;Z,FWR;\D>-6'SU#T\E"RD]-<)\-';\1A 4N3</ Z>\1QU@4
M#1')^+SC= XE&^#Q\Y[]%]L[];+@&L>R^#//S&;HI YDN.)U83[*[6^XZ\<*
M7,I"VU_8MKE1WX%EK8TL=V!24.:B_>=?=O-P!$C],P"V S"KNRUD5;[EAH\&
M2FY!-=G$UCS85BV:Q.6B69294?0V)YP9C3],)O?SR=UT/H.;Z5L8?YC.[Z>_
MWDW']W<SN)CS18'Z]< S5*M!>,L=[VW+R\[P]F$BA=EHN!,99M_B/=)X$,KV
M0F]9)^&[6EQ!SW>!^2SLX.L=&N]9OM[/-'ZJWY8N/$W7[)UK7?$E#AW:'!K5
M(SJC5R^"V'_3(38\B V[V$<SVHM972#(%:QJ4RMLO)"7=0D5_TI[Q&BH::(5
MK'+!Q1*A0+*J/M5'9Z73?<PW"JEBNZ HLERL88:5P7)!)?>+ B\ACF/7]WWX
M"[DZFQ@!<Y,PL8D4QA2FO70?)A3V67\?IM!S?1;LPSZP*++!7!I>/)\,VS7(
M19&ON=WT 7/#J-7T'K6&O*QJ@QGDPB"U9X!ROIFR(["&"T:U6RFO84I?2#LE
MPL C+^IV,2RV:?-[=."[(4N>:HL?)7CU(F5!\(8^ THUH$HJV]1%X/;#GY9U
M"4**R^><+R%UPZ1=A0[#1@?#1O^38>EX4:1L+_6D93MK_4?+]OU_X]C>SMBM
M7]/DR*U)\N15ED9'3NV'K5,W9#6^(L-!$L8_8%[F]L*HV[O/9N\8?1&'?I='
MSD/)NF[B1__@W"[\Y?>>94&G8[O93CLV<,,T/NM8[^A0+%&M[=&O82EK8=KS
M\3!ZN%W<M(?J4WI[-9EPM<Y)2($K@OI7"1E2M<=]&QA9V2-V(0T=V/9Q0S<D
M5$T"O5]):?9!4^!PYQK]#5!+ P04    " !N@PY9V+L[3M,$  #R#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RE5VUOVS80_BL'MR@V0+%$ZHUJ
M$P--FJ'9EC2-DW7]R-BT+50279*NTW^_(RG)3N<*'@8#,L5[[HW/'4F=;J7Z
MHE="&'BJJT:?C5;&K%^'H9ZM1,WU6*Y%@Y*%5#4W^*J6H5XKP>=.J:Y"&D59
M6/.R&4U.W=RMFIS*C:G*1MPJT)NZYNK[N:CD]FQ$1MW$7;E<&3L13D[7?"FF
MPCRL;Q6^A;V5>5F+1I>R 2469Z.WY/4YLW@'^*L46[TW!IO)HY1?[,O5_&P4
MV8!$)6;&6N#X]TU<B*JRAC",KZW-4>_2*NZ/.^N_N=PQET>NQ86L/I5SLSH;
ML1',Q8)O*G,GM^]%FT]J[<UDI=T3MAZ;(GBVT4;6K3)&4)>-_^=/[3KL*;#H
M)PJT5: N;N_(1?F.&SXY57(+RJ+1FAVX5)TV!E<VEI2I42@M4<],IO<?+OYX
M_^'/=Y=W4[C\^'!U_QE^N>>/E="_GH8&/5A<.&NMG7MK]"?6"KB6C5EIN&SF
M8OY</\3(^O!H%]XY'33X^Z890QP%0".:#-B+^W1C9R\^/MU#67HCR6$CMD]>
MZS6?B;,1-H(6ZIL835Z](%GT9B#$I \Q&;(^F6+?S3>5 +D \753FN\PDS4V
MH>:NCM<5;_2AH ?-'@[ZAM?.SRW:A'MI> 73%4<QW'G('!Z02>4 &JZ:F6AL
M%\'4R-D7^+!V$7DAB5F01!'<R.;DXX97Y:)$]4/ /,A9'N"VT4K/9;/1G3"@
M+ [RK)-=[*?N(5F<!!$J_QC-S@QD2>0@ W2D/1WIT71X/W*]VT^0G4-4#)H\
M3 7<( IJWS["M@]@\8N^^.TC;A=2PU+QQB"$!$66!RFFFKEG)Q=/0LU*C8@3
M_'6SN(<O1&GU:!&[!2)Y$;"8[NFM2V7E>1#E*:3,4@7W*R7$L]8^-K;$146=
MKZ-C:\E+\Q]2\J$E&'4<Q"P>8C?KV<W^&[LGY]Q&]JSL+I_L6!PB>M#Z_R'Z
MLEY7\KO 3GP)<9 FN)!9@>,D*/(LB&/F^DSLH;(H"EA"+";'#D(;Q]&V[RFG
M+" TPA%!GU% 2?$O/Q35LYQ9#&-(%!GB(>]YR(_F8<N5K2 -O)E#L^>][3P-
M>+G0!J5ELSQ$RJ"KPZ1\\C[#OMJNM-X(P"-5=#NBG;'G(FS6KB9\$=N 6V6]
MT^ZEMZJ<"5M I?*UY"T*5:+%&V A8?;^Q("E2*HE.!YCS;?S-.N@#P^0A83@
M'&& O9M%L:5BS+#QPSAZAOT;2$AB"\T R72]]!**,4TA]X(=]C/0D*0>2[,6
M2F@;0_H,>WV-OBBUX!SB. X2W#@0/699)]B!;V[0&4T\&#,,(MQ';,0I[00[
M\-T=D,BG8=%N?R^<Z2SM)0B_P+7%VQ:N=;_2:(MYM5<O&"7D#12ABR0&0MK<
MR3@N3N E'>/:(3ZWXARWGB*T"TK94 &SOH#9T06,!V;YC;N3J2KY8UF5!K,\
M5*F#-@<K5?=5UQ?;_,>RNU5R)L1<[R\SGKTI[986^2@"6I .,)UZJEP58!$4
MD!#F7FFOF"2Y4SFT9N'>/;06:NENVQJO+YO&^"MI/]M?Z-_Z>^P.[K\&KKE:
MELAO)1:H&HUS/%*5OV'[%R/7[E;[* W>D=UPA1\E0ED RA=2FN[%.N@_<R;_
M %!+ P04    " !N@PY9C"L24ED"  !0!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q]5&UOTS 0_BNG,"&0IB5-TZX;;:1U# VDH6HM(#ZZR:6Q
MYI=@7];!K\=VVE"DKE_BN_,]CY]S?#?=:O-D:T2"%RF4G44U47,=Q[:H43)[
MH1M4;J?21C)RKMG$MC'(R@"2(DZ39!Q+QE643T-L8?*I;DEPA0L#MI62F=]S
M%'H[BP;1/O#(-S7Y0)Q/&[;!)=*W9F&<%_<L)9>H+-<*#%:SZ&9P/<]\?DCX
MSG%K#VSPE:RU?O+.YW(6)5X0"BS(,S"W/.,M"N&)G(Q?.\ZH/](##^T]^Z=0
MNZMES2S>:O&#EU3/HDD$)5:L%?2HM_>XJV?D^0HM;/C"MLO-7'+16M)R!W8*
M)%?=REYV]W  F"2O -(=( VZNX."RH^,6#XU>@O&9SLV;X12 ]J)X\K_E"49
MM\L=CO+%S>KNZVH)[U9L+="^G\;D6/U>7.P8YAU#^@K#%3QH1;6%.U5B^3\^
M=FIZ2>E>TCP]2?BE51<P3,XA3=+L!-^P+W$8^(:G2SQ660?,C@-]/US;AA4X
MB]R#MVB>,<K?OAF,DP\G9&6]K.P4>[YT_56V D%70)J8 +3$W3O#$JJ66H/
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ML#VZ?S]ZQ:K6W]E/RN(+X,4:GUS0S@'7-TK9H^(2#(_XXA]02P,$%     @
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M)6M$)5JHR8&*OF*+>"6YS),IIV(W$3SN3^^N)Y\OKK\$X>T4A=_N+^]^HJ,
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M1NKF UQ/4.^7C,E=1SNH[E+>/U!+ P04    " !N@PY9IBJ]70 (   (3
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M+[NRAC(BX;8HLZ0-KFJ01.GN/_O6GHB#@(HC#J!M #T.T-\(T-H [3A >R-
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M"7,FPQ]?40<:<9$YO<EP4#01Z!*9,P#!>N(U]^(UI>+]R,NZT]QWH+5^"Y&
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M#PH=0/,1Y^JNHQ>HWU*#OU!+ P04    " !N@PY9FX%L 0T#  "/"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R=EFMOVC 4AO^*E4U3)ZW-A5R@
M@T@M=!O3H%6AVV<#)V ML3/;@>[?ST[2E"T7VGU)[,3G?1^?V,<9'AC_*78
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M'6<A+QYMP>1Q-6Y7TFL?:2/U5*%+V*AQG^PS>]3KCYM_[9OF0@;@?4< /F0
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MY2U;?X5:CTDP8;DP3[2N?/TK"R5+(5E1@U4&!:'5&V_J.NP %$\[P*T![DN
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M1AS!'( '#(GCYAP\.(_"S3D5;G\[&?\&4$L#!!0    ( &Z##EF7BKL<P
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &Z##EF)FG1@[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &Z#
M#EF97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ ;H,.62E/"F/(!0  @!\  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &Z#
M#EFV84Z_D08  #T:   8              " @0P.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !N@PY9)IO3E\H"  #$"0  &
M        @('3%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ ;H,.6=O=J<G#!   WA$  !@              ("!TQ<  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &Z##EE^H6<FO T  %UI   8
M              " @<P<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !N@PY9<ND,2PT(  !Y(0  &               @(&^*@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ;H,.61<;S-D<"0
M3Q8  !@              ("! 3,  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( &Z##EE#0Y(VX 4  "<-   8              " @5,\
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !N@PY992IU
M._\)  #F'0  &               @(%I0@  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ ;H,.6?]=IB?R P  3@D  !D
M ("!GDP  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !N
M@PY9?JYBE*$(  !J%P  &0              @(''4   >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &Z##EEQ\"E\X0(  "<'   9
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M970Q-BYX;6Q02P$"% ,4    " !N@PY9V+L[3M,$  #R#   &0
M    @(%5;P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M &Z##EF,*Q)260(  % %   9              " @5]T  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ ;H,.6<S/#>Y5 P  T <  !D
M             ("![W8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !N@PY9J:)P2*0"   J"0  &0              @(%[>@  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &Z##EE*MD8IZ0(
M %L*   9              " @59]  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ ;H,.61=:XNSA @  -PH  !D              ("!
M=H   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !N@PY9
MV0('1_H$  !D'0  &0              @(&.@P  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( &Z##EE,<":5W (  %<)   9
M      " @;^(  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ ;H,.6:8JO5T "   "$P  !D              ("!THL  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !N@PY9ZBX)M_P"  !7"0
M&0              @($)E   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( &Z##EF;@6P!#0,  (\)   9              " @3R7  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ;H,.6;H*: HG
M P   @H  !D              ("!@)H  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !N@PY9N/IZO5@%  !6)   &0
M@('>G0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &Z#
M#EEQOQ%<8@(   ('   9              " @6VC  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ ;H,.61\>81VK @  + D  !D
M         ("!!J8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !N@PY9HG?T>S\#  "<"P  &0              @('HJ   >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &Z##EGY$NW[K (  .L'
M   9              " @5ZL  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ ;H,.6<%^T6*$!   ]1P  !D              ("!0:\
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !N@PY9]N6:
M/1L#  !($0  #0              @ '\LP  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( &Z##EF7BKL<P    !,"   +              "  4*W  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( &Z##EF2=7^R40,  !(7   /
M  "  2NX  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !N@PY9C-]?K6X!
M  #=%   &@              @ &INP  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !N@PY9!E="=X\!  !P%0  $P
M@ %/O0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     *@ J %T+   /OP
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails4</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails</Role>
      <ShortName>LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails1</Role>
      <ShortName>LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SubsequentEvents</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20240630.xsd</File>
    <File>cvm-20240630_cal.xml</File>
    <File>cvm-20240630_def.xml</File>
    <File>cvm-20240630_lab.xml</File>
    <File>cvm-20240630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cvm_10q.htm">cvm_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10qimg10.jpg</File>
    <File>cvm_10qimg11.jpg</File>
    <File>cvm_10qimg12.jpg</File>
    <File>cvm_10qimg13.jpg</File>
    <File>cvm_10qimg14.jpg</File>
    <File>cvm_10qimg15.jpg</File>
    <File>cvm_10qimg8.jpg</File>
    <File>cvm_10qimg9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="443">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10q.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "cvm-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10q.htm"
     ]
    }
   },
   "keyStandard": 172,
   "keyCustom": 60,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 10,
   "memberCustom": 25,
   "hidden": {
    "total": 23,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 16,
    "http://cvm.com/20240630": 2
   },
   "contextCount": 128,
   "entityCount": 1,
   "segmentCount": 35,
   "elementCount": 319,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 443,
    "http://xbrl.sec.gov/dei/2024": 30
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "longName": "000002 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2022-12-31_us-gaap_CommonStockMember",
      "name": "cvm:WarrantExercisesShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "000010 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "000011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "000012 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/LossPerCommonShare",
     "longName": "000013 - Disclosure - LOSS PER COMMON SHARE",
     "shortName": "LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "000014 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "longName": "000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "000018 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/LossPerCommonShareTables",
     "longName": "000019 - Disclosure - LOSS PER COMMON SHARE (Tables)",
     "shortName": "LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "longName": "000020 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/StockholdersEquityDetails1",
     "longName": "000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/StockholdersEquityDetails2",
     "longName": "000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/StockholdersEquityDetails3",
     "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/StockholdersEquityDetails4",
     "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)",
     "shortName": "STOCKHOLDERS EQUITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-29",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-29",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember",
      "name": "cvm:IncrementalCostDeemedDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember",
      "name": "cvm:IncrementalCostDeemedDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:InterestPaid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:InterestPaid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "000030 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "000031 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails",
     "longName": "000032 - Disclosure - LOSS PER COMMON SHARE (Details)",
     "shortName": "LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-06-30",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails1",
     "longName": "000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)",
     "shortName": "LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-07-29_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r413"
     ]
    },
    "cvm_AccruedConsultingServicesToBePaidWithCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "AccruedConsultingServicesToBePaidWithCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued consulting services to be paid with common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r413",
      "r515"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r440",
      "r441",
      "r442",
      "r443",
      "r497",
      "r516"
     ]
    },
    "cvm_AdditionalPurchaseOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "AdditionalPurchaseOfCommonStock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional purchase of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r218"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization cost",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r163",
      "r437",
      "r500"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r135",
      "r141",
      "r403"
     ]
    },
    "cvm_AnnualIncreaseToInterestPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "AnnualIncreaseToInterestPayments",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual increase to interest payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r64",
      "r77",
      "r95",
      "r119",
      "r121",
      "r122",
      "r123",
      "r125",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r238",
      "r242",
      "r254",
      "r294",
      "r347",
      "r400",
      "r401",
      "r413",
      "r425",
      "r466",
      "r467",
      "r505"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r80",
      "r95",
      "r125",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r238",
      "r242",
      "r254",
      "r413",
      "r466",
      "r467",
      "r505"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AssetsPurchasedUnderFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "AssetsPurchasedUnderFinanceLeases",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets purchased under finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r93"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offering price",
        "label": "[Class of Warrant or Right, Exercise Price of Warrants or Rights]",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "cvm_ClinicalServiceTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ClinicalServiceTrial",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical service trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r58",
      "r296",
      "r334"
     ]
    },
    "cvm_CommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "CommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r148",
      "r149",
      "r390",
      "r463",
      "r465"
     ]
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan (Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r440",
      "r441",
      "r443",
      "r497",
      "r514",
      "r516"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r335"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36",
      "r335",
      "r353",
      "r516",
      "r517"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r298",
      "r413"
     ]
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ConsultantsOptionMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ConsultingAgreementsOtherMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingFeesIncluedPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ConsultingFeesIncluedPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fees inclued prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ConsultingServicesPaidWithIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting services paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r21"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DueToEmployeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "DueToEmployeeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EarningPerShareBasicAndDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "EarningPerShareBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r116"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r115",
      "r117",
      "r118"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Expense",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r72",
      "r84",
      "r85",
      "r86",
      "r96",
      "r97",
      "r98",
      "r100",
      "r105",
      "r106",
      "r108",
      "r120",
      "r126",
      "r127",
      "r147",
      "r178",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r271",
      "r306",
      "r309",
      "r310",
      "r311",
      "r323",
      "r375"
     ]
    },
    "cvm_EquityProceedsFromSaleCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "EquityProceedsFromSaleCommonStockMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock sale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EquityWarrantsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "EquityWarrantsExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EquityWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "EquityWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ExpirationDate",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "cvm_FinanceLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "FinanceLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less net present value of financing lease obligations - current portion",
        "label": "[Less net present value of financing lease obligations - current portion]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "cvm_FinanceLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "FinanceLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three months ending September 30, 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest on finance lease obligations",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right of use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "cvm_FinancingArrangementDepositBaseRentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "FinancingArrangementDepositBaseRentAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement deposit base rent amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "FinancingCostsIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r394",
      "r403"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2024",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r394",
      "r403"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r394",
      "r403"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r394",
      "r403"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r394",
      "r403"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r289",
      "r290",
      "r394"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r394"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r458"
     ]
    },
    "cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r357"
     ]
    },
    "cvm_ImpairmentOfLongLivedAssetsPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ImpairmentOfLongLivedAssetsPolicyTextblock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IncentiveStockBonusPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive Stock Bonus Plan [Member]",
        "label": "[Incentive Stock Bonus Plan [Member]]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IncentiveStockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IncentiveStockForfeitedAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 incentive stock forfeited amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IncentiveStockForfeitedShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 incentive stock forfeited shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShares",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per common share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r316"
     ]
    },
    "us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseDueFromOfficersAndStockholders",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from the purchase of stock by officers and directors",
        "label": "[Increase (Decrease) Due from Officers and Stockholders]",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from the reporting entity's executives and owners."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeposits",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Increase (Decrease) in Deposits]",
        "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r62"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncrementalCostDeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IncrementalCostDeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental cost",
        "verboseLabel": "Incremental cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r393",
      "r394"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r289",
      "r396",
      "r452"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r446"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest amount",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r92"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;amp;amp;D and manufacturing",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r76",
      "r78",
      "r128",
      "r129",
      "r130",
      "r284",
      "r397"
     ]
    },
    "cvm_IssuanceCostOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IssuanceCostOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance cost of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_IssueDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "IssueDate1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LandlordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "LandlordMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462"
     ]
    },
    "cvm_LeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "LeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2024",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r95",
      "r125",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r239",
      "r242",
      "r243",
      "r254",
      "r333",
      "r398",
      "r425",
      "r466",
      "r505",
      "r506"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r59",
      "r300",
      "r413",
      "r439",
      "r451",
      "r499"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r75",
      "r95",
      "r125",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r239",
      "r242",
      "r243",
      "r254",
      "r413",
      "r466",
      "r505",
      "r506"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of loan",
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r60"
     ]
    },
    "us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableRelatedPartiesAdditions",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional loan amount",
        "documentation": "Reflects the amount of new advances made to related parties in the form of loan and lease receivables."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r60"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r181",
      "r219",
      "r253",
      "r283",
      "r307",
      "r308",
      "r314",
      "r325",
      "r326",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r391",
      "r392",
      "r402",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r468",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r181",
      "r219",
      "r253",
      "r283",
      "r307",
      "r308",
      "r314",
      "r325",
      "r326",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r391",
      "r392",
      "r402",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r414",
      "r468",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ]
    },
    "cvm_ModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ModificationOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_MrKerstenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "MrKerstenMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Kersten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r49",
      "r61",
      "r73",
      "r81",
      "r82",
      "r86",
      "r95",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r107",
      "r108",
      "r112",
      "r125",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r233",
      "r236",
      "r252",
      "r254",
      "r305",
      "r355",
      "r373",
      "r374",
      "r423",
      "r466"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r101",
      "r102",
      "r103",
      "r104",
      "r110",
      "r111",
      "r113",
      "r114",
      "r236"
     ]
    },
    "cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "NetOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Of Discount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NetofissuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "NetofissuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "NewAccountingPronouncementEarlyAdoptionPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued",
        "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "cvm_OfficerandDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "OfficerandDirectorMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer And Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r399",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expense for operating leases",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Present Value Of Operating Lease Obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "cvm_OperatingLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "OperatingLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net present value of lease finance lease obligations - current portion",
        "label": "[Net present value of lease finance lease obligations - current portion]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "cvm_OperatingLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "OperatingLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for oprating lease",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate operating lease",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r412"
     ]
    },
    "cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermOne",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Other Indefinite-Lived Intangible Assets]",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r460"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "[Other Nonoperating Expense]",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name Axis",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r165"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r335"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r165"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r335",
      "r353",
      "r516",
      "r517"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r297",
      "r413"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r131",
      "r132",
      "r395"
     ]
    },
    "cvm_ProceedsFromEquityWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ProceedsFromEquityWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r81",
      "r82",
      "r89",
      "r95",
      "r99",
      "r105",
      "r107",
      "r108",
      "r125",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r233",
      "r236",
      "r237",
      "r240",
      "r241",
      "r252",
      "r254",
      "r292",
      "r304",
      "r322",
      "r355",
      "r373",
      "r374",
      "r406",
      "r407",
      "r424",
      "r435",
      "r466"
     ]
    },
    "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r270",
      "r293",
      "r303",
      "r413"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r68",
      "r71",
      "r302"
     ]
    },
    "cvm_PurchaseOfNewlyIssuedSharesByInsiders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "PurchaseOfNewlyIssuedSharesByInsiders",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of newly issued shares by insiders"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PurchaseOfStockByOfficersAndDirectorsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "PurchaseOfStockByOfficersAndDirectorsAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PurchaseOfStockByOfficersAndDirectorsSahres": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "PurchaseOfStockByOfficersAndDirectorsSahres",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors sahres"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Axis"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r179",
      "r181",
      "r208",
      "r209",
      "r210",
      "r219",
      "r253",
      "r281",
      "r282",
      "r283",
      "r307",
      "r308",
      "r314",
      "r325",
      "r326",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r391",
      "r392",
      "r402",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r417",
      "r464",
      "r468",
      "r498",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r179",
      "r181",
      "r208",
      "r209",
      "r210",
      "r219",
      "r253",
      "r281",
      "r282",
      "r283",
      "r307",
      "r308",
      "r314",
      "r325",
      "r326",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r391",
      "r392",
      "r402",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r417",
      "r464",
      "r468",
      "r498",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r180",
      "r275",
      "r276",
      "r295",
      "r301",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r352",
      "r354",
      "r382"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r180",
      "r275",
      "r276",
      "r295",
      "r301",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r352",
      "r354",
      "r382",
      "r504"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r319",
      "r320",
      "r321",
      "r358",
      "r359",
      "r360",
      "r379",
      "r381"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r394",
      "r400",
      "r513"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "cvm_RestrictedCommonStockFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "RestrictedCommonStockFairValue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of restricted common stock fair value"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r54",
      "r299",
      "r312",
      "r313",
      "r318",
      "r336",
      "r413"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r97",
      "r98",
      "r100",
      "r105",
      "r106",
      "r108",
      "r126",
      "r127",
      "r147",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r244",
      "r246",
      "r247",
      "r249",
      "r251",
      "r262",
      "r263",
      "r309",
      "r311",
      "r323",
      "r516"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock at a public offering price",
        "verboseLabel": "Sale of common stock at a public offering price",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfCompensatingBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ScheduleOfCompensatingBalancesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ScheduleOfDerivativeLiabilitiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity compensation plans",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r55"
     ]
    },
    "cvm_ScheduleOfStockOptionActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ScheduleOfStockOptionActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r459"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesSSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesSSMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Options/shares Under Plans",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Exercised",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r186",
      "r205",
      "r206",
      "r207",
      "r208",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "cvm_ShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "ShareIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs",
        "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SharesIssuableUponExerciseOfWarrantOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SharesIssuableUponExerciseOfWarrantOptions",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable Upon Exercise Of Warrant/options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36",
      "r39",
      "r40",
      "r72",
      "r84",
      "r85",
      "r86",
      "r96",
      "r97",
      "r98",
      "r100",
      "r105",
      "r106",
      "r108",
      "r120",
      "r126",
      "r127",
      "r147",
      "r178",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r271",
      "r306",
      "r309",
      "r310",
      "r311",
      "r323",
      "r375"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r120",
      "r263",
      "r288",
      "r315",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r356",
      "r357",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r418"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r120",
      "r124",
      "r263",
      "r288",
      "r315",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r356",
      "r357",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r418"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plan [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service shares",
        "verboseLabel": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r36",
      "r54",
      "r317",
      "r375",
      "r388"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock amount",
        "verboseLabel": "Proceeds from newly issued shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r36",
      "r54",
      "r323",
      "r375",
      "r388",
      "r424"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r36",
      "r54"
     ]
    },
    "cvm_StockOptionPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "StockOptionPlan",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r51",
      "r337",
      "r353",
      "r376",
      "r377",
      "r413",
      "r425",
      "r439",
      "r451",
      "r499",
      "r516"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r94",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r250",
      "r378",
      "r380",
      "r389"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r279"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type Axis",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r279"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r279"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r280"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SuppliesUsedForRDAndManufacturingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplie used for R&amp;D and manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "SuppliesUsedForRDAndManufacturingNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r503"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity [Axis]",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r66",
      "r67",
      "r69",
      "r70"
     ]
    },
    "cvm_WarrantExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "WarrantExercisesAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "WarrantExercisesShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "WarrantsOfferingPrice",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre funded warrants offering price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "WarrantsToPurchaseCommonStock",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240630",
     "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-8"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001654954-24-010651-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-24-010651-xbrl.zip
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M8$H!XSFZV-?5#U=KC)X6$7CGO@?L:X#5'IDS<!L3%$!"@!WZ,8-"_@NLP+T
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MK["&4V&U(]I<620@X_EX!7'B5>0A<&*/-DM/%K!D-351I[_%CD+W[T7H>S1
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M;$M>1-:_PO<DET>GELK^R"YE0L3U0Q)C2%_<&K:5+(Z=3$W;',V2C:? & V
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MR@QOQ<P[4LQ)\COZSR-L^N__#U!+ P04    " !N@PY9PSYL([]$  "S= ,
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MAIV6?"P[L'*E>L1V!V&YWA$NE988(>O'Y^#M@XU<.FV2?UR2?] JX__X_3K
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M+H\(<95%\DI95 VZ0"2^,.LG:V(O30B[D83)H1-1ZS/TYN: GH+UZ]X+WI'
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M%&:KPW;;INF-H/< 7?O6OX9[%_N+HA-AD;3"@_9JP+EC=KYH,K=92R.VE:1
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M*@M^H]*ZCZ2.>.Y<']WB?XJVP'B"&@A2@LDER5&*'1$NQG,CK@K4X:L@"]$
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MY>HU"./D-:ED$FFT/.OF$^H7;5TV#6\IUT7YS$I.H;74Z<WT7[.J\14',?0
M2DX-[71#!&:^T*O5?T2$5'A8)V^J/;V@^\,KV78)PHA&F?G!J^O3_Z2_DO=]
M+/*#ZQU(CM,D$HAX:P?VV$^324/%YU7/.>J:M#QE]?]M-G7 W7RF\X1>;ZVK
M!G28PT*'^ L"_A$.=?3L#*!49$<PL5\9*K!'X65$TW=8&6"]FH.5'[NT4;#Q
MVR*+[.TV\P+E"E ]))M4JSRH9+39,TN3"5*6 *]^6#3'745LO$IQ+^VD.! =
MR].=& "OH.PG_('55U<4_U2047C]GP<N=^,_*\#N/XTG:&)"1&8%M-)CZD04
M$%GP&Y&N2!;15VAC>B.#[B!=!?XA(G<S/J'7'0J+([M2F+EN,S0<JWI7K^9Q
MMP9H.>&Q3#79VZ7*@&B#WYA^'TGCI?I"MH+*8F.[)=!(]^-ODA!+S[])4*8/
MSMP'_E\/T',=%]F9(PV*.1(R1TI+4="B? 6.$8KU*BSN:3)%0]TG3HW!EH*T
M O_R6$)"+E8&95?4IT7*CP$QGP1RBKS5*I!'IY0GQ([XIF-<9=V^9ST\[LW(
MC)GIB@C=O$R7/8023F)2&HI?GZL&7GIOCB_.%@=39S@TX?*9-% ^Q7+GB9I\
M(+'IJ5/0Z@4)C%&U-)L.IM/=!)KI"W%Q*G>A>TI.L"+'BL\T!/KJ_23RP +L
MZ(+M_D#@)_%,T>H-NA[9&O@8A#^3(TG1*.SM<[K3''379/6Y$,[_5IIOP)K;
M)MAF);4LWV=YA2ZYD)QXDM$'NET:@<\T?/3A_/ Y?:,SJ1%MA>C6?T"A&]@_
MAT$DVN3JY4O?P)BL;ZA.AJ/X,VPU/;20UK 5914L#L)$#U!%9'_CXPT;'@>Y
MY SVV 8]-33W2]_.>*MHJ"['&^<S28[9)7*,B OONX*B\98H?KLCCDWY#[@S
M7LA/N#[TSUVWL_ SW\!8JVFB3@::X!OL)8 )@C,3WE_KMW;\(0;67U%HN=&W
M.\(24['^NG=#%CS0\YS&_=(W,,[J&ZK+.8WS&;;.F:/Q0N=FB;(*BN8TJJA_
MO!UVD6N[,'S?PN,=FXKP@@IYM<]75((N/E_!%68;J?9T@HSPK>1@EO9[8?9"
M4UU$@IK,=DE4/X54>8C E528P4X,-)>UKBS&1OA@,9[I/*N4!EAZ-"M1Z"5Q
MS^GF2.5A=DE(V=FU %[FJ+H@P4;@>&?/=8>!UF'C'42C;CJ[.[. PC?70H)Y
MUZ,?IY&M)-+UV7?_16-6\;1*LW9>P[T;0X_\=?5*LJ#4C8FNOZ;!//738%P3
MU^VGV&8:V@V-R&:BI)*"(_^>;GF>_^*/!Z/H>/-O$SZZSR]QA?M7(:_P99\Z
MT+G7?$3"+%1C-QQ:)FQE2\(LO=I#U,#& 8DBV(2 J@*BVP>YHC#.$ O_UXE4
M^#]^?R3+)@Z!"K_U3Q8N&$*,W ^T=0>CQ6*J,U58!:32,2 1ZZUS&UB.1^21
M2UP/,(S?GS#U(I)% :]KK]ZSOU28DB8%J$RNWK1:^1SKLMK).=-TL31AR[$M
M[O(A-94&5!QD2P)7[R#_Z_D<YL<_XJD:1??BN,?\[XKB'7F@CG&.V1_9>0B<
M6S/MEZS%L$I.#A4%][W&M=)O?/Y<T[$G 94]6X25[]KT5[81/]X-H>Z(^2I<
M@L[]_+G_WOU[3>?^74??_KVJ:_^>O9J"G*G^7#5B6(*._7O__?IK3;_^JJ-?
M?ZWJUU^SVVC3X71IAC7FPA+TZZ_]]^NG3S4=>Q)0V;-%6/FN37]E@V/HC&PS
M^I:/2]"YGS[UW[OWM4Z4'B^JVHW*.BRCX1#.=1[NU.$2.5(*/*G'QYK>/0FH
M[-TBK'SOIK\F:^3I;&&&)\7')>C=Q\=>P^EK-F@^L?2SW,[G_*YFHX8+*MVL
MR?W(%B(3R])Z:%L#J]CQB6B?@_H:K[$/7DSB687CFB.C9F@+P:6CNR20''I/
MX$QW>KP::*4-V9.XUE$.OU:/\OSOBD8Y#]1QE&=_9)O>$X0LG;MC-;!*HYR)
M*AKE+(Q(9JSG)96/>!Y0SKC/BB71"X/91.=]'VF 538@C?;J\_YE%!W0#8S1
MD%.![(^*[E66X!SO4!Y_85ER9\/=5'<&(1&FTMU((@>(8!\>.0W<)9\@]\$^
M[TFF/1:.>SH19#SB>: -E!5Y\HVK<_3RI3639Q?LJ:WSX.X<S*75 ;O.EQ8$
M2$G'L.S,$>^')%EN#SQ,O_80NJ>VR52U\+L:-G%!I83)_<@>!(,SVUIJYD0%
MK%(L7MK#5+:73DT#E(GUXH+-"ZCJ5AZL4[]F?TTN">VF2%6>*G''BG&5>S:5
M[6W>H!L*VVW-3LY)0.5.3A%6?B<G_37)R3?;(>UVO *78"=GN^W3KUO35U+2
MI.S'"SH\5HHD%0WE:J#',<T72\SCSAGICJZ5 E@:Y>PMFU2KJXM4#1@AG*VK
MI'4R@S^3BT79GOEB9 UU/U0J#5*6);W-^@]A8"%D1Q]Q7\@;$BDM-=1I4(&4
M0A(JM)<FRX'>[>-68(N42@L I 30DQDZ.TSP*83D-8_TO::K]YKTM17RZH(
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M[(<0[:%K)PF5>"&R<FJJ%PGU52BO%,0Z;*O-F5@S0V+F&Z"M6#,XN C@LC+
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MV-3EU0Q-K W_@"F)J4!*\MRB5[2-\PS>PV195R",;L"#IBE+8G,S VHN/W@
MBK7:?T$1QK;%4YSYSV&4/\M+BM8U<J^A(_!L7862Y#=WY!\O1+&6>P5<BST2
M^(KENI+H(1VY5 _J:(2/Z\[J'='^M"!OS7/P]-@8!(&O6I(8!WVY2H%UM,''
MQ=>\)BA*LSVD SV8-23J>@##FT);$IVF(X<;L8FUU// UF4<Q6?H&B)]*3V
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M.3\Z0"QJV$O V*9SI-H6:+:&7$F2BSH0OY&)9S#[,8L>48YM5I0NF9'DY28
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M<7?6 HAT?2HZ[.T:+'U'*C9LE3K-KY&/-?]X%V'#?/[=0VDZ>R8_M>1KW3#
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MMU*]6B]?W, #OQ&^7HX NXOG=)/N;G]ZU)SO0M="G\EP*X)E8#L@<THPJR&
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M"#VYK0QUI)O UC+4+[V[< UJZ>)&K9?%:D794'":.2)S>*W#2TT>7FI):IP
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MO0  ^'JEP8OP@PR (+1S)AIY"8+B[#QZVWHH]6[;PFWW^:G[W.RWNYV]"<O
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MI3<L!\$Y0-"<V#/<[8]CH+@8N-6FAO=!)(&#(.<@N$,C8VAP25!H$) 64ZQ
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MP7WSL?WP^W6D_B7N7?!+NW,MP/N^""&R#Q'0RX&=Z"$$V^+!KSP;4U%'%DY
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M=P'S-G(*+N"^INII&#U!9%85]L*];!X&*I)<%@P+%WLUWA ]]\/[/D(&Z=/
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M(2'F2_*/T&H$$F8@G"9_$1:/D?[0*/083MDU7"\PN(B=!=2=6<ZBOBO]$;"
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MI3D6R$3W"3DDII#)DXD.Z(X'?+0$JQ!H+3*!K&:51U<2D8(8 1[=/YB:XJ-
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MS,)/  %JT#@_K/-3WYX"B52E^OE:>*266V##KCZ)JXYL?/$RQ? EF,<RS9
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M"-ZA[[C4IAV/AX,B><:%=LH@2;8KQTF ..%O%$V@%#/L33L.'YKL)U[G39S
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M!+1#,_SM^CWJ8%:U.\5S;A?JS47%S4P]^J%Y_79Q4^MVU5JM>/[B=9/&MYB
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MK]57"A\<+7X<0/QWMRK^_Q6+#+2.R/J_NGIC>%%K;$W^7UU%+J%Z'16 3JD
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M^7SU\.7=Q=?>_<6Y<MN[N_^7<G_7N^[WSNXO;Z[[Q]MJ*JTVKI+Q 8S0<'W
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M*S=?E"^7U[WKL\O>5^7LYOK\\E[^YNZB_^WK/?WDYO;BKH=?],/1#O&,EEW
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M[=W_"AN]^[UW=[[<9GE-,(Q;,^L!\3*AD@C%WGT ,IZ %H#>HB<0<(S7U33
ME/C3B)6B5$P!QF/"M88LQ'FRDQHY$N\8U0Q)O$1D'@^#J(-FBGOP.2S":],7
MVB<:&"<X+E(%D!?+S:D#9[*E>2"MC*J"/!-13/G9<AST)#U(%D^4^7?=#I#?
M8I01Z1I4#GJK[N]12]]F-6*MVC+M)5/B'BQG &Q)P"FID?(U(Q88/V9LC)'%
MIH.Y]JU_KOQ5.VU7FRTP\\AGAERK7L-(BY1WR/G.>K_<X85TJO6?XF,(\;:&
M.C SGD>HBLI(^AI8*I^+;P;6_<5%MO@/%'9WXBY1#1CR&$/7)$-/'_'L07Q=
M\B0@DEPA1,*/1/D(<G9Q>C$M#X0_.LDERDF_IY>0HJ0B#%T2-'B<\-V+CPAZ
M WR 6U'EL_C+N%034L)C9-0#?^* QJ>[IAX31Z@:\KYM6"QC1GA"7#GVD.UN
MW+GE.8E+' <N06,<&*1ZR+MF @=5>%6&,?']F??QPX>GIZ?J0))4%837AQD0
MG5=Q#8O,\0^<FJ%5M.X'!G<EL>\*;Z#R!!<^J0!B59JMBD"LRF!>0<2JH'0;
M55#EJ4B*K@ D!1\Z>544^HQ_90(&"$=J,$3+6!<JI7A+D7[!1@?BK(66X +%
M,E):X1R=YJ<5E.N4HAO8YI\!A5E#A0:0*8=SQ"N%3>(?Y'E=$:,>S$=0OL:F
MZ_FA@%GC<> ^)$C(2PSB1'^P'<_T0 \UD!YCZF1D9_&T4:IU#H#JW;EX\2M6
MH_+,*52!2;/UN0S"M%/!GDZS)F4U*9NW%"+$!!'22ANA?P\V"_ R<*2MC1IS
M-*CU&QC2*KH^]9&N*A<!V#"@/%QZK@Z,!A?I>:9>!203*K=82$5$"?>G"U.
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M9GU'E6N ];CXP.VY]D%>-M,.ZLF^(6HH/H'$-VR9Y!1^K+P/GSN!5\/.;+(
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M2PI=(99*D%11?)E'EPUC21>S=/!]W+5>6SKR=NG(@Q?7--#'#M 00Z% D[<
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M,EQ=3S+S6'T8)F<*OHJM$3#1+KF2U+I#;4>JW%F5(YT6E4BHHNTC3XN2:5%
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M6H_WTLKL116,@TV#4MO<C[99+[7-_?-NK9;+O,7':>Y=O,/%O#=<102:%JF
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M9')J;!A-?I_P!1$I9L2)X>XF)ZN+C <[G9&,V<VE^[ET/Y?NY\W846\T(IL
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MV3(O*UIP@#J['J<FRX#3C40\1X"1 HMA]M( X6]AH 5GT"NSP,5;]47'X<@
M24T@%J%TTK;L&(I17E/\MU7EVN'AB.QAD'/5\;Q3MDG!D)<>&+R2!W35\/OG
MZ%#P%E_'0A0\!II^N<!J"8'5DE/8+B.2.48I=(VS/3$Y(7"%UQ+9!V(:F^9
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M]WNO,XOIKJJNZ57KJ[6^U55!_$2L .X]4U11!*"@H !>(?\!$/, >0 &.O)
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M(0"@@MPV$ &0+H+?D'I/(@#_+-X:_M/B?]'ZG\5_VG7\:),C6Q[GO*>+:P]
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MAGL!K_7H<1" >*OZJ\HC(%S1IR$\DYM40TM90X$4\!\("H6KT5$C L!"'HL
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M.$%>%4^0YT5E;TM99P!K2W:ODU4] XE@(*G@Y;?A#6L/SC:])WFN30.W 9<
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MJL[HI31V3,W(T&C0&H;,IP GK9I(0OZ1%=+7-?EE?T:GC07RYC6)_CHW^IW
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MKZ#2E(<7^Q)>NG;.BAI*.7C!*I^LYG=NI*:'>T#MT4)B%G4_4BG4S<S[C,[
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MX,5A7P$"@(<K.)V08AC ,0'>#@<1"&B,'YXO/@#I">'%LJ]Y%0 ,JACX+A"
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M0Y($J5EDV$.:ZL FF8?"O%=*FR]Z*'-7!T(/_G@/9X/+EV:*V[S3/#,$P"U
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M^G9W)=+N6^3:G$N3C]^/?']X$:@]2CN^S<Y1Q<XUR9@FO; E8)B4E^BW>#U
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M8UJ'NB+HD$ TJ.7J)AF% MDHG(Y&39_F3D3 J"<$(>6 @J@CQ]M[_L)L66'
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MCFC>'W3'QV8H-$E'@2W4D V=)G/BE:)>NKJE64 >&7WT]5:%TGLS$(.58"0
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M-W>UY .[MMBJ&M"<PT)VR5:6^R/2SX/4GO7]>DSV[=]AW']7.*G:Y@\W/9"
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MO;FN^<4TLHYVJ*NN?QD(^^4]VE]^U!6Y>70E<G/U^P79*)=3(?Q OUP^TMB
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M="B4VO[>3)BF."&I9)UG9\+6'/UB%'P"JZV'1>*^CB$V8_IMQ>'U8W(JV3[
M+U#!=S9[JX5,4HZU+9)GVW3,U77T>=%$8IMZI%7:'%D$O*JH1Y?5K=_;3=*J
M.69W^_==@U]"NE83L/ADYDFLOS-Z@6A)564]K+$V3CU@4DYXI"HV69E<$@T4
MGZ)EMV2WYOBE!#) 97I],;_XPG567N<AMR-T&@[J^IXF@)'[3N,;WLH#+^A5
M@#W(/K+%IB;*N$FD0#37>D;7CWR_:AH%D"C<W<]4@H-1RT<5Y'RP %)Q@@0N
MCP(1MV$R?_[T#LY2\K/F<Z(9Y='8!5>@!V[83;[LX>N2:K=JR]@X6].M&0%G
M"PB?<Y)?)H]G5@:^J*B,&A?=-6;LTC(.H5B&<39G>HQ.MY/&,<&KG"2#J9Z0
MJEK\=)@/,H8E[PJ_F0%/K]&_=NM0D(B42$#15(M_MS<FZ@>1&^$1@G*HG%S;
MYB0L/SAZ4@(Z!X_&]+E];*,F*'G344@9P5'P#7WP7N]XRPHW:@68Z$8"0V"0
M_EH6.[M 7LDJFYQ(;OJ:F@*)3DHGHT?&Q;M3T#94YD='/V="9 )O1?&EI:>#
M>D%A1_22Z>X\+)V4V++2<:JY*]7/Q5B(].VP"0CTBI,QK65$Z#K\9<);)N$*
M;-WYLQ>O_;WH(G6:AAHUI:9B)]KSX-Q%DBT5#"O4<>E.QL8D8P8\X7NF*V1B
M5%#\]M@V[Z\7M:U'M3:@'1O?7!JE9?5 Q<.G;TR8YGCXN]GN/+RFQ&=;INA\
M:U^<E5[]"6IYSGN$2YYP]19&4^+45^I54>0_<.9&%0U5/^/60P327?+ "L,,
MHVU9A_RZN,S@D]L$VVIN3E"_K*[V*L/+>[6O;W=;JS>R<F<;(@S_W9[C/Q7H
MK\?_D_VT6OQ0PCZ>4 N2QTT35W:"";U4SRKIL1F&GJ^9O%^&-UP=IY-[JIN.
M2:J1E6='\JU$L26P\S+%T$[%JJWD#;X]6!C$5EB85BP_\ MJ&'#BTV$5(:QZ
M76?NONL@2X/E@V;,K#D"ORRQ #\3-6]@/ ]')Y/U"P62FF0Q/:'KT8TZ#S^X
MA;/S,'RMB=K,BE*L(>+.L1]*3UGM![ GPLZ*2@=;I\^?YK\5>86?3",@2]V<
M6V"7:((?O&3,:UM;$Z92R3+/'HH1F9_&F5E?5U->GG2T]RH C@,W>!7SM2",
M7S]N$!#0:435MH]FYP<A&T\JI!\9SIKX<ARZ148V)HIH;YS'R.,],UAQ?]=:
M]&XT5O:./W=9I"3+')DC"6^HX/B@7FD6CW87G?!\2XK;\K9A@D="?5!0TVUD
MJQ%\1K&B35"MCDF10A?##8-ZK5E^!$%ST</[@+6M3E+,#U43YM1K',H'!]4V
M7!.JEUO0^>Q2F3K.+>>"3>WH2!J%%GAWN$44#DWA/#=4V9UY--)34UP.6>HG
M'R>1P(N+;XP4HINR=,H&%^GRC>,P,"V-G/1L3B^)2$PM^ZID :U0-\#'(;>0
M5%CDN=PF+K4]-6>?L+0ET6!/0?_D52Q[J<PH9U& 'L3\#5^?[^$A\7<$RZB;
M*>56S&8SDW[6X8,@2(-*4./UA^$A(H-'5.J?AZJ5.Q6I3Z!TY+9OI4=A?6^E
M6#IUZZ.D[-L$-OE-X0UL4[26,5W40;X4^!9I\6@GX YH+GRKVE"M(Q-#/.BJ
M:[QZ@)[H.2-0I[/E'B 0]05J=_G%09I).'E13'I@R7%7U+6%@*=D@E"B8AY'
MKP?^_0U!LR^TD3#".LDJ';LCDDJV"3$PYJM0LF68'\@PZC_&B&&PI1 OR6<I
MJX<#6I%<>36(/1*O%^:+G=Q^; L?N&&"![>X.50HG-F<7HN9UX:&I0L0*1>O
ML8MN2)M\VG7]EX5 !UI\L3,^ABY-B8BW5QJ5#R$7EM;ADH9P(7H$[:<6E7:6
M4I92J]OB%T@@PQ2A9'J0O6N8?WL'"1R)(X$@6TVEG[I^/^=A6^DGN$B@:QM!
MXE?VCTNAE&PUGPW.!78=<]*V0%[0W_ IB_T.O@6FJ^?:C.%&"G>LF8K[O#FR
M<-B3ZUQ\ 1Y6$S[;$GUMY<ED:7/VF-XI</2PCUMWT;U&Q$G5X,T6U=[PN*I!
MAA=)12(Z-HTWY<@ R3FE!UD86][CK# V "7HZ2@\%,B&_ &'3=NXJ/+SXSB*
M_9EB(P$%F,-Y(:A2Y8;OY%9I2(%4T>Q_Q^[_IVS_LZ]1I>7!C"$L+PFE?U>Y
MX)IP7/>'E;@J KX49V^K)NE&)+ DZ1'KZ<58F6KB5<JH#*:=Z">N8760ZG1?
M,/?G]96JC=W^)O[;,$ZS9[<I6T"N![4K$WI4-FO23C%NZ^%\VZ(/^:DJG[5G
M.>(($^<.]<GM?.^E[BY FLQ2F*<XDI,462'4+#EF&T]^/.(A:3U75=P-,PVY
M:I]K*;33+9]D$C#RVK7GZM_T_@%^<$G'H.&)3A\#]Y?"_9%RX; 3]=GT%D>W
M=M/((3.GUW:A%KPRZD !Y5X*JJXFT\K!^ZCH5=H+^V\]G]>H_UK38 ,W7LSN
M'U?B4/0^*4DNNS<YNZ7KL>_UML*0C*/0=1'$2!UQ;,Q-RL.^IQIALK&^F^N#
M.UW %'6D[\'YU+TJD'P=>ULO>W0A81%\4Y<=$U\1RLCY47P\TL(^R7@NV^YY
M:J%PJGM!+_4VN5\=;7!"H0W9JB$5":R_-W>[+[?3(8TIAD>#9Q/Q\WVU^.&^
M8=+K8?4\.<&?E(KJG]]%)-E>WO%PYT7EAP+U&8I8,?0]1#2K(\+MYA",^N*=
M-R&"IE>7,E?<Q3X7D<]FX! \/QG-$TT%S0__6<']/RB^VWR?&HLOM[58-CG5
M41MAFK+5%YWZ*O<\%I@0FID@7,+'00+@[0,[R.L7'SBX#E0(G!Y'GF<,'$3.
M>WJ@D/N"@B?[X/GGQ'"<N%XF+^9GG[B>I<?'I/RM^$9O\Y:P\<:@=)G!#25,
MG1US+UTS_\%Q!J2@;8).4+J^$4$"1(+)8-UKU7)8[6@9]S.62>'=3_U+/27/
MI35RTGNA@*LT(Q*(>7N\V@V7H?NL%^J9O"3R@].4SA:N:E-A*TQDG/,R12S5
M \T?";A:PYL\],==I\MP[V;7*UR_XNN]5]?&7TZ^5,,*JZF-X/[!SJ9%[JCQ
M1DE^P+NCA%DPWM*B\KY)*MFJ*+LQ"+2Y%H9;N)V,?:.] ]E=9)^'>^_?XO8A
M@7=W07Z%=CO7GZ^5D0#'#>1G*V)DHF7#Q/$&YYE,U>G^U4/4G+U#5%V0;;+R
MMTM^,]V5\D$$H>CYM_?9U^HF2"#3K>6 @=,N3&B/=EBFIX7XX9^M;+_W9ORK
M-WA6I$](5?11V8_V/QO_-@3H[T,L[C+>%!_R0?YLC?YS,&@1VT2MS_^K.@S_
M*QV&_]0!]B]T^$L $J]5?_7EB006GNCTJ;ZH&:'G_\VKPVFX-E)D:?Z]&]BL
MJH'&1[V^ 2/Z$560]7(9Q?I!SLFU:4Q*.<G2I9'>DAL$7C]QBUOV*^2JMU H
M9+ >"5P0?'+FUNI0'FL>S)8*+7R0:YZ?_/YF PG4M-"?G5SS-GUI@=<OHR,!
MDNW?!\9QPR>9FIP&M2]JLFN1AC;)=98]$TJGLJD76H7"QE8(A48#R"6[[WPQ
MO2Y.RX?7F(V]?A5JVJ_#6B[%#KJ>_^AG%>ZNXK=_\W-\3%*E:KGU4BIDFOB&
M U8-6]ID='%:Q P-%G[G&R*3"^XM-G@:,>><\L!_0B3G @DHCS6J>&5,JU,G
M5BN\';F7GD0S[R%C2(DX7V$-S4G2-8V^_)P4$B84;NRC&/V#DEK<R'D.9\'%
M$[HFIDCE%#W>H!KY! ''KHU30].PK.Z_V[EJ(G]H\?TMRZ%2A&#HKIL^>%=S
M7$)!HH;I/1F7$V+CIG@<NG,J?-#H[C&BP)*Y@A$SPD!QV"_0?]_BN;9SO*$[
M2$I(2E*-@R_[>0Y32D[J<'/2AF/P3&:(MV$?*%+S!?Y.U0)DX!L2N&=:M65Z
M<M_T!H=NT9@UT44Q;"UO3%(C<4W45X(D8?JC5]X!>N!Y%!^\9'K>/M;("-H1
M3JW)B$8<GN'[/:I)-/^G_VQ6^9ZCT(==YMAY%14K'6:"&;3:,XIVN7R[I)SR
MR<YB6WL+J9[4GKB[=QY3=#XSZO(8[[@ET7SQ]W7]WTJ)(SZD,W?^]JT:*JUT
M^RP\?1!2//]X<<3FWST<C:R_\%E4+>XMWM^)AS74=WZ1*N038PCMUZOK[MY/
MVBG(>.!C5%4-.\BI/CO(<9*G5*)\=_Z"T)\S<U<?P83".H?]#9D3!AU)@S*5
MQ3),NSGZ$/5DS:2.V;RH\5G<QG[LGHP'7J(W;.C96<T<!W.P)7R233H"21G6
M'YS3-+H^4/Y=7EA=J>L&@WE[WCL05:8NJUW!]Y<"QCR);DO<ZHN?@LO-H&KV
MMR%%,YN1U-[M[=.FLZ%+[,Q5(2Q^WTV$E"1DG5W: 3\SM9F[] 3*6U*<W6\I
M/<MA4#V#RF:1R"6J=/[#G_V40[IBAO@<!.2?]&?=8W544VKH(SS7W]W8+I7A
M&FY=)1M<V'B&M#>S-%0B1D<=K<+&!1P;:[]$'T21/:YE(D;5LJ>WI N&IAWX
ME)[O;O M,C:\Z<ZB/S"-+M;%+BUIOVZQ<+W/Q)7-%441MN+M,MYTX'.:@?F?
M1>OO5=HZ$H _6]:JN0!#SBARPU@]L^MC>1L_"OBO;T;!@B6I#M)&% Y.1_0W
MA1,.&GG-W&-QT@P>W[M96.V6BO8^OX7(5DYP,<'J@YBC%-@V'^WI:8\2;IIH
MYB#Z$7>'A3QAG'ZLKA]EON"Y&$F6/YGJUR1?T%43Z(4JJC68^FQX+J.6)ZRF
M14?B&[F*PRQ; IL:YTZLR!7&I]V$JY:LJ7UP*/PBKC--]+#-UELD-+TM@=A&
M^"J;[9UE[$.SKM].NB7CX$T6.K=I-U3%%P%@PV-UYW.BNZ4,48O#N"'4>Y[?
MOPL-3M_PEE<="DU\@&8?[>]QD_5UN53VF-9G>N.]U*J)><Y?TT#WW;9FSA=6
M:&?"=)@8+$VU99@8RA)P8S]LNROHE#^OV#HP<&@1X5IZ"\.GMJ,C@\W?-_"L
MVW6%DO7CUK4,C:VFHZ_I[#0,:$_#O"7GT7QYW1:5&P682_*?!^SNF]]9?!_*
M2?<E\)3NV>0!$F@UYFR[^G&5EU;1[N($ILF)9NICL8C>B_*Y/L\:*'] 9*]\
M7AU>+.TM_?@BR.-@ZWRIXJ)?PN9EHZ4:QK=F]?@*\-%4\]FQ<71K\FKCQ>IR
MJDKVX_!P/VGGD"*':-%;^[KD,Y\#(_CQ5JPM]'C@+!'V\ %WFNG^Y\H:H0II
M_(W>9=AAEA*78?68;BS[E,4;+*P5:NI[W"NF3+ J".9JYI1G:*#IA5?\"M40
MBC4(N<Y]^FE_<.GQEB9:;,I3Y@2K-'T8ZC!@8MH6="WS,S:,K9C_=RK?VXPJ
M[/-0BXHQ'1*0$RHTJ#F+,U)Q%&KL)?E8;E;G@1X3IFYN69YYH3F0:S$#VHX$
M/YHVG<YI?]YA<Q= N)$&E85F\R,!&[L$%VLJR0;SVN7TI=-<"/W:D8A-B1QX
M"7^7:%V[ZIHU\1W=5/_NU';J+,= 7 ED8(7N? 4)1#X\PKVD?*'+E##W"#$8
MNCP*Q<S07F.HD0AW_SZKZYMJ@8#0(X$6UAN;EH^F72,W;#><(MUC2&#]"/_Z
M"-(1S:J'!-*[9/91-(420M\2DWNA>:'K&%>,!/X^ .USU!HG\Q$R'X<0] U
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M2=QH(E32EOZIJS81V,J**2V#=W8+GV3@ D160YE0GK_YEG:4U_IKF%ZT#?J
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M@I14U>QKBF93D@1C>1):'J@WM )&__4;9!V\]X@)#Z-^FQFH778W9D<4#<I
MTS\$8#S(?'/-M4 _\18PNJO?BHCZ7)=?59]C27["1MD9AA'KIX&9LP=CN E%
M!)W]#NJ-_Y??9?J;?N)"KH9WTCK;-\88E]%GHLB@7/,[+F_U1N:_3WW"?U.W
M9L^#CIYCH*0-;OEH_HO%*QS7D+#HT3\ZPX:>C3CA$E*55;0YH='#=4]]9"DF
MW[OVR[!]CEH2=*U:?L?RRSM::34?WL0+_JSM'![F=>I9"$A9(V-*__JO%- T
M$!KXT/0Y[?6/.0.IWYC_HR+/*2+^%I"QE[JZ:5_5KF,@W#SS\T"4O;;&?2E4
M=H';<5V*W&P6UFB?];)&9]BFN'Z2(/8/3,@7E81 DPMF@\4^W@4R+OXND9G6
M6G4.FXI:?0IR:6>3 "D#[?\P$F-_) *'=/IXEC+,(^1,> BUD R.FR'#LC2U
MZ1_M9_@3_3'UK>WH&<8.'AKJU%1'J//>K> T/ST$T^>$ S:W@.-=.2:_L]7M
M.S<"07^@J3OFTZ2I5)OY1Y)</S%4'/O@Y,@]2*AU[R]=^2->"G\$S^. 8(O<
MZ\U4.==C3ZLW >$CG.I%K29_#B?P#S2V2SKW5KR9M%\NFOW ZVLH'M[K;2W!
M?G#*??<,Z0RIJ\/V96G0OW]\I;A$_KQ$E2&NXO6G%]V^N+_0Y@J,J"5CI9F4
M:QAO@8G_2%:F_X:*N6GR8X,.12^KC;ML6#"W@W"BX3)C>[MOZD3??H#AO+,Z
MHJC\*4U^"]37!EWBZM]EJ9._OJ7_$U7=(0QDT'\DL%R"L#SXG6R_C1@*_V9<
MLE9)HR"\NAC,\X^!#WJS>8?N_X5P;\B45[N0+YK#,U<ZAS >WZ@_# RHD!#3
MP/SQ;WJ0WBP9V\51,$NTS:A^6#J-)(AW+9HWC),<9F*V]+[ /5KSW/K?.I"[
MW,24WKFN:*'/9-\474T;]LM+T(Z.1 &"O2IJF4&F<:>6F80%1A&4CBM@QV5%
M<Y/(:%+";QJ8T?]T4G5@FLOIH$4JR/JUU.Q^8<CX$_ZX<@6L.C8H@=2W2]73
M^,\#SKY.G%W#%M&C2NO8%(#CPKZ,<^]7G+L+<.5&KW7L41S@:4&5*_\LH?UY
M.:>J-'QLO>^%XZX3(J\GTP]L/@>+[ZRPOC_9\SOH.K(9Y8RR=-]0#+@%>&Q7
MJ4YW^M:\=DRB^2%^8W* 6]O3,>Z35M'O8N2>Z<A+W)!Z<TKV"EQK!O_80[NT
ML&/#+"DM1*63@/>XZN2,8OBW%&8--696Y@.1_I$O>\:MI&AJ1_/&^D,./:'?
M8]_ED;U.A&!OF1A#SVFZTYUCCO&?KY(8ZAMPXEGD^ 3?NPJ^>334I.;G.>2W
M=^?W(-LW!(@Z?'?-EH;#*UFBC_',BW$-W]VCP!MB*9%F!$^Q.&:*H7B_A6AB
MC%F&D?O.DBMLKYC3KG9)[P61&*7%U:HJ@*<$<G9_,P^.\3KO$4K9UC"&YK/(
MNTGWTRX1+7Y%LJ&_/_?//8^1&3NA<28Q[O#UEKANP!7@'&HUI,U:$!FA*]/K
MT74W\3$YPC5^[&D[@Y\:_^Q#->TM0.+GS=3&:TQ'BK;61G(8'UD;1 <O,3)H
M,7";B0D8\* -"9;^)B%K'=^,]=3=I'J^A+16 Q2CNO3;0+XE[(9(EBYEX:BO
MC.R<QP:X^*GFHN(:ZDLEN!OYU5QG;0FMO[_$!DHH@)J.\&RU-VUH'-WM:?T6
MLBH:C_1:5O[RI*%8/)2WXV"\01P]SXZ:\-WR1!TV^7UR!<LX,*^.Q#.BWH,B
MLNDQ:5KU^&-3(I^P3OZM0)JVT'%?]8. E8'U0LDE2Q&C3/<M_1NRP_W6PO//
MZ[> EK:.C?(0GS+8N(I=Z^?-@V"R#40K=310Y-.@"1Y.=6/6D\..6O!FKQ=F
M]J:J?#@> $)1(\X4'&7!54T-U0CJ4PMBE68S^*?[(^+6V#YDF_8K>U(WQ$H>
M#%7;C_8Y*<SM.I_F+PGM?V1M=82_M>8,%=[/]6:.*UW*A-2BN;6$]9J0H'IA
M*_Z_GR.V<6'<CI(JBK!4^:@5C!)Q:WO>CK7?'!-%4P)SCI*JSU=N%L44FWR1
MTD3^;@OLX'W8>@*<K-M-6*-')X21_CU]1#!O ,WKMP7G4NH3)X]G79W)>S6N
M#OE<1RIX)^*5!U"G,<7VNGX>?I9E(Q*M?9^PLUXQN4CJ>IIY%^^#!&<>3[7$
M;J81\3,YFE7<U]I\B\_@4/L+[\W*HV5O!P+^>",-$,W2 O$OM4G!C)TANMHF
M[BQM^89[X)^X.8N>K*[,R=DS=&5YTUR%+8<WN;9XSLS)TJA2^)V6,U'B^3'X
MU3;'Y<QJKJA\7(ZZI +S+/<74QA-4-IQG093J DWO7E*\A/__% .\'W_/@!W
M)4ZL!RF9YXD30P.^;C1/LC"W?;!P1->X\+#O(BT,8C]K'RM%),[2K'-:C@R#
MU<5U&@Q]_,C7=XX46F45"_=8OQQZ45"1>X^I_KD%P\-CR0]H:WYI(0&O>*(]
MLZ3G*G)MW=TWQ)U='BS(]<Z$;.?Z)<R[\)H4Y"(7P.=!ZC7M&2/-$1@0??ZL
M02Q"B>W[XG*Y\!*%(J$2)R>+A*XOBO?U<+_:^]&Z\2,*VQ ""X(FAF7Y.E%C
MS$AORC/:>]\\J"14 ==L\<.1R+H<HDTD)!K55Q_=H6E%K\V7BJ&\,Q4,Q*>E
MCQ]ROU_!!RG=K<^5//%_#IX=&7&BQ)Y]+ >Q>JNYPZ4Y&C\'B_#0V5Q"FI8&
MAOA5K/37V)3+WO$QFNFCB>/%0GPJU#LE25#R::L#;U4T:J(Y!*JO>'GG+76D
M+^1_'%@77[7V^ W=I9"DG6Q0NOY)3%D0@9R8G5X4=3G%/:E'9";6'8Q4N.1,
M$V'(5KMHH,R1(=F65,2\ZOG/.7<7L>SUQB!:'[6=;H.XNI[8IW,CSHZ\*@MS
MEL0I<]2$#DGJRR;A<H!K.V'M6UF9PTP#KURG^B/.V %*LT'2U0.B7O?L3&TI
MXEIC/=/#^%.O9,(,)B/Y<;8$)@>0N'78L+#@_"MI>M>E6P#?)T8%Q?'#+C%?
M>NY#MG8C'VZAF!<>O?PW[/Z=]/U*<EM.:Y4 JG0AHM >^5W7)!':J;N,U7G,
M@'8M4VM\W\3>WI\&7]M$Q9YYUR+@\"!%3)%V6=UH[9?)EAPIVFHV^V%0C" /
MM9U?:H8=<UUCU15[5?,,SFH"5N"I/\.'$U;!>1\QU?:) +JBK<ND"^\'"E5I
M@4=8:GQ^UI1;W_:,C4G1-GX0BXM5^L0H58?)75289V8-,6K',-U[3JA9E A1
M:%5=@I&?O9P\L1\88E>56+>,17-Y;!C<]'MK0VPF2<T/CV!J84R:BOY13<ZK
MP^$\2_OVX6RL%T=K,[-,-5Z5K(>5P=?FA><9BI-U/%S+D5E5OC'5W\4SH1KN
MC6L,'U8K[.<VH=@S3IHMP?+"2],)BSZ$/?0ZK;!WX?J/<W:G-8UK!*-L&RXR
MCWXF_SP=\B<C18/[,,A/"KSEWN:8>VV5-$C-\8KG(U-G\%#.Z4=R>*N%3TYG
M<\%IZ]L2<.^T[C3Y%V9$I8>.]2SW>BQZ9VCKU73^W: 8+_W .9]00KT3S6XM
M,32>P1=&?N9HVY1T^?Y1G!A+QNF\\M7?=G%Z4%BM1>?VSYL0)_*NM@ZY.0//
M=]U< /1*@SS'56<"=>B,O:8I+*L"6HY86?-U.!_VD3@ORV8Z7$];@1&K,NB'
M_ZQ-3)E]]3U)>\V- Z1][KR<90!7J&J$_.0Z?D<TUT,[8X3G.>SF0WL"Q9B2
M9-PT<,HJL",JGZY'9O*XHL/K^*F#E2Z^_PH;=;-;.;\%NK@*"[:WL;=[&3?+
M<9\S"VM>7[?=I##Y\,BE?^\<WZ9HAO0NJH #5FBP5T$-1FAAR*K5<ZUEG9JD
M8<4[C[$*85%B&7XNM*2$GIR]D0X<F">R1#''-3 !WQ5<M73$##UK:R-F+9)>
M$6,0,EE^)-2:G_K^?_U7 6MUE3BJ9784:4K%V(%C9"VOO9(;!M)\)?R/*UX'
M$LWVYL+VE^L:9XEI(A_.,<ZU^X(D#'U&QELUHX%?^!S+.3.!##LF5*DKL\.?
M 08F<65I@+C<?XDD5J>2X)Q\0QX%1C WUA%!$^(?$5=_M\!-28SZ2<+ !B?;
MO%/BI+EKWLE=Z[;FJBD'Z*?]U/5%J8?1%OS$1AO>#^.!U>C$0-(O8]2C=OWT
MT".%YE/A+[V,&<PQ%2Y=4B^GR^YH(E%RS9"^3P/>.WE'9"A#S=5214*5<"_V
MM]O]EP02$CO0JD.NQ;0E8\,7U*$+\\:=T1#MXOG$TF W=<UVF!\^*=I/_@#^
MELG"]$M')8>;N3;?/?'6#BOAHV&9#>M!B2,)MK!E0Z5BK+OFI2)$T(X0\^N;
M3E8+DNJ#2YGH6R:P.XD0;._T@+ T-#569TM:$#BV>27W'87QCHCY,+7RWY"U
ME11EV1D:EME'3.[=]%=IA/TB6^"H(78#6-%A?C])T3!X?850/8T-J;G>]$7H
M9!+_!R_N_EYT;L8(O"[&-KP&G1C\)W;V=#FZ/4<BVC@;48+KL/QMW5%Y)'0J
M5SXQA(2;8@(@[;M,!TZMTRF[J![+S<7-?<2S+K0=>,3+7G&?L@\D/**,,OSQ
M_A9X(,AQM:"\JA'"[;P72\R*5'F$?P'$-3KP "<P%5/L:_EHLZ$5YBAHA$!D
M#S>Q/@504[&H71%H,HFVDR)WPB7)^S#I<@%#P2&\X-672WH?P0TD15B+!U*G
M/) 1!5OS]IH^<#%82&G9_)[X):F5SPUDU]5VR!!%CNS>NJ1_EZ;[<,4_XD-J
MRWRY. )3L6_X((-5 B5-#Z?KYI=FC;!(>L1'!R9CVM&HR#6O8C;LPW.K[YM1
M;/0Z!HFG+ZF''&0HU4/&UU5HA&N;."'A&X0U?;ON3?FO,K/5%-S!7NV$@IMR
M@\FVS9Z3WD\S?!SWF:DF1AC:,+4YGM%)@T)&#("3XZ:&).\&B,^B#:J5+,3R
M$C)EU?*K8Y%LLI9FDZE]8I?57SO15)^8MZF5TSV5<F<GZ6W9Z"90^DL5OT7>
M/DJ3V:1BEY2P>RIZ^>:AC],MT$--5U>8/>O#G>05GO-F$&#"2%# " L5Z0$\
M!USQ("@XGUCA,_8OC]TG)%/L6E8[;HBFCNG<].NPZICZ;9 ^]Q>\!CM"+"7N
MF17O=%2<;I,WUF13KATM*L[JP ^3>-,!N\79)C2G7,=A<\H$VB_;[:9V32:/
M\ZYY4>39J6/]IPK:"6Q>:3QH>.5.:#C/^!V9Z*0E5/T= :VD(\03>A'N7(4X
M[^;:8#)333%"O^IR*MDG&/0R=#O]U_I+QD%@1%T93(C&9J4]CMC\<>]ZLT[O
M%%!"E-)Q AIO!75Y/3,P#3_>$ST;N))KP:6Y>)'21Q<%Q?UE9#CWN=]5]'EY
MAXP7SGT)D,36V+PLOV+B8)* :EWGE\>$N<>"_>>K76>+#^LGDM5#Z%>0JT,0
MO4QH0X"94@.&I,B%&GM:UP_L[46RMZ\\GWS^8*34J QK6G>HXB,)B=W8SUQ%
M!$M@)*"Q!HNE%Y"=9/8*1FQ344LK8R00?_.$5[!+:"ZJM-(?(00(?CU'A7-K
MT,::NZR]M1_R,$7?2:6XH0_:G<-^,U'$Q]GF=6'V'L,78P_S,HE 0<)=FKY)
M?Z\8W&M!;/(\XA%&2/ZK+]F?-F(1X;Y894M9;L:RANG3LE5-8:\:Y\>,C)T7
ME3JRO'F^=PCCN/&/V $GEV6/>UIXJ(<$7&O?VX',<'-D=E[9GMX"YA-<CF3*
MG+S,K_4;B(*Q^'_L&%7&B$L5[T@RCM;A2U*&S2B"C5JZ?1D3OY[Y/#R"0J"Q
MHR"'<EA6.0$! :&L>H5S9S.)3Y#:URID&<GBD+ARA2'V7F*2[Y#*BN.S5PAQ
M$?_"+;_WIV^G.AT,P^A_0T\H^[;Y^.<$T(H;R _8HECC,BL.<T,>^UG39Y\X
MM81UW@*$ 7)YYWDR;>GKLUS'.^KLWB$U&P\*G@/R2RVA@6_N4_7:3V_>RY_6
M'2T3."/J+HGKF6&CVLJ<JLA#MFB!S\U7!O94P&T9^O63J4?K'.^>MRDYYD[I
MU#1Y05^'0%QGIBO!LH_;LAR=^9E42)5C-5XKH8/0OT!Q51\]1%O0SOXD/,1'
ME=L8J>K,ITKCX6'V[>91RVIO-@C%&B6N;E\"WOG298G?\@77*C8BLL52/R5D
M+3.D;TE/=DF5X*JKC2Q&M5W1/-'""KS"N*LU2@Y@29Z3HDWQLY=8,:+ULT(+
M[S.](;/05-X'Z/.FMXS@D%HZK>X;XI8QCRQ53I8LKQI1<F)N$=E0;-"D+L6[
M *H558J>/9@]=4_=,9^MJ_XNY%$$R_.G9?TT"N(G(NO!$NQEGW)IVGWR;-&:
M:$DF!,[PS,WBZB*%F:VQ6@QOR(+B6@8*D[M/O7%98.3YLH9?KF2YYVNNYXG"
MPK?&@R6:H;9,>CB#Z _4[F_<*ZH4F+HF@6VW234C*@05N07*XH3\R>HL+7QD
MT8(IZ<,CE'K]-4!Y99S15(J6XJ$B6-#T%5P/0E>^_S61MG/>.UB-7_,6VC8\
M?HFH'^O\22"O([WRY=HWU\0GIJM(O;:JONEC^_=?;1-HMT!V3(*\PD;L4I@T
MG;;W@T$+<*&"S9Q]N)ERCNRFW9!+-M'A?D'^>9KN)/?N;OE*<[3P*;+I-4>%
M.ZM,[$;FVD:KYW2TQ9?&F'[]F-[O3%9(!LB[TR'@T0_PEWC+2<[';Z*BT!:[
MBND+*_5B;'\0>*ZAR)-AK7%Q83U"%S#S#P(/'GSWEO_J7SPWLY&DZJ\*:"9=
M?A=*M&P.I^9TQF?$Y)^0_%26I5#G*]^T]%M%$R'XM?)<7F!::;3'87T)*]GK
MF>*%5AJ(QCV!%VYPS$6 6(%W7;Z-6V6Z2R[YFI2_:K]H$/ / ;;\[*ONF/W?
M^GM5Y? .AUI??WH\,V=HCEY[2>LA..)3V75DOU7P45]SI?=2+#SQ8URPM2O@
M*;R5WG?NO2RAU>GU#($,>W[CD)LXU2#^SII[*&1:@D!Q(UF:/DS[9LK.2E&N
M6UX)S4)UE1.D"?+CWEO]6IV-T%F@[7L5S&Q!!,E+_]5*T>%]&0A;KFT:VT7.
M*0>C^Y/> FV+SS!-Y+V !;2U;#\-4+&.LRC91VE+&8Y[';CXW7XKY=/9VY)D
M"&Y)KJU%UG#'FRYG[*A/.>OH^(D-5,.*O=CTT%%0KC;)?RI*$N5TV5=,=)2@
MA)NDP(2SISJ!8!8DS;;$2#PF<O^''>.F:8*,&2& 2@=VT/#0M!+\HSTMMX3L
MBS;K=3EHY.L/\U_KGZ5\ZWWF?8DH 'CU#<7 M+2T]!$Y1B/A'N2'O]N*',/!
M%3P_FR,Y4CO;1).'W=.WBN\12O((2UO(/*$)=:*)/.E1-R+;"*]3NF&6J6"2
M/=6Q6?LUP"#TM/C[:_2K<C#O1IUW+9JNTN=P657V7EQ,S#XJ5NCE5.E*@.<R
M3+9; QQ#%NK\.%\7XL5>:NP5I0!:E^VKJ%\4BD"PF<@R/<+D]JM"AP'ZQ>;I
M')$O$OJ2<C?[9D$H,A6#Z@S-4>?C*_\P9\%N0FIEJ>#$8'N2#E&Z]; \=<PU
M#4.!B4^ZB(4&!0!9%NPBFL+ILSV)-JU-'R#I&JP<H?&,%.\9VDYT=J.8%.ZV
M[BU 5"'83TWB,'ATOXM!2+JO]"'35:GVEXU6P#O%>#V"12Y)6SYA3WH0S7Q3
MPJ[')?#I85M1A3VUXU#9<_.H@.KQ*GP[[S+?_NT9S=;F49#OJQI.&^,9]N)^
MYB4T35U0M,! EGF77K-C?G2R<IZ->WC  Z\<\U@&&."@P.S66_WB^V87^W<W
M[%-!"?=LD@DG@2!"N*U7%?QADE) )$03& 3+%XW)]'C\>51/3W %IKDC?SBU
MF&M^&E0+KU4X+9RE5T'K7_)>9<8[JT@M,S+L<D>?F^],EF5$CO7EIKS/!<$
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MU2:PI6OS7S['\/^QH-_._C=02P,$%     @ ;X,.6=M9=-(=6   U&0  !
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M0+YOPHIP? ;?U3DUH/,P)G]-\G@7+."=PB-Y7C1M1[@S)X>=TAOCA_)*R<R
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MP:"M8<BZ<E/F8CGA3[3F E&S@%)G.#98D@G2[%O2N&^%3\BL>)Z_U :W(#/
MLQ#;D3&4039M)KY;.@GC@P-V1$L6JUZPQ^](1Y_IY6)X,)FGJQD3D+YXK%\>
M7H9#VJN]/]3RY&3M6^& S"((<@&1^_=K,;^J+"F@M4T+M ?ZUM^'_*ZH_$_Z
M*=@PN:#E]&G(CX>@7[^2R;/0PXY05OE(5O.+M*$?Y<(K<8#,\B'-?CYX^Y76
MK[I!2@BR5;$P?S5B:H3EY>;MAEQ1@G4_HEDWI@G=/KQUUC337:5&0_ 9,Q[#
MD;7&3"TC_4E/ 9ELZ/=MR:_?*?)YPQ#LW='N^ #% 7AXL]E$G_P5H/3Q "61
MB^SJ2;O2<_QHWE7#GK]7A$+P&CD!U=+*W()4X8[/,U%>:^;N3)<[G4DCO?UW
MR?M?3C.IW: YV3)L*IPS=QEWJ @KJ&T:S;C'L%P+'<O4B'WT175SILVS@)Z<
M@+EXH/46>$?NN'-C7_%&K/%7LN: =#ZV_35"/H_7&X;W"N?D6=S+ZM!:%9"M
MHM)1KY+&$;Q4V=G#N(NE:P"^#0@<@%4K",:K,-9?\J*@7!V.%EBX(B/>OJJ$
M'^@C<Z5MEF5BS$L8,C3>AMI#/;YXJ,?R*//@2!![#TO]7W3_AQ^BT.C;U]8E
M,9[&03P^G_! [_9Q]_13]+-Z05"9%F4:-]2I'+6CED]XQH<).4/ IW$2*3PG
M311/[STIQO.$-(C=WND5.XNC/1[L.][V _.U<U56U,=UT%\Z1"R\/H"./?'N
M*+(B5(+)L9BZ_V@D-5K4IF4F_377($/A@;)=O>&JNPA>P^$EV3PVX4%J75$F
M*F7H5X0\F K2/A\:/X0C<@_)?NZA8S/)\#0T&0<,1WJ NDP%ORZ<<LS3XC.4
M$)YX,.ZVA;5R%""Y-X>R"Q 5]\O_,10*[7$ \J (,C6$'7O8RLO3H/[T7Z0Q
MJ,8#'6^"E\8]OZ5Q_-86!>P>5JWL;ZFV#WHLQ8/P>W$ZVX%:8!_7M:O(EH'C
M#Y^(LSR9*S^90:8@^%SYI+&!XF*ZO0'H:.:7OXX[G50,5;.>A+[!AHS#00%4
MON-.A1+>(TWSS0>%F>Y,Q5?F#YU.LBCD)M.P/$EM>.+JXM!46H?6W /A_61Q
M=IAXUH("M)R, F._XH7Z^H7&U!4L,YY0W,43BK=9^-6XY/Z/_Y/GKP:1#ZTH
M<@5XT.C\./I2 1I%NWAYP,,'7\-K0D?)!*%B90G]HB.50% ,Y7Y45J;#GK41
M(YVA(5>0JOZS&(KG*F]6M]W,C)WQU,41'&_8/ (3BU.R9;H4:Y20DE[9=YY+
M-FRU[RI/L^-C)$()]F).-?U_BKG.J*:RKAT&$ 2E]^I@I!KI-4  I>ED:%)#
M$5 Z!$%*$ R"((0F50W206I I(0F1;I2!0*&W@6D]Q:^H#/SMGG7>O]]/^[*
M6LG=^]RS]W.>^YR3?8ZF;Y_.=1]VK$DB/5ZWA8;B57CPB28SKIT/RM')*9(%
M^/3)@U*IJ5CYN DCT86S^401/<,.<HV4PYID@>LJ]4X7[6PT SYXX]:?2R7U
MG8#M<^H^2S;F>O*MFB>!0K@3[ %^)"J<#%JQ_$N<I(=#]^+,/<6^LCH<I^TW
M?,0PZZM>85!X;)!'HD CQU3^<^++*_WDBR;'6L@9P'(+^4VMCM7K<<.J,'+F
M<3IRN"[MB*Z$K#N@S>@,\'7ZU$L9QGZ"0%I<E-6KR>IF+_%>9.=?EKV+R)(R
MI_'4AQ^\_D'9IH5FL<2AF' &(*J_;*BO%V_]CTDC1+7^,C$AK!L-IX@8HL)#
MCAB3;, )6EABTRM=YSQ.^%A_H^0<F^FY&WS1_P+-77W\6#-H,++Q\,MA,'?H
M$.\Q"%84\>^20=%J+^H,$.=\7M<A^'.IWRO ZE@3V2G_GB@V$G[\+:Y0WW"-
M0-MU^!WY@T/[K=00S<0/%>[AH!ZIPK2CU3/ >]32OK'0U&S4C45"+?)[9@UT
MZ)!@?8(X(H+3&A+\$YQZ-7]"<] MG8;"!'Z0,H$<OFEZ6(AN1K8L;Q-J.'I!
MW8" H8T5@C8R%/F=FX+(6/E$R=A[$C=Y"3FB0$M40P;_M +QWRY#F=?SUT";
M3YNU$*1+RPXD6]WSL1PEKX6^91VFJ4*/!>,7J@Y'^QB8GR0"=;.%U>;B/XO/
ME>[G?R-=$,7_+C<][*]\U:+AV\_L2J];E3>7[!$"23J/%=..F'UIEH\C,6>
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MIVH4N2UT,-#7CH++N$^9+8KYTO$T8@3"\G"!.SN$'UPH^K=X":'.GK8NY_'
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MX?2"S*^'P,[.I9]3J=TTL]]=L>%M:%VHB$QCTESOUH!--EWF)"FBH &C^:X
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M24"<$2<.EWTDV8:9\X!)[C@\T#^9+>)1+.*F&J8)8Y/,]4^YL=RBTD6XRI2
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MG+AWU2T?D0#?YNS=5ZPC+_CAAW%>A(_%OJHCE>V99V!P^UV.TL;2V)FJ)-V
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M19_N$')*Q^X?;;5XG]YVUFEHX2PXC234EA=(]8'E@XV+9U+OA Y,@/X819:
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MZ+IQ-'^*1'6CJ,GDQ,'#6O@#&K6.N?&QMR^8[[Q,$8!ERXR#8#?(79"W(0(
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MGSD4J699:<25G94X/00=A+*?(5Z!U4'.;VJ1"&[C-KD%O15=LGTV(\<X*9@
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MMY<4,T3G.)2V%Y+=GBA4G*C')X H9I,$)6QM"^>LZ4D3D&>;<\P8AL.A3?P
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M,:-9X"8ES=&;9547?VI@!2_!DZ$/4OS1GG&$8)IRORI!Z419" =P8T?9H\%
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M0SV"04-#4U]4[E1 93 %RH[.5!RTY.WI@+-,;H"*QIS+,K4P)[$_F_VW\&8
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MFQ(49^U\R@/C'PJRWSJ$^(0#*ZZD:G09J\^O"M85[DN\#FB</';N/N**>1=
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MV3QL$D 6N'B4[QA-J4F@1IUT_!3*@?RRLUK%Y&NKC?+IPP#1M"^3E\5.+C#
M;O:#NJ9L+9%PU>1"YA=M Z-B3/-G^<3E\H6"S.8&_J%^% \"$P-*?3% QS4+
M.N*+OF_6@BH&N+LI\:QAS\/)]B+P'8DND$Z''=A=?UM*]RPA6!#]50GF4GDL
M_71Z9LMLYJN;Y:D"E^D2MX0R]S<+UT6^="+)GZ );;U1&!.9E'7)I7VB\N0)
M@=*EN$<Y>Z8#KWD"0I0GDT1I^]K)8__$Y$-Y%<ZE,>HL6@I<)'WI_;7((:MB
M*O?TT;=><+I IXK($:O8[!&>AO@*O09H/"*T5XEF*6""+47,4D!E.[K-( &H
MRL8 =IR!DFZ,=:7R%3P0CO'CS3FX\;8+^!1?5##H$YR_5IF?E7I4#'MZ^]*X
MI@;%$7:)E4<V/:LJE#QO-.T;^R-A5O^JGUU\,&BJ<^1VKW(^<:"NGMQFY_NX
M,*(G-ZOCP13M17W-M/D3K:@=@MOY>L7N>'9S?&?O-.8@_(.-!58#T]%HB;1C
M"TJQ]VZ _,0U2U=S;TYS;FSYUJFAD]9]4 I-8-[CW1$CEE7Q/;0&Z.?^%NU^
M<EC5%[$;WFDHR=X%5M3=C#BP<^"3UY^WFOFB]X0^>)IQ$F1'&+"Z2"DWB@[G
M M0=P@OP2P5441[I,MJ2;0H#S"8[CK(=Q;K5U;ZFRJH$R?6Y][5<=/P$-=8B
MBV+)?L2R>FIUD*&U3PY'>ZJ(MH-YKO)/>(F5D;N&:T?HIX).$V9!F9Y;:D.E
M3: OW)OBPHX:* R0&"CX=='^T+=LP3Z0UZMPBT,EP-->N%V<E4RMJ=WW-D\W
M>,E)_$".Z>4KY3L$_!T,RE4Y0HOO&(5<Z.%^N=QUK0W9O0V,#.![AMV5]04&
MZ2;0C<$ECPD&#P,)EQX^,G1&EPS]Q('7;,#7>"-YV.HOEABQJ:?(#'UW<ALI
MSKVXGZ!)AZ'[D5HTZLP)3PKF69\>/E9@4*7',GNX;48JG$A\R8X<1.MUISZX
M_KC,66>0'[-P^WX@A=SXT$.VN$@S7KS=G(TZ/91-3:7A3*!S:PL*:"=1*%(G
M^NA#Z$)Z6PMOKC0DP@>\$N8G[@"<(V)^P[IE2:5>6Z*P#0),O.$+,&74W<A8
MXJCX5AO531OMQ4='1QL;;. E')GC44+T45^-[\;3](MNC?DMP[P88=Z[M2?5
M\;<4[DBR_@Y?YQ'!VHH!SIE^) :PG\P5\@CV,QY_97.*V=X>7/0,[SS7&\J5
MFJRK(K[T12W&E7_.!7,KC^U6G!AQ#DCNE23H")1>'SN7+JK]@CI049XQWOE9
M"#MYM[LT(4/7\\5NU:16=NO:#7<"QR4)"*='!FUB[]^2P\D%]AT:6VO-O>>?
MN@JX,2.:J@@==,_/WE8(76EMTWW4V)I:T:Y=($R62@H;W!8W7CVIRJBK(D"'
M**'!J.:S%^,K#4T37NV[%XJ*YJ]#?X,&7^62IX1( !>L>Y37ZA\W%-<P0(AK
MWX;JAOR:'\3!Z?IZ.7$$HH!2#*]3)T(3&T"FA#Y(\2_O61J/4R[*)UR.TM\I
MI[0G6,5=S-7V]]"YM&;/*)R^5!\+) MJZ3RMMA=,"UL=<+'WAA&T608F-<D1
M *[\\%"9_CT%7Z:^H3T^8S3#%P>X67PNOE,&-V-V8)CD@'MC_(PR;\,!&,=[
MV$=BJAIA!Z&8=I#!;FB8XH-3X_G<YF<$DG\ZWU)D>/]MX$".,4J-!T] ;O06
MQ!Z=M/,E>,1_Z@M'8JN<\]Z#=.655LV2(>%>LBN&0GBQIJ]YC-^(NR,Q(K*@
MQ"$K)V16XJBG1!^-9Z*JZ%OUPNYL>QMB06'.^"04V&@GQSHIIAA!RVQHM")E
MWOB5[5\$3MU3=FNI^F")6W.0M5D*?(KA_$]1>>-QFPR#RHIVK'I#S/6:#GN3
MTGM5KJIYPND!['I_W6(_V>A @Z^;\(P$KVRF1WY"FB73AH9S@O@^+_I'=JER
M\L2?ATR?_P3YN2WOX1T:;;3^W'U$IQEOT6K/FQP_R#=O("#C*HF=HZ,ZBH.6
MN="\_@E!5B9[^:R5FWI.:;;LFC4WL>9W]!6["Z"/>F@#)?8JYG,_!GRQ-WRK
MVY*?L'P_19SE" L>RQW)($UL*J$C2^-HROX+0K#@FP#3RH V>$<4)?-H0E4H
MY6[M9PE[@2#D9-,_0?DA71S+J0@2!&O^5OLL]K499##7YX5ML&".6YZ*OA3'
M<K9)L/H](]\0M2C]#,F#E%^4-J/&C30;[5(PCI42&-@K$7?1$!VV/CZB9@&?
M"N#4>3H'NOMQ[RQZ*; 0&R8\Y-N'8'L5J#CF.2_9D]YL'9E6^<0RR/D1Q8.V
MM,Z%\MO][[" \YJ0FGY0F<,"*;*^S<?%K\+70^W7(W#[Y)"/0TIKX$981_*H
ML*/>SV.S>_8;:C"A;+67/Y(6%.8(N*P\Q<R?*UA>*C4W5Z,U$5^':'()/G@.
MO;N?+@(?[!)X FH0'I*-;U4NA!07[N@9"OF,S1C,SYCP"%*/YK$JK F]SEQU
M[??>XVYGC5@/E7RSS$=0&2HE(27Z.<02NV67R2JQ?\3CXX?9G MM*E,"9'!!
MR%5!T++)_>V]9$O!86NZ)IW>7P/&2^:6$[=:+ZXI.>*,Y$6K[7]^,MC6TY6(
MN+"?4/K&HT(KZN@5PH_M#&48;J#I'-:_\60*?@AE\+$TN[36X'!YBINM(P]B
M]67, 9L'WIV8LJ7X01\L>*CDT"(>6EWK5]$O82;"+;V,0ZZO<Z.V=/V=P?OZ
M<3DW4U(D?KJ4K1D/9MF1D6J>W*^3-M.,,^R>*..:F<6;8XGCI+=M&A"C@);$
MGJ@Q>8VL!/'H0=C2!:5&:PF\;>(?X^/Z8N>&?^9:&^VN(K<7H2(HF[&'4:5.
M;\&\0RPBM:KKYJY?]FEU#]1>SM#Y>';LR#&6-3OG--<X,IDWT,8^Y87O/H/8
M1S-T$JQ(>HP(QOU2S;N+#CXR:8!5UDK+K&C74T>>JEK9%S+4-]$PJ >?#&]!
M'DU57!(@I$.Z::6J!S[=7I4_M:VCJNZ[ER31NY8IF%+"=OCY6ZM:F>\A'U;Q
MWM[^^P8]JBSC](K7ZSW?!KRH?8MP/WPW7W%E=>58(\<:]S5;SHN\Y"O;IFT5
M<9W?SL@X6B38B;XW3)SE/E:XPA+2/36<]S:0NV014O!ZN8UK"C4S7\E2$\]F
M@0$"][%E14,,$1F]N??U^81B8]NX>!UF]8/$V1(&[2,F+4@>63;HS>GC 6M=
MH;='GVCZ^B!$VJJV::U2GGRVGV*:EH6?'<AF-NDKH=)>Y7"M"2CCO-F18_#,
MQ49*(:$XN41C5I'SC&*%CO@QO97N@WAS@#J;SNR-.W<^-%AK1>YG>K A*VJ'
M'Q0Y6[U3XJ:S<L\/E9,BO'/D>\WA&TGMPK/:\+VY)9U7>O>1[I2C'8')RY]Q
M41:CM&ESU. YL8X*L)$&ZB3O72N+I4AU4;>SL/ARL\CI=_*F"/-'35J_GR^A
MTC?L1\3RB>!F=WV]7>[)5\W9&09FM;(Z^50Y15HQCL8EE+3[.P4S_'SM:RA-
MU"72T!A0FLF;1+WN*M_?ZKI*EDZ? \NV#R&7T@PJ6$"'7Q![?X!;KUT2.:V]
MX\WB^3"V9M/=TB%5:DR2X#^! 99Y4._U7@T398)+'=4*C,S**3_IQC_+H#:O
MSO@]R,(17QS=1XZU5?5I2\!X85ZM&"[4@,)W+K+3KNLVOT<R(F,-Y!(ILI<9
MHV6[&KSA016P2*&OT4(_@F(>\JQ8U_6I\Y!$;$I8%KN*0'A1(M4(/EP"AI 7
M(C!1G_KSMV[3/R+5'XJ"K7SNDKWY]7*7T5V1 A01^!HQ[#[T<N)2EC$#+$1K
M=IH&=6"W?YM=^2#>4G<Q#<'^8&37BE #]&D+0C5^W$ZZ(\-<%]]>6Q=.!2]F
M=F<U*2T$7/'\5X]@Q>H<48'2PFTGY?"[;Y,<2'_#DH6_4S2E)N8^B9-T%1>7
MNK/:OLR%PC$CZ0TOD[?_O%4SNCKC-W68&@AY>34V=^M5\!YTT!KDD)HZ7A\(
M1A <$&TFJ15#<3+.&NI/*??<4LE=>-Y@-^*0XBEWL$H+<&*[:(]Y?G3OWFJ>
M2K/]8D!*/3O?\;U7:=/[&VO,IUP29+D$?19.,,TX3#%I/P"W)DZN3WP@D4ZY
MG^'KC]>HDIA:$S/]\4KVA#.=-A29@2*/;LJ< HZR-7E1$1;4XVH>C?MA=26S
MLC5HY7/M;\\@6966NI_.PK&E+LOO:X0$WL/+J"GT-)->JFRT ?[$E]P8X!8&
ML*Q,PP#XIE%7.=\S>TI. TTUDN*H9AKHJGO=LJ8G/.=EE2<0$\<MU#P\R]0)
M"W!^>CO!'%P R]04 Y!(Z=A\AR\8;KF;FL[:PRC9'R1;OJE</ZP?2G_0Q>AS
MMZ797-,/1=!M")X[9R]@3W,)LO^235.G7J-R>J%6!;\7K7.V+_60+IHA"!?P
MEZE>G@=UZWYQ0=PEA>J^8?JA5 4>M];M%<"^)9AP\M+E)E0BNKIZ5[J:GZ5G
M>?Q.=Q7.L>;-%G] 16WJAVBL(.A=X$K1230"RPP2R!+WE&^3+CX?ZT]1LKY:
M'.JZOTN?9,3P;OT+1W<BQ7.^\N&ZB)YSXRVWV=$'1:??FDV&UO*2/U03A,F[
MY0K@ @%J%(B,!3;4QX-8(3 %GY/YKW+AK>/?GQ/$<2NZ;?I&%.T:]ME 3.S7
MA>)EJ$N-7ZS?99A;)LP#IFN55^T060H1):HKSC):2OA*\[GZ1()RC!L*?KEU
M%8'/?A[KI#@&R6ID[#G4F&R=OE([=?2@>0"?_;'0+39[V"[?0F\1+]M-I9?+
MAP0?^[\7U;UF'M^G?&WW _PCV<DK&=L\L74E.3?T.)_XQ7\FNZD4V>FLISH_
MK?8*_.I1XC V&_1Y[ U-%MZ@$C7)K!WKU9L#DS1RK%3'HJTIB?CK D<GUJ9)
M!JNFH.[?<644ZAS8 %:/)HHCXMB,REY1&5:QWO2=M^E3PKH^]H5H^J!^ *.$
MGK("X 8O@6( PAW*9NO*8I<@*4.#NXX8@(P[C?_;9G=Y: W1CQG6J=JJ5N&"
M;74[&-Q)E-A6PKAK7\8Z66:';#(W8+UA,Y](9:+SW' S:RHJ:-V!TO!73_>9
MVX^]2#*F3)"X3A\U"%:LF[B\^+:PMKG.1,2D04"!507F(51J(1YK%7&6+W_V
M- DDMF-21X[5(PIMOWT5#>\K&:4^*FJTO]^6*VZRBF7%LPP56<)[(B8LZ0OJ
M4@MR],ZRCZA(H9X2LTT1^_@: V@S"IM7U= [@RA@FG+TJ6A0EX>Q\9Q:$5Y
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MKR?/3[ TECVF,M/^E+LB(1650-N297UIIFDG^:T*!8Q/1%GE_B8YY^+U^0^
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M$4A**I_S28HF6H)MBD^X-NWX@E-OK4.CN;Y166U<R(H=]^G*<U6A?K'KJ0<
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M=H;:F+COI4?#F*RDV\]T;IF3.L@:\:O634N4+8'\R077L'DEW#<HR5WZF@V
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MS<S.& #3M0>+[0AGYA9V>?WJEM:]4XC8V3!1T9[)N4PPU&7TTE'K#^[;'L?
M=&69QOE&&QF9[,G>1LO1 Y_A+YS*\1ID9G=F6BT!8U2-;07THALS*WYRVA\:
M<K1'Z%)O+L)\PH0=59N===.W.[.)Y8OV&H/W<"H,H]@';;ZQIQVAC3-B@(XT
M2' Z<@#KT32JF#:MA$V\FR-,B4;O7OR8/_11%(258M/;H<">EN<G BCI("[:
M)V[@**2WD@+\>E[O>R])'U*U16F QCN(F#[&JR=CA=-%G^$2Z*FVUN/E"P._
M%PT?+JQY%\4XD-$5.6 N2Q,H)>91<7G6'N-LN0KTY,JI4\90>5WN=*B(.;O$
MP38R\.;JN*T;0/?LI!I9NL:F_5&@Q2K)MM2B'_:WJYI)1:!,GRV8]\HM^4I&
MW%-#&;ZY1,/P<R G-P[EAUKJTSL5S("/,Q6G_VZ3'2&<$7K[DQ+$8>P/Z-LE
M&_ 1DZ!S-\L?0 *)O0M+]XL,VCA*AGQ$96QJ-]WSEE^A\ $VL)$&M1O61KTH
MO=765]\^;-J[,GH#)-"Y&)FJUEC36!7:J=-8!VOR BD9=B&2'P#JSQFI@]@V
M:)L2X)6[2SCPO).L[+*]]-A,YKIOTYQV(([;M**S>@8S_(G @*^X\=@Y!._^
M$4C+P7KK&I!?MK4Q_/S4.6U8=,Y8C T+TF"]?CCG!0Z8['3^?9.^Z*RI1>CJ
MZ*^(\#;[)[RQM2C= 1V_;[B_7#@2V:7C)BB9N_%G-A<T[?,:*U)L#YH >F2"
M?.S-QQNC8KQ6$4&>H<M*C<W64*60&@C*IEG;LSPF_-ML*647$6C'G:0JXC*[
M8/<:7E#0DE$T9&I_><K5N<4%]U KXO!)"![$/=.K$R&/X,O&>P"8S>V30:,P
MLDDAM=#X*G,V--$^C>@2BC8*1EIE -#36,^8"*G^83IE"BQ[CB.9^)NB-WN5
MR<E9?VK DUYF2DQPI5E29JH"[%!4'?VV>DYNK.SYCH+91S^OBHI_UX?_;MMQ
MT1&R73(ZIOON1F+&5UM*,:T-,4W0;XST:@DPU\/CQ_W--N&:C::T5M9W9/Y+
M0<LO5'+I61<ZM9\B8V4E?]S:".H<,DH=VAC+@],@:9<]9!I?W Z0/DU4,JG:
MX%I=CJ3B#KU5*D+B:$_H32LG7F[)VMA7,@&CK)\(P:6V42-T+1S",#XB<_!4
MD#I4AAD=+4PU,,3A[^D(<QKM 1ZF6-BWO))7@U_Z,8/;P<A;V9PA+R];NAJK
ML]F7/M^[!K]K^*TM(!Y7\<667D"0K[)#E#-&*M#2%E2FMZR[ RKF.YG_R<@$
M8[*\$G3$?8:+UURC*_( ^.IKD4+5 BZ7H9V-[+A>OB/]<U5HFY!G$<*(3H(^
M:%&U+C:*65(4*\;(7#N-O49-&DKY#H]7@52L0Q"$Z\E*\\.:=G>)\<0R+NR0
MPSI]R6<$REN.8X=*SHXSV"L^A2_>5\E<A5AJKARZ*\ K3_4@\^"]JWC7_$RZ
MF'(E1K#C7HOD>3@[U]+&MICVSZ%5T7;,+Z"#<2Q3Q%U'OPBE;ET.U/,REY$S
MJ+-"* <G:CT&_>B\&&Z^::?GLQ>T^JNJW2'7WPM;DDLI4/Q,_]J]I&@/_O9,
MJ3GT="&QQ8*+PL*-QI5QO*E2&4$061M#WY4P;Z K/DRL,H9B?^6.S9-D3J9&
MVO<Y9S60K2@K>=H3M?.Z+M@:'&"'INB&]UZI2S-[V%)+DYX7I*K_RAM7%=/E
MW^O31%[J.:@R[K9>N+#;F/2N1MJ1_U0_NZ:3Z3<9/X>*,$?.(1IN]-0B0;<S
M\#IDJ+DPKK@7A)LHQVT5HT5)26T[YV%Q2N P-80LZ[SGF+[85\B;.) 8 GJA
M+X86<AD)<PA4IZ'*!%4GDGSIHQ>LLRL*NZ4NF[F5@DRU5O&!R:CE&@4%O7U_
MZVL29<>+$";/.?6Z"/X6:N-#V9O\IP;P%?NJ.R)*=L3S"PNTNR1.>EV6B=KN
M3TMSO!.%A5!+P'M;OJKW+"KX"P$=]$"@1'47A[']MUZJ)_[6PQ.)F,_-T=;Y
M4&);B?AFS:#Z?N1:6??Z)>5+W<^-12@9#(<IR'I>2Z,1_XB<AS?)@G)WX-?)
MF^ )11<.)QE;(H=T1>.C'@SGK(9M5+3MR!7Z=KTRI'\/=2O*+E57_(C367N)
MG9RN5:(J=L.9[R]81!\[]$M,OCFIMR,N,N/^&:=DIX>6^W53HP&9(^W$4C_:
MQ,=LW[POWV>EJ'6VQ8(>DTG$?;/U&@XV-V=>UI(."] G"OCU)1-1I:8I,CBA
M'8UJI^PK@B"4NTFT<(^@F"WR6*,E\5(AI-/ 2_AI::'<YC")Q4F_T!JL\5^?
MBT<FK68'624J%HS3YB=$\=Q8K#.=!L3"]-A0HQ\ (?HKQM=/6N\Q5!X W6./
M; +:UGJ.'G"+F_T B*H8C@2L2ZYJ(<GO RL? %^2'MF$:T '&,%]AV+\ $!E
M?61!^S6/,64$J=F"_@#(87\ K%@\ &X-Z1%EOC@/ "GM!T!;_P, V7BPDX//
M>T_J^"5@Y^GCF/*1P)#+W[Y:?O( &"5] "#>!-QSP43^CTK_HE*<(>6_:!#W
MUX?<754Q*?^B0MY?IF&828+2\Q<5=OXRC6EK68!S]E\U^,L\W&;'I&BL_V*4
M_Z/2_Z(JA2 -5]Q,.N5]@Q/NT_[EY_YS_\/N_^%'^ZNA#-CW'7)UG1YGP1.F
MC3A*6X7IJU3/VZI'>7$QI>&D+?Y20A=#&6]>JC<F\^5$&$=#%""&0.6,&VF&
M&^'&6E@*7)=AV!=J,ZO$734$<()+B)U8)A>%-E&O+JHKG"R'.X =*C;@5M_F
M]9J>*=9D9D0I)I*L1P<I:P>O6X>+2651Q'5(D%<GGAE,<!UGB;\]R5.RY5PV
MK]A4K[=^_DQXO<"#*K7#&&5/A"NIH"[2'EQK,\=.]JL^<4[AT_UU6$SPL\5V
M5M8L2)XE8KO]VN\HV</\9T%YNFQTNMOW2'G-2&R>9O=MM!]NPA+G*-MZ 3V.
MQ)X_ESO=6_ 0X.BYGJ(\"8@;Z=UN))NYHE@>U6OU%&M,M!64Z"EQF36!UCSD
M<O?<P5@#=**)$J.\472A/+Y7XG(!M5#CO&<5#O,9"9;$/W85YU9(DL^B]GM%
MR0E.QYG]^>WM@>Z:+6GP&Z*/TDR:-W$A]YA91SC9!UCK M?F-H,T'W>I]9[)
M?^O#AZ.R4J(%]^7@^]^L%8(=R_J+=)#6-V\#D++$79_:<>L3=2GKKAACL^X\
M*[C6U\ERU[C#H-/36KO6?J;EMG7'=!D>G$VE+&G2ND3O=(DQGV^ ?)V<C>(*
M;BF1/GE1$,A8D8N'F>MLNL_NIC6T[\6;885V5#23:&=U:41J.X^.\6Q_T:)A
M1O]A!1<75V5ABI?>0C#@#:_#W%>GOV7WO8:^%G#P1=F=TCTA3 L1FKGV8K4L
M*LG5?\9ZH=A2Y_)PAC*,<D'VW3*5F"(=E&/<4ZO/TWNYFQX1,_29F_H0M[NN
M/(INP<2C_]I[VI&U(^#)@F<3LM"0-N8$IG\9;:# N;3I_6'T:,:"?HE1>*M"
ML%,%HXE8ORYEZR7D2T7]S;L?2ZC9O,?>#P "%3M <Z%$<[D>T-V?84(N,6A/
MWT>1XUBP"8ZDMNS;$A 6<Z.HI)\OM;D'G%Q"K-=H[;8> !_@S!/VW<,Y1V5$
M0_AC(X!3N:-ZEN8B:<12W.HNO\#XBT3&DB7QN^&K+.4)"4'"^LR\+Z?1*+N:
M^0CK,*MQ?L-72F0"WN!Y8\.B] = T_?J*OMMQF]&F(^$E;;4]P.<C[!<9V].
M/,^N+E5+"[YLD:CX(@#B,*._N7AZX+OBTL.3/H\XCN0'^W3,377:[EJ7[ XQ
M?1*KZHLW(*2PB,=$Z3@+(G@>W _V4VE/QZ_D*A _S*B=BP\>3F9Q=1I--+-X
M?AM=$(%;SV_^#K&5D3,S K2^C)#]':H?4;'MM9D6CLIQI"@&$'_-ACIRR[Y>
M264\X\DP?#FHU-@ZS6'5VMA )&9+\JE6*CZ'IHJ(3HB2E#[,G\,8J"[MQ1)*
M_KX96E\?)+TE!^JRT_7=I7WGZ212TI%M!%G8N<= '(6)?YOS*]^Y)!S"JTQS
M80K"VK2TEL7MQ?EF@#^S3OJ>/M2?.%0W;*:""9(HG*O_TF'3QT;-X"I(* JD
M/"N.22G4#7#2"^MV)%%>#7@&#FG)P"\#Y156 ETHDG,UW]A;B+8MR5L9?[O1
M&@:OCU#8)B[/S>]<@WY?:T70U?@P&HBP;_OOK%.P,K&B(=CS($C'57W/([B2
M?ME64Y6(_8B/%\<!_&HD-<4\D.##YU?G1IB(6R?#CE$#E<LA,5N7?O')1+&4
M=7>21V]M.V94-@.<R9=)^6.()E2S#<9 IZ[U_$I8A];6',RI SH;S/X(L_QD
MBA[/DH!52\]0<8D5P;"U#-6H3S55D3);\_,+.$%R\M]A7][B>XI739/.+GFR
M=HH$-2[:!MDLJQB^#DVHNG0##31[!Z'@32^5S-U*(C;KV9D\H..02<$89R\O
MCM/:^ = Z6 -<<@V:A%+H-"A4B^=4.)6[\>:NG&0&W4 46^^,='PB3)UYU;)
MQS=-="Y]C+&04<_]7O(E\L:Z*FAHMP-K37T3\7+?(#%%T/WFV^A4LP4?5'B=
MHR_>ZI""4>WE9Z;4U*H](F6\KH0^*&&Q9@*EPBLIBG7:.R!!+QWZI)CL&BVO
M-N2&N:\:DCAKTEB?OI#'^_),2Z&ZZS8').;1QX<2OTS,?R@PKU[?,F:2,B\[
M#N(^IFF(M&6NEWOYM#>('!? E(5AUU-R0FR$^*W7G!U>FX$Q><B1,_F"S$4X
M5&'CQ]N!^5 9=KIF:O&RG+%; B P=T$7^27#H&G2WK1ZBJL"6])>9^J;!7$O
MKM>>=U*ZCC\-4M>U64FE =(X2:P> JJP;&EZA![F_G?XOW4U%9D <@3B-JB"
MW9+/^/$P_G21N>N):5?O?MH=>MK4+;;56'_J]!&?9YI?7O5D.I+O8MKU)@9_
MSL]<*7$L2I<OL?/2:]#_/(?.=+;JSZM3)ZRR].F.3*JSSKG"C*)^)ZAW>8JQ
M/:P9EN+%$KOD%O_D=U=P8!MA;-XX1'MU.4RKYVB9_%39S9EV,G7<^,.TG$(/
MHRD/J--F!7<=[3H=4  ZP29?=<A;!]:#*EK:DLB4**.8NK$!>&TD3.NO.MFS
MO+4Y2SS7N_V)3^3 Q9ZE\(6"U##SAMB!#FN;_.0C=]PC2ESLIRK"-''OSWWH
M,7<$6JB;1M$S5$S]+8&0AH0"GY2DXYH:(IUL [AA9:<D]G_I[+K"X6#8Y8KV
M18^HT:-&C=X6$<'JPJ?7Z"6L;E=-U+!*$+TET<L2@B76(GKO-C985B=Z[R?_
MN3A7Y]R<B[F?JWEFWF?F>3&WWS2<_<LE%[*FUH.O!SP9/Y.W& KW 5BC?/CP
ML_\:E!0<Z,\&(IQ267(;.S?7);(/WUVG)\Q,%@U\$*T+88\0W3+@[;:AMQ@*
MP&1$EL(\1,QB02B(L&5#J7&"8,HS:\"Q"4>RC$Q-QM3R/2#60WV?LPV5MJMO
M=7F.F!Q[!M$0#1GNWK7,$]'5=5?3([H(P@E<K-=Q^Y-NGC*]7V_& AU)I*U%
MUVKQD_CP/_VE$U<=6B)I7VS.1J[8@'GZ+1TU@]1\<]RTXHE]_@A1(SOFUF\3
M;[XV,WUN?";%9MM4/PUV0B0@,ZENL_Z8K@/YZ8&'A3_4VP+:#]Y!P-<A.Z1@
M+^[KURBZ>X#KQ]^DJ4KH2]FY==_\7SMCYBLA\@=E!E-[DVA]5+1?D]:'_1[X
M\'6C4;JI'2AY@(YT[_)A)P,##6#7'N<<UQ#*0SJ4* *R*/S3-,O=J!7GY$LG
MQHEGPN]%X? & 21;FH'MQSW91GP0D0BE&PR55JYOG'9VA\68.269:E=_ + _
M?]W)2US6YH<I[&HGV1Z[RW;W?R(9O_5=G7"UCKOG1P2=[(-OBT3KO=#56<X0
MOHE]H$XUULU'CR<_F"4?&>!EI44MH:]F,I0E@/<T;90B=!.?:*>O@&<2J;QB
MY3.ZR'2+KQLJYQ2_'J!!+6N;4-_]F8IRI'GU"'(.3S]L*OZQ=A;[]5?U%7RO
M32&!/-1GA$"#ML&G]4",B F/OF4T"&T!7<)28%7A*KYV9I+M KN5W([44#=:
MT<BC);ZMI'3KZPX4"RII16JJ4P+=9W"MTS:<HIU)2. X,;WF$X^''_&?B0I.
MCPU2U'5EG"MY'KLKQ)/BJ3CG=80\^R;A0& P$:$/>LB1!VAF/[:PYCQTP-A$
M^2VXS;P-V55> MU<YW47V ZPEVHWLSSPP6IFV,2&,88*3_9*MG_7<EE+T/((
MES 8Y+:=?,@L9>,+T,5!JX)B(T\4M-2F_ (0&;._M1R"Z;YG+Z5.5WXB9 %Q
MKG$%1[C@)TZ%\4 B3:UX^O0FJN\!C2+^ @M2:LVIH&45S^B;#I+]3H9+$#&V
MS70JC.,"ULWVZ\HSY>L<3YTW^?QYH6M^U",AY)T* ;LC3$E/&2TYM16&?S *
M\W7W?V/_U-)B00_*A#R2/2ZUJF\1U-6B-(=['VS\/%9UJ0('NLRFZG$9FEMK
MD46.^1Q]\;?5%&=.!_J=?*8012KC\*Z?6^P,097.IKB<1XY1/KV;P@L7)Y>^
M2>F-H8?XEA-,UE/^<"6M9,,I7&,SPN^'(R)5=M6E%]<5L.;@">!N[EC_ ;Y0
M#A%>)+(AR ?> VPK_^E!Y%V2,$&8OK?6*K@#0Z0/ZNK;$!GR6^O('*8X$1Y4
M^IX13C:JN@0A/)S?#'3X*T)K:%Q,"V_L_CI,50/L=VOD=YV]$N,4PY=@[8PA
M,ST..*))ZMZ0*:]!B;CIL1929);.65EKE3:5B,:M-4=WI!29KKA,?S0M\NGP
MV%261/<=['>)_M9A^8'MDD#;7>ZMM&=9,IY!PYRS6P,TO8(?:4AWV9 TIL.K
MJ1;-;@MD.8[A(B4Q9JEJV*?]VYW%9%C1>3VN',#*/M(^: QW:V"#X*XTV\RD
MFH.NTR/$6^;%%+=6/4][!9113R'1_K X)M7Z)Y*(#YDOH(KC6!>?X<KZZ-YQ
M?)E^WI0\NQ]:M8 +IVUH0DYPY8@[85Y*\=%3H-<WE_?Z7IHIG3L)23$-3)TH
MMF#HDOOCM;$*X5KV8YO<CX.=5U?E*V4L?/BP@[\QC?0VN'LVX' S :-ZNWKF
M#4H96E=>RWQ@QE";893@8,N<D(2<K8'CQJ@U<' 3U8/11&>(A.F;G(-%2P9S
M>V%3]4>]--&6>YYB+\[A6DH/( %]5E9VBP(E*3RIZ_+V@1Q-\<ZCE]0LOVF3
MUE<I<8H-([X=86R'=,68F"_D@R-<[H0=B!^I-*V)&ORIE<^I^;@.0D%;+Y@=
MK,4.C9/AD*]7((_]!@&;1Q9S2OE>BR$:$@$#3=SXGK3%"P,;O QPTN0XD]DP
M61A(2LI@:])MJ#@,IY[JX,0,&B;.:)=F-9-_=U-5D]:YR%: N9O5>KRZ35_G
M]K@\)6:KZ.CL^<8[8/D%L_>>6_*-0"'9/>"M<'G3N>KD/>!:5X9\%?7*1'8@
MW7ZA@5J#-\DGU 4_*Q:G_D%8@DE(HV'A:;];X"3&+,Z3*Z6IVU(\:R90EIN(
M-LB9:]+E'D MN4]C[C*+8IH0G#)"UC>CFBVV\NT2W^1U-GI)4X^6,?9.H"6G
MAY;8*-J2<MW)I /"Y^J')*N;$#X]@DX&VI%!30%UP(25LI)7]P"R$-[;Y#>E
M&,S"+YZ"[^H$&8'U7?S%-=:OQ 0\^8=]E'G>R;8FLT**- ^M$?[5O^94OK@6
M,,%,,@:? 0<F7SJ1?54^:M*&C&D#0MW:;X1T@K#*,_M[2'GF^KE?/:&D:CSQ
M]"+L*J2,-"Q=['N,! &T\\GX%PY6G< @[P25LGR10>KF> MK;YJX_)J_:KT$
M&CBMU+^1/D &A:XE3&"MN@))+*0Q^Z79J30>0T_H[%XK Y;TB6C/84C58BPD
M]HZKW7/FC]\.8PYF%J?QAO7M]V?\6?,!A ,8::GGQ+0%!8J'3G"EJ"083[Q=
MV\S&MS;^2;'^"E*9GQ^?<+X?1+"__X4.K8 HJ<P*@VN$X6O7.B=>ZH(3NH?-
M1V8%3TM F,'1/D[BG,I"RAMQED]2*)VY#(']78X ,/>U1O/O;_V."\VIA<\8
M>Q=%XP'K$M@G[B8F7ILHMKIX';5S_>E[ +1B0;Z'QGBR\G''O(_#"QJO(L7T
M\6W69],-X:2;F/6*XAXW9V3$;X,$RX=T(PY@P6;_Y7<^A>]WXW-VEL]C/#GB
M[".V!UT\RY#QZZ-[IDY)&DF.F.V.=POH,OPD0JO<GXILA9T^$"DM*C]9H9$J
M"V);3;:S[ZT*Y\ZR&Q)X75OW 'JNUKB;769EN47MGR+/4S$^+X^%QO_RT@?(
M.?:\;KIH@TN]#Z^VA'BPTD[J5KVUI^Z%131'J/D#ZBC^<5R)[-,\(0437%A/
MF<<:1X)>M<;J/ &^-8N'Z2L?G:5%CI.MR#",\D>W=RF1=+D'VLV>9](AZ'K[
M511.)@6IJ!\FL5N<NW]4W)/#&]<GEJT)T3VD2RY'I=W&>BB6.=K^B%[5OYRL
MVG>:(].N.&^JN,S"*YC9.I.V\9R"UQ* J0JXTX:\8W0ZF-F\<[K00,HOD(@3
M:VOXO.$EFV/ZG[U5A'A7WJ7!VS=M4"";X8X5\_,>,)@%R4_-]^DIW^9G,KP7
M=/]]\Z78[Y:C+2@"EV#=Z0+04X<TU,.5^P5$>+(;"+BG29J;-1/ZZ6'XA]78
MGT%A[:ZXAW!NK=R!CT)9<:])0&7K')J95MEKK?Z?*97O 5&1*G?S=UUWLPUW
MTSMG>K(AB]G7+6.Z8>E&-V;++GL%DWJ/7*N ;G\F&B>)])%2:L&!M7*LI(=\
MTQ2P6]A;6T7N)_MG]X""W*B7;X1'"L.'.X[:6Q'M;JGHY;:-.0F]!A=,L X8
M5Y5HOIJ?H$TQ1?MV95W&;^6&#W^"K<>:(5D[]M^T;CI21R_&+WGSP@,/;G?+
M@"NH9VAKOH.%I&QPQ:)[AK[I0GAY,W2:J^W.L""<Y/#W"+'Q7P7N5J) W'!Z
MN<%Y&JNQO\V*4\J/BN.DZC,NC7[D,?L#9YJ!E"L"+$KJ"2X']6R[C Z(^@*:
MU)X]1XJZAUR&UY];R-<24HE?OV!M%6[[J@P%NTO!G=+FRR'VKM,2E;XQKPO4
MB5-,@\J2D=+VR_DJW5+F47(EJ#Q]W:8T@?3Y937H2HWO)KF7G%)7.[7IYOCE
ME6>V<(G'4O^)B_E:5#_"%K6VE1_+67":&WBPTQN4D8T#2'@SMHW#)2X\:L$<
M8#%0#6E]"G74*XR7:($2/^!40;U/CKSTD[^ ?/\I*..*7%'9E;\E2</1M!>Z
M0OC^RKCO[ YVB[B-O86[WE8D8AV.,T=ZQ<]]"_)N!8;\E8@OBDQ;T9*;0&F/
MXL$^;;HKVY:$W-KZ^<OA/T-'%0)'PM".#99G&6%XAV1A8F*66VAZ.CB.;;<'
M*1<A*%HAWY35<4P&.Q<]!^W_-=BMTT#O$K.0EU,AU*+")5#\!9EC(X)'-0"N
MQQE<!0 6/(4J W0/*\LT1VM.GU5=2_RPTS*NV9@JV9C]0 :(%L#5$F^;G\-.
M28=L>#!,[>16KAH!("S-D=RNS,X[\?X:\Y6..[[9AIWQ1<:&\44VTK$O?0\L
MU7Z>F<PUK,F8HM_T[H7Y=GRF?#5[$[P<2JS<A/8\)<C5;48F]7AZ9&E&J(=&
M<K&^.U6H;((?/NX*4D14;4D;#I^;ZR0$14_VT"VER/_1IPP8DSGAG*V\B.T\
M<E.D.^B%N9=B;G/Z]!LS]GZOF=ZD&W !_!2" FM$+"_TRBTP;E?.L=V93>=!
MCTUOOQYM0H]UT?SW 'E;5DX T1\:$L#)M=YCU\#8?W/D(S+,'>X!3CG;RDV/
MV7N7JH-V>5T5Q/OL7[N'"==-G+HT9/V1)#<T@.@,-$XM4P.]\1-W4P&,2V2K
M!>_0/%@*<",;H<T%I<&/#'*Y49N+=.SOT<&CGR.M;P>+/1UE"0K;NOQ'+')5
MT"'/5O#AD'"--)O&EJG47E-N%"E0C^D[Y_ZGFT&5C]#^CIT73**0:Q 2U)OI
M7N[F,V27$Z$")N)RR5%A4Q>((:-0[A4UN CNP=A\:/"M?)GV2^6L[]OKH*]B
M1U4>'%X@<"X[%90=35_KTD[]Q.RTBHE)5A+61B<D9^CJ]91*WE(<9(]=L/=\
M"&QT0;Q[<\@6?6(E=ZPS#11A30:^9#+=1X#C_I'EX>E=&1N&$O.V <#SD!5-
MQ"'SE=S<MG@N%-?TXT<$-H1NLA]/U8<"2M;"3B4FIFH2_@'#'+C_,.GF%_?&
M+R:COVEK$Z:XFTNZH12^MI#8VCSB*[<1C=1>?&X!)U:_9L&,O/WF/GOU7F=V
M"Q%DU=TGSDR$'YG?E1*?B!3!E1P4WP,H5R9P<F\SUU5GR0=W+>R]-X[9L&+O
MT[<2C@NF\69T#DG58PT*%CS\GU7O[O4D7'TR[H';Y7UL)74&B@*^$2HOI5@)
MYJ0G> 340A\P25!;$GVDY 9QB8?[V3Y.VW2/FA1$>BQ_:CE83/N*63#7J-#R
MIX K_+ST[A3L-:&D4\EDRE:347HV9J[' N$UG47JN7H77=KKS7S5D;=:X.F]
M%M-8K^*[X[D^7+FN9],$["X?TD5[5X4[=%:;#91[8,\<L[6S>GT1LEMCDRUP
M^SZ#K3ON]G&_0K+%'82<8W5@YD^,Z411XKG'HZJ/CF\YO11B?+PM;]LCD<KN
MAU(*+[O4+72DKXWVRP);DMS-J+H-AY.D6-\:%GYB*>811TNT4P'%JW>"9J9A
M2ZU6KCKU-9D5&!M2IM:'7H'$:1SQ>UWD+7LD.8!-X1MOKIPNET6F@X4S1#!A
M@XF)&XM0QHP#06^2 ^=YU(, ^_=H6OH;P1'A%=4I8;\VJ:MKH^D]Q_I(#9*Z
MT3350ED'P8#/VB$CJ;(,HZIV6W*\24#Z*BNWUZX5N+Z9/W#%^<,%;F0%E.RE
M5/BBK9@BWBD!*X5;?F%$B-E7K>*+GZ3!.NHV,'T4JGTJ%2PLK=766A2OQC"?
MR]DI0QZSE?*"92,6J>4-M[+9NHJ!!19M!Q "-WGY-P>7TB&K-NG32\GZZNPF
MLKS=ZT_\T1^$;D0JK"'&H^H:_A ,D%9-@*OBD?RB)/M-5RH>^Y/-$'EIF#\3
M7/.X.R?DB5'NGZ313D>STA=XBT=R-RUV:C3. /_U9JU0XCZ,]'O/,,:M*S+Z
MYQ*^9N8[R0$PFH CNJX!>JQP9;?M@X?X*3F DSC@Z^6L&H]=QT/"*-]YFD>O
MSDE8AMX9 O*._N%$2[*FX>#2_\Z<*@A9_#F7DDYVH#8&C X]D:=A >'U0%%?
M#E"W?DH,OS!;9]]'H*SY1+G :I2]$-+[&7==>N=+5:/#FL)JB+$(U<YX)_%9
MSLZW[1S\RVSI[QHD/\]:B8<?ZG><L4?^&B>NVE[DGCPI)+?9V16;_VVV9TSU
MW.Z(:&XM^0RV[+WM.GD!4VUL;YP\)3<8'3-LT1]P%MSFXCK#!Q[WM7F'/3T8
MSJ'L%+ 26S!?/LD6 M<T'3D?;6B4@7V\=HUJ@+)P=5QB@&F(2!DD9JB;?A8Q
MX49OR&[QKZIRX_3-AN?/@>] A*<+_GAFMSG33N(7X3HGS->$7&6QRZ*$V_F-
M,DEK)5J(I_MZ':R;CMJ*'YA(,L]A6P[R33CK'"L5&($C:7&JJ(:)\+K=;JD"
MSE"/QGN @O008WKQ[^_[EU'2&;Y'2ZS!1KN\RW=E]O;+8AC'3R8!K!QMTV K
MQD &1VD9^;IC:NYDSK\^HGHRC!VB9'YPV]3B7&L&(XUU64DU>P5UW&[FK9'M
M*W'G_= @*YDY83\KB#54G9^%B66_Z W;\YW*.68COR V;[(A--W&".587'A>
M79;Z/@5]K^K&/4OW1@L347+2F%WP=M<MNN8PYR@@O5SOV#/-/$)THS<2BU-U
M6A7O 5DJ'T;#K#X?06CPYEP4Y:9.>\:Y+&3A16B[_%WSE_]@'[\IDMG[EXYU
M,%2@J99^0D+!70<,N# ^&[%'38K4@HLAQ12UGA7\5:NA"[MR9*Q!5R;E6_1/
M2F8SP=[5KEME-G+K[@Y9VG7,)Q2 A4M]HK;_Y^NH_X <4QS#3BW'ING_?W=$
M_E=H.QBSUT?\N^I<5S;QXN&T;W\1 P,SB?G_-+KPFID0MLZEKM/_/UYL]W/_
M!5!+ P04    " !O@PY9E#+]S2Q,  !:5@  #P   &-V;5\Q,'%I;6<X+FIP
M9]2[=5Q47[LWO!&D0VE))01)Z6:('U*2TJFBU B(= Z@= D(*$B#-"/=(-W2
M("#=S9 #,\P\XZ_N^YQSO^<Y]_N^?SS/]K/X[+W7VGNOJ[[7]UIK1/] +P&W
MU!ZI/@*PL+" IYA_ 'H.4 1NXF .[%]_<6_>Q,4GP<?'P\._141,0$)QBY*"
M_!8Y.24-XQU*:@9J<G(Z5CH&)N9[]^Y1WF'C8+M[G_'NO;N_7H)U$Q<7'P^?
M#!^?["X5.=7=?_M ?P-NXV-Y8*5A8[$ -VYC8=_&0G<"S " =1/K]P/X\\"Z
M@8US$Q</GX"0"#.@^A9P PL;^P9F_A@!,+U^F'X Y_9-\GL"\K@4.L_P6)PI
M!0/CLO!9%<K;J'1'C]B$GK\)(B"DIJ&]0\=^GX/S 9>PB*B8N(2DXF]*CY15
M5-6>Z.D;&!H9FUB]>&EM8VMG[^+JYN[AZ>7]]EUP2&A8>$1\PH?$I.2/GU*R
M<W+SON07%!955%95U]36U3>T=W1V=??T]O6/C4],3DW_F)E=7EE=6]_8W-K>
M@1V?G)Z=7\ OKW[)A05@8_UU_$NY;F/DNH$Q"P[>+[FP;GC\&G ;Y^8] 5QR
M>1V\9\X4+(*!^)0*<5GE;02L0KI'5,_?C!)2LPDOL\-^B?:[9/\SP8+^7TGV
MMV#_D&L6(,;&PA@/^S8  A!\$9R9-_YNW*OJL8R^!J'F\(2<;;'9X#VZ[G)(
MOEUR*??#49.9=PFW((&/2=U7F06)73/)*K:@GWUOP\ &X[X"2_-BQ@VU#>!#
M_)]@<LL=&I*- 6>*9]KETFMNAUU/+7WE88[U!3.>^5I-YI)7)\O-!P5W8Y01
MTD]XOAT2)9S<Q,/9_&P3 5S51%QV=*"X8.Q=/6UG,+$9-T9ULS'^,FK4U,Z*
M8%B-RH[%PW8)MN>:*_URTF7<V,MD720V1G GL9 #UI-GHTA^YP+SX<(A0?,=
MS2$^8F):"O)5L JI_#?:73EF0QU+8?ZN6#JCK13<C"4T0+)5D7DDZ9G]K&#!
M3"!<_^M6B;IP*&#EW,?!7K?A8+4Z'9E?-[J'I%_*V"=JS""; T_?JA+2-'I<
M?YLC.3K3]82>5?IY@&Q<=A/WZI?R0E6$6&NT<+26_M%!'H-[\OM([JG@D7Y8
M\:-U4H:;<2&2+[!GB^&-*QS1TC10,T_E=F^W$*A3CJ<IPAO<_.;8.FV4[>5K
M,YO!YY16XFO'/MIX+:,6-$XPTRX+SJE2X46\;6_&5.5EA(8_[&R@\);@]\!W
M.GN,E&[OU[!GB\R1UK"0C)<PO,YD.M)D4*CT/3_9C+ R-AI#\E@>I6["X,%/
MUL.:D3UWF=" DN^A%:RQ:P1N:=H,TPK==[VSGU.3K-G44-6@PH><)OJJ^);[
MX9YA"!JP_@2&#?30R.),.;$<F;G WZI/C:O%TZY^4N@<O0QQ<81XJP4./DW:
ME,'*),O>@J9"964](QRX.T3]Z4;WJN?!1C$'-DEC8_O+.MC[ B5L!!YHP$>:
MW_(C7>&J5F2Z( SOG8@#A?JH@Z^4'_,[/I$T?6C9"^/2[Q;\?(O6I$?]*E8]
M=QGH@*LW$4?,S."&J00$;5N974/S>GI1"E_*K@_E8"6N%;Y5JT0?SMKFYY2-
M5\AG,*)O%DPP2"1OR=GN,"F!\)9PJB6MVL;R9KR2ZD?RQY',0]VK4:O8!9ED
MA9S0=*0^+')%.12IBO?6H8GF6:%G$HE$M7KOGN[*#HTB-X]S5T")K+:82H>M
M592A"W/LF;GBX]"!H_3B/*+FAQ8D%H>]HM2:(UX9S4YB7GI.']ZG*><+8VV[
M&O8O$,"4(Z7%5IH%QWOB/9-1Y/2[W'.II@FE/7ZY.QN<)@J_J79RX>+/Q,CA
ME;HF@9A$-!0Z.BI-9NR$U O@%A?F#2JYU@^U;E ;'='?4Z65V"P%_(B4?!$O
M8> 5D874)15ZI:/YFN+5J)]V!Q<4])Z\8_,OWP]\D[6B;B]:(UV;9*18Z=H,
MXV^A@T>:C#XUC82?327O&7I@/:>.\%3I>/?AJ^6E+:ED&2?V-B%WV^EA9#I/
MPG)3ZVV1CF4-;L7&<G"I#,G@\1#194%8?%&AH(T[Z3?\5\0N<9WPA)7\"-\G
M1Y7=HB9IJ5LFK:%GYERL,IDIHWDQ7N]CY_L0G9?*=]/E,\F*"Z D\.MB,)U#
M:-#^:6JS_<T):262TD%)WM':^H;P'-_.Z'HO<=H^;/&-.@@QT@R&%^Q/:;D;
MXG-XJQH-1)@^&GM5;9?B,R2B^6B@(L?9N>K])[8UWY]'6&?Z5"=#/=U.8>\]
M'_"M'S'/G(6=*5?6+3I)\;BO/%S9W,NY6&/\1H5BRCWF(HJ-3N=I 8/@2M,=
M-%]K@_-A#-,)U?T*J,?[%#U,<L\NO!_22O2)KV%OS7)O[**!66Q,\+@=5&;#
M/=0C.I1&]MR:U1AUU\?LNOI#CO?/HWPS5UULV (#4Q*Z+!F;7N8N>%;JCB*%
M\K26T0 Q7[*SJ^-FO%1-Q+&P0U$FU0+1*EN P&C!KY=W0%L>@J\@W91'+5E?
MC.PDB9-A1B8+\TK.#R;NA+)(6.$*)TC<$-N,42E9#&UED#9<U:+:?KQ X ,A
MLK^@F.OR+.^GFTQP'SJN/5CC_1I4'-0"SR3+W(*FH,0]W^J/^_/8U:B[K6R.
M61VM3YY.M= UBQ[CJ8I_:GEY4\]MQ_NUW5=? UAHB/\M.(<C-,\SIW/ZRFSV
MW;<V9S?V3A6/&])QP;.MW(UQ(4_:-@)DD[);'$=1]^&KG994R'N0ER*)28&%
M\,=@,4F]X#5Q"JP'"@(-%EE"W9)1$^DD<-@J/[D&=2%' !I8D8> /60^][7<
M9HAC;7ATTA>VQO^U3(\DO\SVEPIZ_"E\-::E'8IV3)S"2_:JAG2G\ _H'ZN#
M/_+Q3GZ,S1BB?V'QT55<-HW[1P&0'<'Y+UL)-XAX2]+O2R'8)G=.'K=4.)FF
M-SS0A>TMN=15$B/8/0)8XVNAA^/IC%?-RZ*!=CK]^2])(5*<7ZH-3=UD].49
MR.PK[99B"7Y<IY5*@ZR(3'[4I!(8*?>]ZN'%1P-/TR?'=>080E*/#K_-LAJ)
M)B_[20YN[TN9?,PB6KOS@:?13XP30!"Z6I(U41 ;"'0L^^"/]<^:2CTMQUJ7
MY_/M[4'PUJWYI.S:9I(^!V%[RC*F6X:^2K9.<7W9J1C)VE>+!EQF"W<RB%N8
M=@V\W6)*E^:YSA<UWIG.E$SU+_QFE?U@AV8NS]U5&X]LQ8%B>:'$E1\/7JDQ
M5D9M#=DKE5P'# 243_"G\_M#,[<>",>2(24F3+6K1T_GN=:K$(^.YF<5 IL^
MX@U.1:.&A^);SE)AV.U7R6%-&IDUJ:G@8F[UOGT1W%A?=X]GI;/4$&VUKZP-
M!U2#L[:2/6\/.>+'.O3KRJM@5'E#$S5Q4GU>M\?;U46[+O-PW0< LKN??:NP
M)G=1M^%/G&43OW@F=\QR,PIVY5:8-KK-.8$)E%B=:?'SQM<Y&$YW31),/?F5
MZ/(B?\R:\I6[T5LJ. RP_YPF62^#!='6F^>?0;FGFJ16M"C@/OJ(1V^+^B\,
MF.[>ZGISAXW^\&G\@FP3]6]2AN+?>M0F)X6;O;?Y#-NN')#4@57&PA.3V74"
M'2P6FF.-N:&0?E$A5RGWDRAM/$NR#DB(I*^8/V/-D44<,5V3SV:-J4"-6W3@
M'?%NJH^W!!]Z40GY<L-=KB/Y(M$ OD7B=1K/[IMS3'8S#]$WS]:RGHN+^TYP
M5H9[/-ZM"S<PXMUK4B3]TL $I=JV8[-.0C:W]$1/$[9]W6#)!.J!!SCZP^2>
MD*X4,/RMUE'K><;Y;_%VM>0$UG5U@O?L@G]$'9*3*[0;ZP2RBJ_7 X=.+0QP
M&MVCZ_S00VGFW.&\F9>E#B:3HG):NI]]<R]8H=YMD[X"1_Y''3D[+72CUN8D
M6>-6X25O:DI?R\7<4ECE,6-P7Z!=E9"$D/">23D1#I'FN'EP79<I.M:*5II^
MS&Y?IK*Q_E @]=5L\[,58$CE93V=CC/-PUK14M=2 PO+T(GH,ONYAWBCQNB.
M7(0=6-V-<0^,^8"UY5V3NGSG-!KTK:$[PXXOS3]H85HCGF6TH3VK/3 *R,*Z
M<UIJ;JHX6KW/@6 U'G_:\O5G]+E7\IN7^"_%S^_>/H7>\</N]$C(/V=*+37=
M7K2=:*TPN,PS+M4Y/>2A%B2'%9LY<=(&"?VXQ=5UUA-]EDK4)\PKU4FMJ[2,
MH'>G>3U X&6P*<854)' D5CGJ$NP"G85QEJ #W2TDIW-G [#-849I;3CC;OR
M/M<FS?7&5?SF SL^Z '>$WS;D2O+EA%ME[GC6K#G,*YIY/^])OLARVV'N4HG
MC;I51@&+AU-7T;7M_.3&"QKN:,"^N392M39];.-GCY2P@DB86:-:QQ#6Y3<\
M=W&J;5GIM_IHX)V=B .I5.$9(].*S",I4^M[4"JRP[L],)JHA@!(6.&^'/&(
M/P.<K/TB8='3HYW.X).+X,>UI(5)_8CT(E)QO!%GXZ&CBV7+8 >^,U5I_LRM
MJ5V<<C.S2P+"2]WH"FXQAH>K3'"J#L^W&K 7WJ+1A5I.Q3N2:?T_=X3L;DA5
M8@]S%_<0)!%@!:YJL^HN=>.N3J<<(OVL"BVV3$BN:Y+YLJX3BV9WQ$Q\'S.I
M6CT^((K'KJ V!@ZL:#<IL89W+2B.(%UDN-M79,'5D43JC(1ZM]L;7,58?N)P
MA:\_KM>4P(M:K2L+;<.D)R3WL@Q1QY5Y=5AC<L>N>&5SO?8XJZ;JIT  JY7C
M+K$5=O5SSQR]U$ZMW,$4_K">T'M-W$7*5)_/IVGPGT%XBOAF4D3>ERWAF3')
MB7QO6VZEW)GB9BIG#M-Y=G2V:X+MQ:42?UT87? ^AV2\1-9RH>^[2T(*<%"*
M8D *(-RKG6R697#,+!ZQ3&1'S$I72"Q03?B-J)#,L6'/EIGX"L A5GGFVP;^
M9&-+Y<V>+^H"[V)9V\98\4@E2D<<SV60[:KXOBP4C2O-#Z^&D,VI@CU><6!]
MH6Z\;U;X(SZ$X0%P<GQ1VGK'TW]7??)^;64E3&3^[?8;V8^N<\7AYB(*FX)J
M;14$3 93[R^MR#[;O"=[E#[7(<O53.!FYU1HYNFC;6@I*JA1.I;=4+'FMU3Q
MH/>LY"-2Z.C">+))R^KZ[9<%<W-AT)R.3-G:I_.#V,'>V>^4!ZBCGP3=2DS8
MY9-[FS"A78-]QLGO.92E]W^R#9USO_30TE\H V&;^?A5HFZ5VG_OENH0EN5)
M1;AS\PZXL5?^=)(2?;_IRDLV?QGQ@E\\D[061<7?83!*H^2$LX4&9F"#CM3,
M%64X[P!+F3=RV!);P+YQ2GX;!,=^X>'7Z6J-^]\W-<=/,_:*_1CWG^R5!XI]
M9,,N9XAR;1/IAWMHIEHT1[0/@CLZ8)Y?CA]8^:2^\]SO3@=4:5O.M,2B<V,T
M'Y)1\;A;L"6L5.<HYNVD^&7OO/DQ_RANONF)$9$7M023QX>N$!9!*HHWGU^\
M_1S@T<)U%-LQ5T#1*?O@J#O9O4%8*M[KU6^E3N0N 3?B];U7<4@]BVN92(X<
M:YV*U5TRMR^^P@.?^IP+A)B.TF)\%BDO1UO&O[R7,C'MW3P=(4+C)]0>IYZE
M+%UI+344W6):*$6Q'J:=\%EP8 =<!+>B'$'R'*UYX,,RRK.BF4-48@4*3]NI
M:#.)U(_00!O12LY*]5'91Y%VE,U<R_<6:Z25O_-%Z^SNH<XL4N9()C9B..(5
MDB.OHS393G:.L:@D\..SC[?$GQ/T[;SQ W_-#A"\/^)JUR1/%G9_W&%M\FE@
MJ57CB\%P"H8*["TM^TUV^).C*1\B!UDGG&T2L -;@CR1Z0.C3[!6VSU27+F5
MQB).[#@T$ Q9:A522D#=3L6Z'QSX!10O9ASPY@93Y@L;*A.R$!"90W5JJ0D9
MSM;HPL_<N"&NF2\OC+$,<:R8'[(Q:VMZ3SLI 6]0]$=:[Y L'%K$</<>51H<
MKR]3MX)A(Q03@3]<J29TE #*_TG3<V)S#GCA)@=I<M9 Z+<BD<IHP"\"2(D(
MW3=  R<PYNMSSO\O]RMSRBMCSGVV'%C4&X/U4U[*,<G5S]*>B?=U>UN77A<M
MHOQ9T4!+%[,]AMEDA*&!PW(Y"AWM?]U!6592<K!1D[(R]6"M.F$H,%>NFZ/-
M?" ]%"<JIG,J3?&\&'()CT4A*/W^?AS04/K_X[;1M#=I: '[SJ*=J ?+I8[C
MNZ_<7LL2<I?,H@LSVR:0?\Q1>;84#6RN@!![VC<U0!KE8ZY;5=>BW43<*B&L
M00L"=!S^P)*+B0C9W\-T_OX>5LJL;/RLZZS=N(-)^_,AWO)@WWHB 6N>NK8!
M<DWO>!>3I:=/7W/Q5YNB@>%.R,6/G'\H_(8]%_/_ ?=%_W&?<^>?UX+^:@\(
M ')/IBJ@6E>UQ8F+:N'ZFF871>GH$YO$HLM_N3W?DK%JP!K-*E=01XF%\]J!
M_?-E/%-)QRE34(F7W747LG!"&]NW"K6"TON_Y[)X4);',T%_S.8H/33;;.?A
M_,YLPIWN9')UUZFO[<=JK(8X+S)X7>;<9*?(PIV1I!4Q*RNJOA[GMH-0(M-0
M4C-R@KC'ID&O-1^JB._+,7U:S[^@.<X9T#K@7[<PS#3QU:R#FZZ 9=YLK#!3
M:I"T;U?\5 77TW:$]8+=]&G]UU[X"9A!V]5!U)Z:&@KJL03PF#G5%C_!H5=0
M/@.OYPT_!KR\3E1^1#HKJ(!$!6FJ 9^+I(R?EOVQO*"ZUD3?3_EPL96Q[1;V
MD.X>\XIIMC'^>Q.''*W7"Z7NTQ$PD7+!6_E[*TK$-QQ^XC5;3#:)K=X[,NT4
MI>,/;3*W(IEJ9IAE>I]L6N:PA)_:N=;?J6#^\IX8\\?"0SEFW<M?FBDX'D=$
M7AJ&PHO;'%:AX1:W)TJ14D5V F&KDR(:C[S6@L?$T<"D,8XQH5=4S^9JL$6]
MR($>L/C[W)A,(,X0+C?*_\VECM(?3>]5?X1QF#XV6SI0R,UAUC#^JHIHH/29
M_AYK5%7_=I/@E</A:281Y%4E@F,6-4DV@XE-Z$=1;[=MG=+KU,Y*]CT2BIHN
MY[M<IB,,9^=0X=K:D3,2;/VFY"?CIS_XW8A\XG"P[H<,6R_ROM Y/G#XY#@C
M/GQ'2#;I"H/S)L>JP@BP.D=C@"9/?Y<T<:;?%V&\4'K-\5[IU2!.[/'.,+/,
MI\;.<3]M\M0M[/)VZ?*@X=D5==61PQ.Y$:K9<?3#G*/EQ/1??K1SI9,-&JV]
ML!G;ND' ;I3LPM0$2+!=$88]&K_EB#<PR[<8"SW.S[UGUCO4HHA4_GK*E&@=
M0,B9_6\WH4..D/EENWMV+ZP?,'7^_+:4$*MYD^,<D[0R_3:O,3+MCD-!JVA
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MY+OK+-(; W;(N;BKG/&YT;G;S@DIQ.,>,15RXWQ$X/.=%J\TLL,(_@OMM-;
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M6J2J(QK8_52&ER3.@$%,YIE%%U_-NMEUT(HY/ROS8NQ42\7QRU_;FZ##1#1
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M$</&)R_(9^<&;G0+_*_>S2NH"40+PT&JTA:E-\%0% @E)HA J (;HX *4I(
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MU55Q1Z+(?_Y+_)_@^3'U;U!+ P04    " !O@PY9LWYB=K!.   =5@  #P
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MK!L>OP5(<7#O/;Y)]DP%S\29_#[_.WR*YS$993]NL0BH'E*^>3M"0,4JN/0
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M,T;2E-2-0'Z#EA*OO<FTTSNA*)^$7BE?9X>++&'T]E?FBAK]HY\#A)<(>,,
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MNQA"W4'?DH+29\* C)QA"![]AP+=QP5<N8AH :: ]K&LAVK!R7K;?L\V,(F
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MQ+U"=+F8VGYW8F5)^':1B45][,O$DC('EB!?T/;T43%-R'7MCQ]03=X\SK7
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MAZK84AVR$J9+)HA2C3354D.OJTZF?<TY1\I_78IW.4?2&NS[)<IXUB#X7-%
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MCO.!"-CX.IH#_CB@Y751T]+)N($SK6Z:['T_Z/25-H+^U]R(EN-%8A80Z3H
MH <_&PET26] H\2T&24Y%494%R5;J[J=YB'WO!9M!A=J%\N%KYDXHWSK,D;?
M4K/=14]]:%%D=EOV0%H5A.7FTYNM!&P'XW\P: X,?Q]$SKZ%^/"H3N:7L3D0
MD,$=)FM2P@1#]D3MROEQU/T)"&R:&-=3:9"JYGU?7&?]#0<$V:#LS=0_-1Z^
MH;=]E(Z"^>GTUGOZWW'FIL7$S,QD&T#80%EP:V&DF8IL8O;WIW HTUS1I<\!
M>C,3!*K*[\C/-8Q]AU;!4 >7-]TA,$4DN)2O)P0$_!YFU#WBB&&?(].L$:^_
M+UO/G5-^W:<?X21U^=I8;K,ER^(I>X'C76.'2,(O/4WGN=<L1P,$O.%OF%%2
M/(?"9VH56A?SO/(^/O]R,%WGG(8I<@.VQY3NC&P0\'0H\Z$:7RH.0%?EMG+>
M'V1D"W.C>').I%X9[2(7<RX_7[;K' RH&PQ$2+K*XT>0[BE!AL61;0MF5=N$
MR%.9_1F^5K\Q1ZA6;BG>@/-20ADM\3FG&#)+@*DY=/P9S]F_C*9:#E\6N F<
M;9L'@4^'!]SORQ@BOR7,SLO/=8T-5+0M0,I!8%F!8L:<!8&1X20)8P8W\TW<
MSRMX./8"/1R!INY-?1VR]W]K?9HT$/IK=="#+&2>BP22#'>P_X+:$[.]P.,O
M];/O!R7O0@JE<RC*0B%OIQ-)KT>+$0O>K.W;%PIN7ZCM<(K8ZG->+-4T^&R)
MR."6VC&[P6F?Q.(SL8Y/*A4+GGQ&J7V/YLST66.LHQZ\1UR9B!A73MJH49DH
M_;&%E#4V.KD7^>.\X=!Z<=U#'_Y4;-H9<B5%NB\(&+]H^RQ+>?>")ITG?<@D
M:ZA'B6WF&0_K-&"A6">W?4J7F7D$%WG5V5.Q2F-CA#X=!.;9] NT"PP_9Y@?
M]MS99@&3?1Z'[FZ]Y'6ZRNQZT.!D,'[ 0"(@_)IKSF[Q4;@"T_RT;.)Z\G&W
M'2" Y-G3I'IU7N2;HJTT>6(Z*QQGR;XOS"5;D^7HCY7?ACZCUYO5!;8T:$>P
MQ98]O_-NKAS%Z::U&-1X.;C=0]/.X'G'@T;%#2)<@TV&];H/(_ S#YG%\XCH
MA8]0SC2;R[1NM>"X1A4L$_QE+4\4')@U1;U,T5Q7H\[N#A*_V:G#.NF*'HL!
M 95J+V;!B@PYSWTIKAO=H<2QG5^68RS+[TR8D'^)]MZ9*3[G3LC35WPK\]S;
M3J+AP J 7VU,$IO:7,@R5^0R$'2"AU-6P8P"N@ICN=BQW"%B'R)K7UJYI. I
M&KB++%0K0(7)+W"-[';; J(\'Q]V!/;3QH[S)"AS4D&95(Z_*$_CQQ>[-//U
M12-\=1]?N6)H1N%5-R;Q97U\%8S)"9$K?].L.-C3&.1/DZJ4%M% LH7?'O,!
M@]]5/739^B32Q2.1)>PJ]5Q\1M ])]?N^KVV5['%AC4=W&11&.HY !UJ(;H,
M%1*)4:Q3UXN*#AU3E@S)%LWU*5H.O>79GEXT\RS.GUWRX"LE'GU@'\[FV:3'
MS(>7UW8-.+S"H]U<*_LGC)HLL):MWHL%7UY.[IJ(L=3ZR[&^W$/RWAF@5GI0
MYB-%'#="\8G>(,6KR,4(X,P'JB7Q1K9>8_>.-@N.^-<?(972FG,H7EK$VP\#
M I^2+OO<\EX4)A=>C)7*EY3RWO<^:'NE^@@E>Y'JYE>I8"(JM6$HY03YB3FS
MQDO.TKTJ,3-D/V?%9_()YQ0(],'LB9EODFV-WO H#* BK7BAPRL(V,7--[[L
MDZ^+]/TRVAF ,^^G= ^Z,M !K9W^5D*!A2\FX^]/R"^ML%5ZI*R$T!$?=1;B
M0"!ZBP4(O T'@19W^!#+MA]/+&2%%QLTP2A\!N1S!=:[AWZ;5A:F,/28?SRP
M:58HWQ1%M/KYZ^",0=.L\%,ZL[FFQ25B7(--Y1NL<+5,OUTF"TOJARVFCX"
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M#_.2?"B5S*8D2U8-2Z9M+<2"O[#*!U4KNMNZL_MR04F.>,^ #4A'>1[8VT[
M*O"1B*&.%&P0)2(A=4-5$%T4=@:))A,X%6=I;\;2O%U9FAASE=N+2H*A" )H
M<#D&@,P**?W3#W\[:?ZU;=;Q4L77U>K:&A8:(E(PA88?ZCQ[>@;K##>O+"A
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M2,KX.G@J#\>S?WNN 4IP +U\@>(&7JM\:CU/ZH,FV/^9NG\#4$L! A0#%
M  @ ;H,.6<4D"1<S#P  JY(  !               ( !     &-V;2TR,#(T
M,#8S,"YX<V102P$"% ,4    " !N@PY951<0]QH-  !5E   %
M    @ %A#P  8W9M+3(P,C0P-C,P7V-A;"YX;6Q02P$"% ,4    " !N@PY9
MSDB*05L6  #)3 $ %               @ &M'   8W9M+3(P,C0P-C,P7V1E
M9BYX;6Q02P$"% ,4    " !N@PY9PSYL([]$  "S= , %
M@ $Z,P  8W9M+3(P,C0P-C,P7VQA8BYX;6Q02P$"% ,4    " !O@PY9+0BY
MQCTT  "3O ( %               @ $K>   8W9M+3(P,C0P-C,P7W!R92YX
M;6Q02P$"% ,4    " !O@PY9.DD:AEG(  ![& L "P              @ &:
MK   8W9M7S$P<2YH=&U02P$"% ,4    " !O@PY9%;,W((%"  !_30  $
M            @ $<=0$ 8W9M7S$P<6EM9S$P+FIP9U!+ 0(4 Q0    ( &^#
M#EDXX12.BVD  .UV   0              "  <NW 0!C=FU?,3!Q:6UG,3$N
M:G!G4$L! A0#%     @ ;X,.6=M9=-(=6   U&0  !               ( !
MA"$" &-V;5\Q,'%I;6<Q,BYJ<&=02P$"% ,4    " !O@PY9XW?\I,=0   %
M60  $               @ '/>0( 8W9M7S$P<6EM9S$S+FIP9U!+ 0(4 Q0
M   ( &^##EGZ?82DHGX  %&.   0              "  <3* @!C=FU?,3!Q
M:6UG,30N:G!G4$L! A0#%     @ ;X,.64=R5/P\EP  ^+0  !
M     ( !E$D# &-V;5\Q,'%I;6<Q-2YJ<&=02P$"% ,4    " !O@PY9E#+]
MS2Q,  !:5@  #P              @ '^X , 8W9M7S$P<6EM9S@N:G!G4$L!
M A0#%     @ ;X,.6;-^8G:P3@  '58   \              ( !5RT$ &-V
M;5\Q,'%I;6<Y+FIP9U!+ 0(4 Q0    ( &^##EGGA8#,^@<  "U2   ,
M          "  31\! !C=FU?97@S,2YH=&U02P$"% ,4    " !O@PY9JOV%
M6)T#  "1#0  #               @ %8A 0 8W9M7V5X,S(N:'1M4$L%!@
0   0 !  X0,  !^(!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>cvm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20240630.xsd" xlink:type="simple"/>
    <context id="From2023-10-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-07-18_us-gaap_SubsequentEventMember_cvm_MrKerstenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:MrKerstenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-11_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-29_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-29</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-11_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-10-28_cvm_OfficerandDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-28</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_cvm_OfficerandDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_OfficerandDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerandDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-04</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2023-05-01to2023-05-31_cvm_EquityProceedsFromSaleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-28</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MinimumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_ConsultantsOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_srt_MaximumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_srt_MinimumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-10-01to2024-06-30" id="ixv-7709">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-10-01to2024-06-30" id="ixv-7710">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-10-01to2024-06-30" id="ixv-7711">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-10-01to2024-06-30" id="ixv-7712">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2023-10-01to2024-06-30" id="ixv-7713">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="ixv-7714"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7715"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7716"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-7717"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7718"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="ixv-7719"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7720"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-7721"
      unitRef="Shares">54257884</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7722"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="ixv-7723"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="ixv-7724"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="ixv-7725"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="ixv-7726"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <cvm:PurchaseOfNewlyIssuedSharesByInsiders
      contextRef="From2024-04-01to2024-06-30_cvm_OfficerandDirectorMember"
      decimals="0"
      id="ixv-7727"
      unitRef="Shares">58000</cvm:PurchaseOfNewlyIssuedSharesByInsiders>
    <cvm:RestrictedCommonStockFairValue
      contextRef="From2024-04-01to2024-06-30_cvm_OfficerandDirectorMember"
      decimals="0"
      id="ixv-7728"
      unitRef="USD">80620</cvm:RestrictedCommonStockFairValue>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="ixv-7729"
      unitRef="USD">300000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="ixv-7730"
      unitRef="USD">300000.0</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-06-30_cvm_ErgomedMember"
      decimals="0"
      id="ixv-7731"
      unitRef="USD">100000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <dei:DocumentType contextRef="From2023-10-01to2024-06-30" id="ixv-8684">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-10-01to2024-06-30" id="ixv-8685">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-10-01to2024-06-30" id="ixv-8686">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-10-01to2024-06-30" id="ixv-8687">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-10-01to2024-06-30" id="ixv-8688">001-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-10-01to2024-06-30" id="ixv-8689">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-10-01to2024-06-30" id="ixv-8690">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-10-01to2024-06-30" id="ixv-8691">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-10-01to2024-06-30" id="ixv-8692">8229 Boone Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-10-01to2024-06-30" id="ixv-8693">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-10-01to2024-06-30" id="ixv-8694">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-10-01to2024-06-30" id="ixv-8695">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-10-01to2024-06-30" id="ixv-8696">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-10-01to2024-06-30" id="ixv-8697">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-10-01to2024-06-30" id="ixv-8698">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-10-01to2024-06-30" id="ixv-8699">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-10-01to2024-06-30" id="ixv-8700">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-10-01to2024-06-30" id="ixv-8701">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-10-01to2024-06-30" id="ixv-8702">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-10-01to2024-06-30" id="ixv-8703">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-10-01to2024-06-30" id="ixv-8704">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-10-01to2024-06-30" id="ixv-8705">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-10-01to2024-06-30" id="ixv-8706">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-10-01to2024-06-30" id="ixv-8707">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-08-08"
      decimals="INF"
      id="ixv-8708"
      unitRef="Shares">61493229</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_682"
      unitRef="USD">384652</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_683"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_684"
      unitRef="USD">551337</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_685"
      unitRef="USD">520368</us-gaap:PrepaidExpenseCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_686"
      unitRef="USD">2555249</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_687"
      unitRef="USD">2248072</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_688"
      unitRef="USD">51129</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_689"
      unitRef="USD">4245</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_690"
      unitRef="USD">3542367</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_691"
      unitRef="USD">6918420</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_692"
      unitRef="USD">7800909</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_693"
      unitRef="USD">9131987</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_694"
      unitRef="USD">1548010</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_695"
      unitRef="USD">1698243</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_696"
      unitRef="USD">8613316</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_697"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_698"
      unitRef="USD">173028</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_699"
      unitRef="USD">197704</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_700"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_701"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_702"
      unitRef="USD">71589</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_703"
      unitRef="USD">74669</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_704"
      unitRef="USD">24068320</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_705"
      unitRef="USD">30528250</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_708"
      unitRef="USD">1369441</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_709"
      unitRef="USD">2009786</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_710"
      unitRef="USD">1272149</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_711"
      unitRef="USD">1049581</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_712"
      unitRef="USD">696487</cvm:DueToEmployeeCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_713"
      unitRef="USD">557244</cvm:DueToEmployeeCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_714"
      unitRef="USD">1949245</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_715"
      unitRef="USD">1771804</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_716"
      unitRef="USD">219019</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_717"
      unitRef="USD">197431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_718"
      unitRef="USD">5506341</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_719"
      unitRef="USD">5585846</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_720"
      unitRef="USD">8477784</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_721"
      unitRef="USD">9949565</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_722"
      unitRef="USD">1486138</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_723"
      unitRef="USD">1652949</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_724"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_725"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_726"
      unitRef="USD">15595263</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_727"
      unitRef="USD">17313360</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="fid_743"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_745"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_748"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_731"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_732"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="fid_751"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_754"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_755"
      unitRef="Shares">54257884</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_756"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_733"
      unitRef="USD">542578</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_734"
      unitRef="USD">474223</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_735"
      unitRef="USD">515832848</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_736"
      unitRef="USD">499832063</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_737"
      unitRef="USD">-507902369</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_738"
      unitRef="USD">-487091396</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_739"
      unitRef="USD">8473057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_740"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_741"
      unitRef="USD">24068320</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_742"
      unitRef="USD">30528250</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_762"
      unitRef="USD">13684204</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_763"
      unitRef="USD">17203823</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_764"
      unitRef="USD">6547866</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_765"
      unitRef="USD">6804729</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_766"
      unitRef="USD">20232070</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_767"
      unitRef="USD">24008552</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_768"
      unitRef="USD">-20232070</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_769"
      unitRef="USD">-24008552</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_770"
      unitRef="USD">-571102</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_771"
      unitRef="USD">-493522</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_772"
      unitRef="USD">7801</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_773"
      unitRef="USD">61525</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_774"
      unitRef="USD">-20810973</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_775"
      unitRef="USD">-24563599</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_776"
      unitRef="USD">-659456</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_777"
      unitRef="USD">-171552</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_778"
      unitRef="USD">-21470429</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_779"
      unitRef="USD">-24735151</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2023-10-01to2024-06-30"
      decimals="INF"
      id="fid_780"
      unitRef="USDPShares">-0.42</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      id="fid_781"
      unitRef="USDPShares">-0.57</cvm:EarningPerShareBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_782"
      unitRef="Shares">51479454</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_783"
      unitRef="Shares">43761395</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_784"
      unitRef="USD">4703160</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_785"
      unitRef="USD">5727789</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_786"
      unitRef="USD">1967075</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_787"
      unitRef="USD">2453968</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_788"
      unitRef="USD">6670235</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_789"
      unitRef="USD">8181757</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_790"
      unitRef="USD">-6670235</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_791"
      unitRef="USD">-8181757</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_792"
      unitRef="USD">-190705</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_793"
      unitRef="USD">-181670</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_794"
      unitRef="USD">4382</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_795"
      unitRef="USD">3854</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_796"
      unitRef="USD">-6856558</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_797"
      unitRef="USD">-8367281</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_798"
      unitRef="USD">-659456</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_799"
      unitRef="USD">0</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_800"
      unitRef="USD">-7516014</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_801"
      unitRef="USD">-8367281</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2024-04-01to2024-06-30"
      decimals="INF"
      id="fid_802"
      unitRef="USDPShares">-0.14</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      id="fid_803"
      unitRef="USDPShares">-0.19</cvm:EarningPerShareBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_804"
      unitRef="Shares">53994384</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_805"
      unitRef="Shares">44254363</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_806"
      unitRef="Shares">47422304</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1082"
      unitRef="USD">474223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_812"
      unitRef="USD">499832063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_817"
      unitRef="USD">-487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_822"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_951"
      unitRef="Shares">17724</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_958"
      unitRef="USD">177</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1052"
      unitRef="USD">48730</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1097"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1067"
      unitRef="USD">48907</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_965"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_972"
      unitRef="USD">886</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1053"
      unitRef="USD">201421</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1098"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1068"
      unitRef="USD">202307</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_993"
      unitRef="Shares">2490000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1000"
      unitRef="USD">24900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1054"
      unitRef="USD">4955100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1099"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1069"
      unitRef="USD">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_944"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1055"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1100"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1070"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1007"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1056"
      unitRef="USD">-470229</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1101"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1071"
      unitRef="USD">-470229</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_808"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_813"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_818"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_823"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_826"
      unitRef="Shares">50018601</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_827"
      unitRef="USD">500186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_832"
      unitRef="USD">505950994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_837"
      unitRef="USD">-493800920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_842"
      unitRef="USD">12650260</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_952"
      unitRef="Shares">27373</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_959"
      unitRef="USD">274</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1057"
      unitRef="USD">53211</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1102"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_1072"
      unitRef="USD">53485</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_966"
      unitRef="Shares">162744</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_973"
      unitRef="USD">1627</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1058"
      unitRef="USD">379243</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1103"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_1073"
      unitRef="USD">380870</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_994"
      unitRef="Shares">3875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1001"
      unitRef="USD">38750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1059"
      unitRef="USD">7711250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1104"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_1074"
      unitRef="USD">7750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_945"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1060"
      unitRef="USD">1432540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1105"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_1075"
      unitRef="USD">1432540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1008"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1061"
      unitRef="USD">-717621</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1106"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_1076"
      unitRef="USD">-717621</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_828"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_833"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_838"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_843"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_846"
      unitRef="Shares">54083718</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_847"
      unitRef="USD">540837</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_852"
      unitRef="USD">514809617</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_857"
      unitRef="USD">-501045811</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_862"
      unitRef="USD">14304643</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_953"
      unitRef="Shares">45722</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_960"
      unitRef="USD">457</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1062"
      unitRef="USD">60120</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1107"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1077"
      unitRef="USD">60577</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_967"
      unitRef="Shares">70444</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_974"
      unitRef="USD">704</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1063"
      unitRef="USD">154951</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1108"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1078"
      unitRef="USD">155655</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:PurchaseOfStockByOfficersAndDirectorsSahres
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1016"
      unitRef="Shares">58000</cvm:PurchaseOfStockByOfficersAndDirectorsSahres>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1023"
      unitRef="USD">580</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1064"
      unitRef="USD">80040</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1109"
      unitRef="USD">0</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1079"
      unitRef="USD">80620</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_946"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1065"
      unitRef="USD">728120</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1110"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1080"
      unitRef="USD">728120</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_848"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_853"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_858"
      unitRef="USD">-6856558</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_863"
      unitRef="USD">-6856558</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_849"
      unitRef="Shares">54257884</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_850"
      unitRef="USD">542578</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_855"
      unitRef="USD">515832848</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_860"
      unitRef="USD">-507902369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_865"
      unitRef="USD">8473057</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_866"
      unitRef="Shares">43448317</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_867"
      unitRef="USD">434484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_872"
      unitRef="USD">486625816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_877"
      unitRef="USD">-454897093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_882"
      unitRef="USD">32163207</us-gaap:StockholdersEquity>
    <cvm:WarrantExercisesShares
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_926"
      unitRef="Shares">217752</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_933"
      unitRef="USD">2177</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1024"
      unitRef="USD">445114</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1083"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1038"
      unitRef="USD">447291</cvm:WarrantExercisesAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_940"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1025"
      unitRef="USD">1703931</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1084"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1039"
      unitRef="USD">1703931</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_947"
      unitRef="Shares">21331</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_954"
      unitRef="USD">213</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1026"
      unitRef="USD">49965</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1085"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1040"
      unitRef="USD">50178</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_961"
      unitRef="Shares">40236</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_968"
      unitRef="USD">402</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1027"
      unitRef="USD">91221</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1086"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1041"
      unitRef="USD">91623</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:IncentiveStockForfeitedShares
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_975"
      unitRef="Shares">-2000</cvm:IncentiveStockForfeitedShares>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_982"
      unitRef="USD">-20</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1028"
      unitRef="USD">-11080</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1087"
      unitRef="USD">0</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1042"
      unitRef="USD">-11100</cvm:IncentiveStockForfeitedAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_868"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_873"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_878"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_883"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_886"
      unitRef="Shares">43725636</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_887"
      unitRef="USD">437256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_892"
      unitRef="USD">488904967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_897"
      unitRef="USD">-462750602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_902"
      unitRef="USD">26591621</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_941"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1029"
      unitRef="USD">1743288</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1088"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_1043"
      unitRef="USD">1743288</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_948"
      unitRef="Shares">23627</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_955"
      unitRef="USD">236</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1030"
      unitRef="USD">54629</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1089"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_1044"
      unitRef="USD">54865</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_962"
      unitRef="Shares">38562</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_969"
      unitRef="USD">386</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1031"
      unitRef="USD">100249</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1090"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_1045"
      unitRef="USD">100635</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_888"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_893"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_898"
      unitRef="USD">-8342809</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_903"
      unitRef="USD">-8342809</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_906"
      unitRef="Shares">43787825</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_907"
      unitRef="USD">437878</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_912"
      unitRef="USD">490803133</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_917"
      unitRef="USD">-471093411</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="fid_922"
      unitRef="USD">20147600</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_942"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1032"
      unitRef="USD">1551319</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1091"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_1046"
      unitRef="USD">1551319</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_949"
      unitRef="Shares">12855</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_956"
      unitRef="USD">129</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1033"
      unitRef="USD">52534</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1092"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_1047"
      unitRef="USD">52663</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_963"
      unitRef="Shares">36523</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_970"
      unitRef="USD">365</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1034"
      unitRef="USD">135304</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1093"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_1048"
      unitRef="USD">135669</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_991"
      unitRef="Shares">913234</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_998"
      unitRef="USD">9132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1035"
      unitRef="USD">1543365</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1094"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_1049"
      unitRef="USD">1552497</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cvm:IncentiveStockForfeitedShares
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_977"
      unitRef="Shares">-2000</cvm:IncentiveStockForfeitedShares>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_984"
      unitRef="USD">-20</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1036"
      unitRef="USD">-11080</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1095"
      unitRef="USD">0</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_1050"
      unitRef="USD">-11100</cvm:IncentiveStockForfeitedAmount>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1005"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1037"
      unitRef="USD">-271968</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1096"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_1051"
      unitRef="USD">-271968</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_908"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_913"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_918"
      unitRef="USD">-8367281</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_923"
      unitRef="USD">-8367281</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_909"
      unitRef="Shares">44748437</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_910"
      unitRef="USD">447484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_915"
      unitRef="USD">493802607</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_920"
      unitRef="USD">-479460692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_925"
      unitRef="USD">14789399</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1112"
      unitRef="USD">20810973</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1113"
      unitRef="USD">24563599</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1115"
      unitRef="USD">2977603</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1116"
      unitRef="USD">2959681</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1117"
      unitRef="USD">5008</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1118"
      unitRef="USD">12788</us-gaap:OtherNoncashExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1119"
      unitRef="USD">778571</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1120"
      unitRef="USD">473723</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1121"
      unitRef="USD">3544569</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1122"
      unitRef="USD">4976338</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1123"
      unitRef="USD">162969</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1124"
      unitRef="USD">157706</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1125"
      unitRef="USD">15708</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1126"
      unitRef="USD">-208419</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1127"
      unitRef="USD">304097</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1128"
      unitRef="USD">24491</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1129"
      unitRef="USD">-46884</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1130"
      unitRef="USD">-2342951</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1132"
      unitRef="USD">-592370</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1133"
      unitRef="USD">66616</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1134"
      unitRef="USD">167568</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1135"
      unitRef="USD">243800</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1136"
      unitRef="USD">139243</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1137"
      unitRef="USD">28173</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1138"
      unitRef="USD">-13994502</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1139"
      unitRef="USD">-17803797</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1141"
      unitRef="USD">75122</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1142"
      unitRef="USD">361892</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1143"
      unitRef="USD">13211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1144"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1145"
      unitRef="USD">-88333</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1146"
      unitRef="USD">-361892</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1148"
      unitRef="USD">12730000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1149"
      unitRef="USD">1552497</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1150"
      unitRef="USD">1173577</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1151"
      unitRef="USD">213796</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1152"
      unitRef="USD">-80620</us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1153"
      unitRef="USD">0</us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1154"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1155"
      unitRef="USD">447291</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1156"
      unitRef="USD">1315291</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1157"
      unitRef="USD">1157371</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1158"
      unitRef="USD">10321752</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1159"
      unitRef="USD">628621</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1160"
      unitRef="USD">-3761083</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1161"
      unitRef="USD">-17537068</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1162"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1163"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_1164"
      unitRef="USD">384652</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_1165"
      unitRef="USD">5135070</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:AssetsPurchasedUnderFinanceLeases
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1167"
      unitRef="USD">20797</cvm:AssetsPurchasedUnderFinanceLeases>
    <cvm:AssetsPurchasedUnderFinanceLeases
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1168"
      unitRef="USD">0</cvm:AssetsPurchasedUnderFinanceLeases>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1169"
      unitRef="USD">1296</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1170"
      unitRef="USD">927</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1171"
      unitRef="USD">2770</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1172"
      unitRef="USD">0</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:ConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1173"
      unitRef="USD">738832</cvm:ConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:ConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1174"
      unitRef="USD">327927</cvm:ConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:AccruedConsultingServicesToBePaidWithCommonStock
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1175"
      unitRef="USD">110000</cvm:AccruedConsultingServicesToBePaidWithCommonStock>
    <cvm:AccruedConsultingServicesToBePaidWithCommonStock
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1176"
      unitRef="USD">110000</cvm:AccruedConsultingServicesToBePaidWithCommonStock>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1177"
      unitRef="USD">91975</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1178"
      unitRef="USD">58172</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1179"
      unitRef="USD">706517</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_1180"
      unitRef="USD">809495</us-gaap:InterestPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1181">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;A. &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The accompanying condensed financial statements of CEL-SCI Corporation (the &#x201c;Company&#x201d;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#x2019;s financial position as of June 30, 2024 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Summary of Significant Accounting Policies:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Recently Adopted Accounting Standards&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13,&lt;em&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). &lt;/em&gt;ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#x2019;s financial position, results of operations, or cash flows. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;&#160;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07, &lt;em&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/em&gt;(&lt;em&gt;&#x201c;ASU 2023-07&#x201d;&lt;/em&gt;), which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &lt;em&gt;Improvements to Income Tax Disclosures&lt;/em&gt;, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1189">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1190">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1191">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-10-01to2024-06-30" id="fid_1192">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:LeasesPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1193">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;</cvm:LeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-10-01to2024-06-30" id="fid_1194">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-10-01to2024-06-30" id="fid_1195">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1196">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1197">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cvm:ImpairmentOfLongLivedAssetsPolicyTextblock contextRef="From2023-10-01to2024-06-30" id="fid_1198">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</cvm:ImpairmentOfLongLivedAssetsPolicyTextblock>
    <us-gaap:UseOfEstimates contextRef="From2023-10-01to2024-06-30" id="fid_1199">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1200">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13,&lt;em&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). &lt;/em&gt;ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#x2019;s financial position, results of operations, or cash flows. &lt;/p&gt;</cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1201">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07, &lt;em&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/em&gt;(&lt;em&gt;&#x201c;ASU 2023-07&#x201d;&lt;/em&gt;), which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, &lt;em&gt;Improvements to Income Tax Disclosures&lt;/em&gt;, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:LiquidityDisclosureTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1182">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;B. &lt;span style="text-decoration:underline"&gt;LIQUIDITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#x2019;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquidityDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1183">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;C. &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Equity Compensation&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Underlying share information for equity compensation plans as of June 30, 2024 is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&#160;&lt;span style="text-decoration:underline"&gt;Stock option activity&lt;/span&gt;:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Nine months ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,967,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;293,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;179,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,075&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;58,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,964,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;240,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,383&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that was amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"&gt;&lt;span style="text-decoration:underline"&gt;Share-Based Compensation Expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine months ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,544,569&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,976,338&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;600,841&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;473,723&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;728,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,540,219&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;230,678&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;188,001&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"&gt;&lt;em&gt;Warrants and Non-Employee Options&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The following chart represents the warrants and non-employee options outstanding at June 30, 2024:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Warrant/&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Issue Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;Shares Issuable&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;upon Exercise &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;of Warrants/ Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Expiration Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:15%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;$1.39- $2.18&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;7/27/2027 - 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;1. &lt;span style="text-decoration:underline"&gt;Equity Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;No warrants recorded as equity were exercised during the nine months ended June 30, 2024. The following warrants recorded as equity were exercised during the nine months ended June 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Warrants Exercised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;No warrants recorded as equity expired during the nine and three months ended June 30,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the nine and three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by current Officers of the Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"&gt;2. &lt;span style="text-decoration:underline"&gt;Options and Shares Issued to Consultants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;During the nine months ended June 30, 2024 and 2023, the Company issued 321,761 and 115,321 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.84 and $2.45 during the nine months ended June 30, 2024 and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company issued 70,444 and 36,523 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.33 and $2.41 during the three months ended June 30, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;No options were issued to a consultant during the nine months ended June 30, 2024. During the nine months ended June 30, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;During the nine months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $601,000 and $474,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $231,000 and $188,000, respectively, relating to the share-based compensation under these consulting agreements. On June 30, 2024 and September 30, 2023, consulting fees of approximately $221,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-02-29"
      decimals="0"
      id="fid_374"
      unitRef="Shares">3875000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-02-29"
      decimals="INF"
      id="fid_375"
      unitRef="USDPShares">2</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-01to2024-02-29"
      decimals="-6"
      id="fid_377"
      unitRef="USD">7000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetofissuanceCosts
      contextRef="From2024-02-01to2024-02-29"
      decimals="-5"
      id="fid_378"
      unitRef="USD">700000</cvm:NetofissuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-11-30"
      decimals="0"
      id="fid_358"
      unitRef="Shares">2490000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="fid_359"
      unitRef="USDPShares">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_370"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetofissuanceCosts
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_372"
      unitRef="USD">500000</cvm:NetofissuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="0"
      id="fid_640"
      unitRef="Shares">794117</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="INF"
      id="fid_645"
      unitRef="USDPShares">1.70</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="-5"
      id="fid_648"
      unitRef="USD">1400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:AdditionalPurchaseOfCommonStock
      contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="0"
      id="fid_649"
      unitRef="Shares">119117</cvm:AdditionalPurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-05-01to2023-05-31_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="0"
      id="fid_651"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:IssuanceCostOfCommonStock
      contextRef="From2023-10-01to2024-06-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="-5"
      id="fid_1213"
      unitRef="USD">200000</cvm:IssuanceCostOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1202">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_278"
      unitRef="Shares">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_275"
      unitRef="Shares">17787200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_276"
      unitRef="Shares">1283760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_277"
      unitRef="Shares">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_274"
      unitRef="Shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvm:ScheduleOfStockOptionActivityTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1203">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Nine months ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,967,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;293,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;179,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,075&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;58,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,964,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;240,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,383&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfStockOptionActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_287"
      unitRef="Shares">1967500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_283"
      unitRef="Shares">6500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_280"
      unitRef="Shares">293000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_289"
      unitRef="Shares">179832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_288"
      unitRef="Shares">27075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_290"
      unitRef="Shares">58787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_284"
      unitRef="Shares">1964500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_279"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_285"
      unitRef="Shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_281"
      unitRef="Shares">57500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_286"
      unitRef="Shares">40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-04-01to2023-06-30"
      decimals="-3"
      id="fid_282"
      unitRef="Shares">13383000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <cvm:StockOptionPlan
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_652"
      unitRef="USD">234332</cvm:StockOptionPlan>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_488"
      unitRef="USD">260000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_653"
      unitRef="USD">101000</us-gaap:AmortizationOfFinancingCosts>
    <cvm:ScheduleOfCompensatingBalancesTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1204">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine months ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,544,569&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,976,338&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;600,841&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;473,723&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;728,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,540,219&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;230,678&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;188,001&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfCompensatingBalancesTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_295"
      unitRef="USD">3544569</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_334"
      unitRef="USD">4976338</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_297"
      unitRef="USD">600841</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_337"
      unitRef="USD">473723</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_336"
      unitRef="USD">728120</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-04-01to2023-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_335"
      unitRef="USD">1540219</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-04-01to2024-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_338"
      unitRef="USD">230678</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-04-01to2023-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_339"
      unitRef="USD">188001</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1205">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Warrant/&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Issue Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;Shares Issuable&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;upon Exercise &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;of Warrants/ Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Expiration Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:15%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;$1.39- $2.18&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;7/27/2027 - 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesNMember"
      id="fid_299">8/18/2008</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_308"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_316"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesNMember"
      id="fid_325">8/18/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesUUMember"
      id="fid_300">6/11/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_309"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_317"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesUUMember"
      id="fid_326">6/30/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesXMember"
      id="fid_301">1/13/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_310"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_318"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesXMember"
      id="fid_327">7/13/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesYMember"
      id="fid_302">2/15/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_311"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_319"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesYMember"
      id="fid_328">8/15/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesMMMember"
      id="fid_303">6/22/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_312"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_320"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesMMMember"
      id="fid_329">6/22/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesNNMember"
      id="fid_304">7/24/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_313"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_321"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesNNMember"
      id="fid_330">7/24/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember"
      id="fid_305">10/30/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_314"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_322"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember"
      id="fid_331">10/30/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_srt_MinimumMember_cvm_ConsultantsMember"
      id="fid_306">7/28/2017</cvm:IssueDate1>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-06-30_srt_MaximumMember_cvm_ConsultantsMember"
      id="fid_307">9/2/2023</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2024-06-30_cvm_ConsultantsOptionMember"
      decimals="0"
      id="fid_315"
      unitRef="Shares">110000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_srt_MinimumMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_323"
      unitRef="USDPShares">1.39</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2024-06-30_cvm_ConsultantsOptionMember"
      decimals="INF"
      id="fid_324"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_srt_MinimumMember_cvm_ConsultantsMember"
      id="fid_332">7/27/2027</cvm:ExpirationDate>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-06-30_srt_MaximumMember_cvm_ConsultantsMember"
      id="fid_333">9/1/2028</cvm:ExpirationDate>
    <cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1206">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Warrants Exercised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_340"
      unitRef="Shares">17752</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_343"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_345"
      unitRef="USD">29291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_341"
      unitRef="Shares">200000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_344"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_346"
      unitRef="USD">418000</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_347"
      unitRef="Shares">217752</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_348"
      unitRef="USD">447291</cvm:ProceedsFromEquityWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_350"
      unitRef="USDPShares">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2023-10-01to2024-06-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_654"
      unitRef="USD">659455</cvm:IncrementalCostDeemedDividend>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember"
      decimals="0"
      id="fid_349"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_354"
      unitRef="Shares">321761</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1212"
      unitRef="Shares">115321</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_492"
      unitRef="USDPShares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_494"
      unitRef="USDPShares">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-04-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_498"
      unitRef="Shares">70444</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-04-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_499"
      unitRef="Shares">36523</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_500"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-04-01to2023-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_501"
      unitRef="USDPShares">2.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1
      contextRef="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_656"
      unitRef="Shares">5000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsOtherMember"
      decimals="INF"
      id="fid_657"
      unitRef="USDPShares">11.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_365"
      unitRef="USD">601000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_502"
      unitRef="USD">474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_503"
      unitRef="USD">231000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-01to2023-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_504"
      unitRef="USD">188000</us-gaap:AllocatedShareBasedCompensationExpense>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_367"
      unitRef="USD">221000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_353"
      unitRef="USD">205000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1184">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;D. &lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;During the nine and three months ended June 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $80,620. No restricted shares of the Company&#x2019;s common stock were purchased by related parties during the nine and three months ended June 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:PurchaseOfNewlyIssuedSharesByInsiders
      contextRef="From2023-10-01to2024-06-30_cvm_OfficerandDirectorMember"
      decimals="0"
      id="fid_662"
      unitRef="Shares">58000</cvm:PurchaseOfNewlyIssuedSharesByInsiders>
    <cvm:RestrictedCommonStockFairValue
      contextRef="From2023-10-01to2024-06-30_cvm_OfficerandDirectorMember"
      decimals="0"
      id="fid_665"
      unitRef="USD">80620</cvm:RestrictedCommonStockFairValue>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember"
      decimals="0"
      id="fid_658"
      unitRef="USD">659455</cvm:IncrementalCostDeemedDividend>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2023-10-01to2023-10-28_cvm_OfficerandDirectorMember"
      decimals="0"
      id="fid_379"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1185">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;E. &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"&gt;&lt;em&gt;Clinical Research Agreement&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#x2019;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, &lt;em&gt;Collaborative Arrangements&lt;/em&gt;. The Company determined the payments to Ergomed are within the scope of ASC 730, &lt;em&gt;Research and Development&lt;/em&gt;. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s discount of approximately $11.9 million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomed&#x2019;s discount, approximately $0.1 million for each period as research and development expense related to Ergomed&#x2019;s services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Egromed&#x2019;s services and during three months ended June 30, 2023, the Company recorded, net of Ergomed&#x2019;s discount, less than $0.1 million as research and development expense related to Ergomed&#x2019;s services.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The San Tomas lease is classified as a finance lease on the Company&#x2019;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $2.0 and $1.9 million, respectively, of which approximately $0.7 and $0.8 million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Company&#x2019;s finance leases is 8.46% and the weighted average time to maturity is 4.34 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#x2019;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;666,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,747,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Total future minimum lease obligation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,456,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,029,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,427,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,949,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,478,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.3 million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $0.3 million for each period. The weighted average discount rate of the Company&#x2019;s operating leases is 10.19% and the weighted average time to maturity is 7.16 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;90,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,345,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(640,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,705,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(219,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,486,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cvm:ClinicalServiceTrial
      contextRef="From2023-10-01to2024-06-30_cvm_ErgomedMember"
      decimals="-6"
      id="fid_472"
      unitRef="USD">12000000</cvm:ClinicalServiceTrial>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="-5"
      id="fid_469"
      unitRef="USD">35800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2023-10-01to2024-06-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_667"
      unitRef="USD">11900000</cvm:NetOfDiscount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-06-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_668"
      unitRef="USD">100000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-04-01to2023-06-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_671"
      unitRef="USD">100000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:AnnualIncreaseToInterestPayments
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="fid_466"
      unitRef="Pure">0.03</cvm:AnnualIncreaseToInterestPayments>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-6"
      id="fid_674"
      unitRef="USD">2000000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2022-10-01to2023-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_675"
      unitRef="USD">1900000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:InterestPaid
      contextRef="From2023-10-01to2024-06-30"
      decimals="-5"
      id="fid_459"
      unitRef="USD">700000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="From2022-10-01to2023-06-30"
      decimals="-5"
      id="fid_486"
      unitRef="USD">800000</us-gaap:InterestPaid>
    <cvm:AnnualIncreaseToInterestPayments
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="fid_484"
      unitRef="Pure">0.0846</cvm:AnnualIncreaseToInterestPayments>
    <cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne contextRef="From2024-04-01to2024-06-30" id="fid_485">P4Y4M2D</cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne>
    <cvm:FinancingArrangementDepositBaseRentAmount
      contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember"
      decimals="-5"
      id="fid_473"
      unitRef="USD">2300000</cvm:FinancingArrangementDepositBaseRentAmount>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1207">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;666,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,747,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Total future minimum lease obligation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,456,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,029,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,427,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,949,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,478,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_432"
      unitRef="USD">666000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_433"
      unitRef="USD">2747000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_434"
      unitRef="USD">2838000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_435"
      unitRef="USD">2929000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_436"
      unitRef="USD">3021000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_437"
      unitRef="USD">255000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_439"
      unitRef="USD">12456000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_440"
      unitRef="USD">2029000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_441"
      unitRef="USD">10427000</us-gaap:FinanceLeaseLiability>
    <cvm:FinanceLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_442"
      unitRef="USD">1949000</cvm:FinanceLeaseLiabilityCurrentPortion>
    <cvm:FinanceLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_443"
      unitRef="USD">8478000</cvm:FinanceLeaseLiabilityNoncurrentPortion>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-10-01to2024-06-30"
      decimals="-5"
      id="fid_465"
      unitRef="USD">300000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="-5"
      id="fid_673"
      unitRef="USD">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="fid_505"
      unitRef="Pure">0.1019</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne contextRef="From2023-10-01to2024-06-30" id="fid_467">P7Y1M28D</cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1208">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;90,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,345,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(640,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,705,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(219,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,486,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_444"
      unitRef="USD">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_445"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_446"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_447"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_448"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_449"
      unitRef="USD">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_450"
      unitRef="USD">746000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_451"
      unitRef="USD">2345000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_452"
      unitRef="USD">640000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_453"
      unitRef="USD">1705000</us-gaap:OperatingLeaseLiability>
    <cvm:OperatingLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_454"
      unitRef="USD">219000</cvm:OperatingLeaseLiabilityCurrentPortion>
    <cvm:OperatingLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_455"
      unitRef="USD">1486000</cvm:OperatingLeaseLiabilityNoncurrentPortion>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1186">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;G. &lt;span style="text-decoration:underline"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;"&gt;During the nine and three months ended June 30, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents is approximately 8 years. For the nine months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $25,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $7,000 and $9,000, respectively. The total estimated future amortization is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;173,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod contextRef="From2023-10-01to2024-06-30" id="fid_424">P8Y</cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_422"
      unitRef="USD">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_426"
      unitRef="USD">29000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_430"
      unitRef="USD">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_431"
      unitRef="USD">9000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1209">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;173,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_412"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_413"
      unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_414"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_415"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_416"
      unitRef="USD">19000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_417"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_418"
      unitRef="USD">54000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_419"
      unitRef="USD">173000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1187">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;H. &lt;span style="text-decoration:underline"&gt;LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21,470,429&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(24,735,151&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,516,014&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,367,281&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;51,479,454&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,761,395&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;53,994,384&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;44,254,363&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.42&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.57&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.19&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30 :&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,497,453&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,824,365&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;17,644,703&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,971,615&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1210">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21,470,429&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(24,735,151&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,516,014&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,367,281&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;51,479,454&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,761,395&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;53,994,384&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;44,254,363&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.42&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.57&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.19&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_390"
      unitRef="USD">-21470429</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_403"
      unitRef="USD">-24735151</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_406"
      unitRef="USD">-7516014</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_407"
      unitRef="USD">-8367281</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_392"
      unitRef="Shares">51479454</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_404"
      unitRef="Shares">43761395</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_408"
      unitRef="Shares">53994384</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      id="fid_410"
      unitRef="Shares">44254363</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2023-10-01to2024-06-30"
      decimals="INF"
      id="fid_394"
      unitRef="USDPShares">-0.42</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      id="fid_405"
      unitRef="USDPShares">-0.57</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2024-04-01to2024-06-30"
      decimals="INF"
      id="fid_409"
      unitRef="USDPShares">-0.14</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      id="fid_411"
      unitRef="USDPShares">-0.19</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1211">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,497,453&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,824,365&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;17,644,703&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,971,615&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-06-30_cvm_OptionsMember"
      decimals="0"
      id="fid_396"
      unitRef="Shares">17497453</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-06-30_cvm_OptionsMember"
      decimals="0"
      id="fid_397"
      unitRef="Shares">13824365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_398"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-06-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_399"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_401"
      unitRef="Shares">17644703</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      id="fid_402"
      unitRef="Shares">13971615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-10-01to2024-06-30" id="fid_1188">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;J. &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"&gt;On July 11, 2024, Geert Kersten, the Company&#x2019;s Chief Executive Officer and a director, loaned the Company $200,000.&#160;&#160;On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000.&#160;&#160;These amounts were repaid on July 30, 2024.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"&gt;On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for gross proceeds of approximately $10.8 million. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="AsOf2024-07-11_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="fid_1214"
      unitRef="USD">200000</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions
      contextRef="From2024-07-01to2024-07-18_us-gaap_SubsequentEventMember_cvm_MrKerstenMember"
      decimals="0"
      id="fid_1215"
      unitRef="USD">250000</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_676"
      unitRef="Shares">3715000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-29_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_677"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:WarrantsToPurchaseCommonStock
      contextRef="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_679"
      unitRef="Shares">7130000</cvm:WarrantsToPurchaseCommonStock>
    <cvm:WarrantsOfferingPrice
      contextRef="AsOf2024-07-29_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_680"
      unitRef="USDPShares">0.99</cvm:WarrantsOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-01to2024-07-29_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="fid_678"
      unitRef="USD">10800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
